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The obstructive sleep apnoea/ hypopnoea syndrome (OSAHS) is a common disorder,
affecting around 2-4 % of the middle-aged population. The deleterious consequences
of OSAHS include sleepiness, impaired health status, cognitive function, and
driving, and possibly increased cardiovascular and cerebrovascular disease.
Treatment of OSAHS improves symptoms, sleepiness, cognition, health status and
blood pressure. There are different treatments available for OSAHS, of which the
most widely used is CPAP with strong evidence supporting its benefit. There is a
strong association between OSAHS and hypertension, based on animal,
epidemiological, and interventional studies. The pathogenesis of hypertension in
OSAHS is still unclear. Sympathetic activity is increased in OSAHS patients during
sleep and wakefulness. However, there are different factors contributing to this
increase in sympathetic activity, which may lead to the development of hypertension.
In addition, altered endothelial function may have a role.
This thesis aims to explore some of these factors, focusing mainly on baroreflex
sensitivity (BRS) in a randomized controlled trial, to test the hypothesis that BRS is
impaired in sleep apnoea patients, and might be reversed with one month of CPAP
therapy. We performed a blinded placebo controlled crossover trial of the effect of
CPAP on BRS in newly diagnosed OSAHS patients. Twenty-nine patients were
recruited who had an Epworth Sleepiness Scale (ESS) of more than 10 and an
apnoea/hypopnoea index (AHI) of more than 15. A control group of ten healthy
subjects was also studied. A non-invasive technique was used to evaluate the BRS,
using sequential and spectral analysis of BRS during wakefulness. The study did not
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show any significant difference between controls and OSAHS patients in the
sequential analysis measure as well as the spectral analysis of BRS. Furthermore, the
study did not show any significant difference between CPAP and placebo in terms of
an effect on any measure of BRS nor in 24-hour blood pressure in the OSAHS
patients. Even an a priori sub-group analysis of desaturating and compliant patients
(4% Desaturation Index >10 & CPAP use >3.9 hour/night) showed no effect of
CPAP on BRS or blood pressure. Patients improved symptomatically with CPAP
(P=0.02). A serious defect with the study was the lack of reproducibility of the
measurement of BRS. Furthermore, the relatively small sample size and
physiological factors such as respiration may also have affected the results. A more
reproducible measurement, larger sample size, and controlling other physiological
factors would improve the reliability of any future work. The methods used were
investigated by a further study of the reproducibility of the technique of baroreflex
measurements, by the sequence and the spectral analysis methods of analysing heart
rate and systolic blood pressure. This study revealed that measurements of BRS by
analysis of spontaneous variations, particularly the spectral domains, are highly
variable over time.
A third study assessed endothelial function, as part of the attempt to understand the
pathogenesis of development of hypertension and cardiovascular diseases in OSAHS
patients and also the possible contribution of hypoxaemia. Twenty newly diagnosed
OSHAS patients were studied but showed no significant variation in endothelial
function in relation to the extent of nocturnal hypoxaemia (P>0.1).
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Chapter 1
Sleep-Related Breathing Disorders in Adults
1.1 Introduction
The obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a disorder
characterized by repetitive upper airway collapse during sleep in association with
daytime sleepiness that has an estimated prevalence of 2% among middle-aged
women and 4% among middle-aged men (Young & Finn 1998a). It was recognized
only quite recently, although it has been extensively researched in the last 30 years.
OSAHS-related features include excessive daytime sleepiness (Guilleminault,
Tilkian, & Dement 1976;Stradling, Barbour, & Glennon 2000), neurocognitive
impairment (Engleman et al. 2000), and increased motor vehicle accidents
(Engleman, Hirst, & Douglas 1997b;George, Boudreau, & Smiley 1996b;Young et
al. 1997). It has also been associated with adverse cardiovascular consequences such
as hypertension and impairment of cardiovascular variability (see Chapter 2).
Treating OSAHS is very rewarding, for the benefit to the patient is enormous in
improving the quality of life as well as preventing the long-term sequelae.
1.2. Historical Background
Perhaps the first description of OSAHS was that of Dionysius, tyrant of Heraclea in
the fourth century BC who 'lived in fear of suffocation from fat, and adopted a very
curious mode of keeping himself awake' (Kryger 1983). Charles Dickens (Dickens
1837) described a case of obesity with hypersomnolence in Joe, the fat boy in
Pickwick Papers. Joe weighed 130 kg and slept most of the time, even during meals,
knocking on the door or firing cannons. Joe had dropsy (peripheral oedema) and was
slow (possibly cognitive dysfunction) and 'red-faced' (polycythemic) (Douglas
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2002a). Burwell et al. (1956) first used the term 'Pickwickian syndrome' when he
reported a 51-year old man with a history of somnolence associated with persistent
ankle swelling. He weighed 120 kg and had polycythaemia, right heart failure,
hypoxaemia and hypercapnia and was noted to have apnoea (Douglas 2002a)
The first detailed description of obstructive sleep apnoea came from Gastaut and co¬
workers in France in 1965, when they published the first paper on polygraphic
studies of the episodic diurnal and nocturnal (hypnic and respiratory) manifestations
of the syndrome. In these studies, repetitive episodes of cessation of breathing,
designated 'sleep apnoea', were recorded and found to be associated with marked
oxygen desaturations. It was thought initially that sleep apnoea occurred only in
people with the Pickwickian syndrome. However, Guilleminault (Guilleminault,
Tilkian, & Dement 1976) reported in 1976 that sleep apnoea can occur in individuals
without these characteristics.
1.3 Definition
The definition of sleep apnoeas and hypopnoeas remains controversial. It is generally
acceptable to define apnoea in adults as cessation of breathing from the nose and
mouth for more than 10 seconds. The definition of a hypopnoea is more contentious
and various definitions are used, including a reduction in tidal volume by > 50 % or
flow rate from the baseline plus or minus at least a 4% arterial oxygen desaturations
(ASDA 1999). The cessation of breathing can be of three major types:
• Obstructive: An episode of 10 seconds or longer when airflow past nasal
and buccal pressure sensors or thermistors is absent despite persistent
respiratory effort which is assessed with detectors of abdominal and
thoracic movement (Guilleminault & Dement 1978a).
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• Central: in which there is complete cessation of airflow and
diaphragmatic activity, which is indicated by a clear reduction in
oesophageal pressure swings. This event should last 10 seconds or longer.
• Mixed: cessation of airflow and absence of any respiratory effort at the
start of an episode, followed by resumption of the respiratory effort
(Guilleminault & Dement 1978b). This type of breathing might be
considered another variety of the obstructive pattern.
The average number of apnoeas and hypopnoeas per hour slept is generally referred
to as the apnoea-hypopnoea index (AHI). An AHI of more than 5/hr when present
along with daytime sleepiness or two other major symptoms (see below) has been
used to define OSAHS ( 1999)
1.4 The Prevalence of OSAHS
Although the condition may occur in all age groups, including children, the focus has
largely been on the middle-age population. Some studies have shown that OSAHS
may increase with age (Bixler, Vgontaz, & Ten Have 1998) with a peak age of
presentation around 50 years. The prevalence seems to diminish above the age of 60
years (Stradling & Davies 2004), especially if symptoms are not included in the
definition. This may be because older patients may not complain of their symptoms
or because it genuinely does not have such adverse consequences as in younger
patients (Bixler, Vgontaz, & Ten Have 1998;Young, Palta, & Dempsey 1993).
Nevertheless, Hoch and co-workers did not show any significant difference in
daytime sleepiness between elderly healthy people (mean age 83+/- 3.1 years) and
young subjects (mean age 25+/-3.1) (Hoch et al. 1992b). Furthermore, other studies
suggest that the prevalence of obstructive sleep apnoea may increase with age
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(Janssens et al. 2000;Ware, McBrayer, & Scott 2000) with an increase in AHI after a
one-year follow-up (Hoch et al. 1992a).
Snoring has been reported in up to 60% of adults, yet only a small percentage of
snorers develop OSAHS (Norton & Dunn 1985b;Ohayon et al. 1997). Based on the
above-mentioned definition, the prevalence of OSAHS might be as high as 4% in
men and 2% in women (Young, Palta, & Dempsey 1993). However, 24% of the US
male population and 9% of women aged between 30 and 60 years have an AHI>5
without sleepiness, although the significance of this is unknown (Young, Palta, &
Dempsey 1993).
1.4.1 Gender Differences
OSAHS is considered less common in women compared with men. Earlier studies
have indicated that the prevalence of sleep apnoea in men is higher than in women in
all age groups (Redline et al. 1994;Young & Finn 1998b). Nevertheless, Duran et al.
in a study carried out in Spain did not show an obvious difference in prevalence
between men and women. In this study, daytime hypersomnolence was found in 14%
of men and 22% of women and it was not associated with age (Duran et al. 2001). It
was also found that the habitual snoring in 46% of men and 25 % of women showed
a significant tendency to increase with age. Breathing pauses during sleep were
reported by 10% of men and only 2.5% of women and they increased with age. In
addition, the difference in prevalence of OSAHS was not clear from
polysomnography data based on variable AHI cut-off scores, which might indicate
that the prevalence of asymptomatic OSAH is high in both sexes, although the
variations in OSAHS might be due to differences in symptoms.
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Any variation in prevalence between men and women might be attributed to the fact
that the guidelines for the evaluation and diagnosis of OSAHS, established primarily
for men, might not be valid for women. However, Young et al. found that the clinical
indications for OSAHS evaluation are as appropriate for women as they are for men
(Young et al. 1996). In a recent study from Pennsylvania and Madrid (Bixler,
Vgontaz, & Lin 2001), the prevalence of OSAH was estimated based on a definition
of hypopnoea requiring a 4% fall in Sa02 and AHI> 10. Symptoms were not
required and thus OSAH rather than OSAHS was assessed. The total sample was
1,000 subjects, of whom 741 were men. Men had an OSAH prevalence of 3.9% and
women 1.2%. However, in premenopausal women and postmenopausal women
receiving hormone replacement therapy (HRT), the rate was 0.6% in contrast to 2.7%
in postmenopausal women not receiving HRT. Furthermore, all premenopausal
women and those receiving HRT who had an AHI > 15 had a BMI over 32. In
contrast, 50% of postmenopausal women not receiving HRT had an AHI > 15, a
similar frequency to that of men. These findings may perhaps be explained by the
fact that female sex hormones are perhaps protective against OSAHS in non-obese
women. Other studies had shown more severe OSAHS in postmenopausal women
and reductions in indices of sleep disordered breathing from HRT (Dancey, Hanly, &
Soong 2001). Conversely, testosterone may have a negative impact on OSAHS,
perhaps by effects on the upper airway (Cistulli, Grunstein, & Sullivan 1994).
1.5 Physiology of Normal Sleep
Sleep is a reversible physiological and behavioural status. With the onset of sleep,
the heart rate drops, cardiac output and blood pressure decrease, respiration slows,
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and muscle tone is reduced. Sleep has two main divisions: rapid eye movement
(REM) and non-rapid eye movement (NREM) sleep.
REM sleep periods occur about every 90 minutes throughout sleep and last around
20-30 minutes, occupying 20-25% of the night. It is characterized by intermittent
horizontal eye movement, loss of postural muscle tone and fluctuation of autonomic
functions with markedly variable breathing and surges in heart rate.
NREM sleep accounts for most of the sleep time in adults, about 75-80% of the
night. It is categorized into four sleep stages identified using full polysomnography
(see below). In stage 1, the EEG changes from alpha activity to low-voltage mixed
frequency pattern (4-7 Hz). Stage 2 commences a few minutes after the onset of
stage 1, with characteristic sleep spindles and K complexes. With the progress of
sleep, high-voltage slow-wave activity may appear (2 Hz or less), which is the start
of stages 3 and 4 or slow-wave sleep (SWS). Wakefulness may be referred to as
stage 0.
There are usually 4-6 sleep cycles per night, with decreasing cycle length as the
night progresses. The sleep cycle comprises wakefulness to stage 1 all the way
through to stage 4, then an episode of REM sleep. This pattern is repeated through
the night with the periods of REM sleep gradually lengthening (in the rarely seen
"classical" night of sleep), so that SWS predominates early, and REM sleep later in
the night. Brief awakenings from sleep, known as arousals, may occur, which can be
detected from EEG signals by abrupt shift in frequency to alpha or theta activities
and last for about 10 seconds.
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1.6 The Upper Airway in Health and OSAHS
1.6.1. The Normal Upper Airway
The upper airway consists of the nasal airway, the oral airway, the pharynx, the
larynx and the trachea. The soft tissues and the skeletal components comprising these
structures mainly determine the size of the upper airway. The pharynx is the main
site of obstruction in OSAHS and extends from the back of the nose to the larynx.
However, the nasal as well as the oral airway can also produce significant respiratory
resistance. The patency of the pharynx is critically dependent on the action of the
upper airway muscles: palatoglossus, palatopharyngeus, levator palatini, tensor
palatini, stylopharyngeus, and salpingopharyngeus, which are active during
respiration to prevent upper airway collapse. The muscles of the tongue also play a
critical role, for the genioglossus, hypoglossus, and styloglossus, contribute to
maintain the retroglossal airway (Miyamoto et al. 1997), although their effectiveness
decreases with age (Mortimore et al. 1999). These upper airway muscles balance the
intra-luminal pressure to keep the upper airway patent. During inspiration, the
negative intra-luminal pressure tends to narrow the upper airway. This is opposed by
the action of the upper airway dilating muscles, which tense with each inspiration,
thus resisting collapse of the upper airway, the mechanism that is, at least in part,
reflex-driven (Honer et al. 1991).
1.6.2 Upper Airway in Patients with OSAHS
OSAHS results from the narrowing of the upper airway during sleep and the site of
the narrowing is usually in the pharynx. The pharyngeal airway of the OSA patient is
smaller than that seen in controls, even in the wakeful state (Haponik, Smith, &
Bohlman 1983;Martin, Marshall, & Douglas 1995;Schwab, Getter, & Hoffman
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1993). In addition, some of the anatomical structures in the upper airway such as the
tongue, uvula, pharyngeal fat pads and the lateral pharyngeal walls may be larger in
the apnoea patient (Rivlin et al. 1984;Schwab, Getter, & Hoffman 1993). During
sleep, and because of the negative pressure created during inspiration and the
accompanying muscle hypotonia, the upper airway tends to narrow or collapse,
causing apnoea or hypopnoea. Facial structure may also play a role in the
pathogenesis of apnoea. Retroposition of the maxilla and mandible causes antero¬
posterior narrowing of the pharynx owing to posterior displacement of the soft plate
and tongue (Jamieson, Guilleminault, & Partinen 1986;Riha et al. 2005). These facial
abnormalities are particularly common in non-obese OSA patients and may run in
families (Mathur & Douglas 1995b).
1.7 Aetiology and Risk Factors
1.7.1 Genetic
Sleep apnoea is more common in family members of OSAHS sufferers than in the
general population. Familial aggregation is generally explained by many risk factors
involved in the pathophysiology of OSAHS being genetically determined. For
example, twin studies have suggested that 70% of the variance in obesity within the
general population can be attributed to genetic factors (Strohl et al. 1978). These
factors which influence metabolic rate, thermogenesis, fat storage and distribution
and eating behaviour, as well as facial structure (Mathur & Douglas 1995c;Riha et al.
2005) and endocrine and hypothalamic functions, are all thought to contribute to
obesity and consequently to OSAHS (see below). Initial family studies addressed the
issue of the genetic basis of OSAHS as it was reported in members of the same
family in different generations (Mathur & Douglas 1995a;Redline et al. 1992).
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Epidemiological studies (including twin studies) have evaluated the familial
aggregation of symptoms of OSAHS. Kaprio et al. (Kaprio et al. 1988) found that the
concordance for snoring was greater between monozygotic twins than dizygotic
twins, suggesting a role of inheritance. Habitual snoring, excessive daytime
sleepiness, gasping or apnoea was two or four times more frequent among first-
degree relatives of patients with OSAHS than among control subjects, independent
of familial similarities in body mass index (BMI), smoking, alcohol intake, age and
gender (Redline et al. 1992). In the Copenhagen male study, the risk of snoring was
increased approximately threefold when at least one first-degree relative was
reported to be a snorer, and increased to fourfold when both parents were snorers
(Jennum et al. 1995). Mathur et al. found that first-degree relatives of OSAHS
patients have narrower upper airways with retroposed maxillae and mandibles and
longer soft palates with wider uvulae (Mathur & Douglas 1995c), which suggest that
OSAHS has a strong familial component.
The racial and ethnic variations in OSAHS are still not clear since relatively little is
known about the disorder in non-Caucasian populations. However, data from the
Cleveland Family Study and the San Diego study of the elderly demonstrated higher
AHIs in African-Americans compared with Caucasians (Redline et al. 1995). This
difference was not accounted for by differences in BMI, alcohol consumption or
tobacco use, which were possible confounding factors. Community-based surveys in
Singapore demonstrated that Chinese individuals had lower rates of snoring and
sleep apnoea compared with Malays and Indians. After adjusting for obesity and age,
the odds of sleep apnoea were reported to be approximately three and two times
higher in Indians and Malays, respectively, compared with Chinese (Ng, Seow, &
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Tan 1998). However, Ip et al. (Ip et al. 2001) found in a community-based study in
Hong Kong that the prevalence of OSHA in Chinese people was 4.1% with AHI > 5,
increasing with body mass index (BMI) and age. In this study, she screened 1,542
men using a sleep questionnaire, although only 150 subjects had PSG. Among those
who underwent PSG, 64 subjects (43%), 45 subjects (31%) and 37 subjects (25%)
had AHIs > 5, > 10, and > 15, respectively. Figure 1.1 demonstrates the findings of
this study.
Figure 1.1 Prevalence rate of OSAHS in Chinese population (Ip et al. 2001)
1.7.2 Obesity
Approximately 50% of patients with OSAHS are obese, that is, their body mass
index (BMI) is more than 30 kg/m2 (Douglas 2002a). In other studies, obesity
appears to increase the risk of OSAHS by approximately 10—14-fold, mainly in
middle-aged subjects (Guilleminault, Tilkian, & Dement 1976;Redline & Tishler
2000). The term syndrome Z has been introduced for the combination of
hypertension, central obesity, insulin resistance, hyperlipidaemia and OSAHS
(Wilcox et al. 1998). Obesity probably results in OSAHS from different mechanisms:
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(1) increased fat deposition in the lateral nasopharyngeal and oropharyngeal areas,
reducing its calibre (Horner et al. 1989;Suratt et al. 1983) and consequently altering
upper airway function, rendering the pharynx more susceptible to collapse during
sleep; (2) reduced chest wall compliance, causing hypoventilation owing to
imbalance between mass loading and central drive (Strobel & Rosen 1996). Patients
with sleep apnoea have difficulties in losing weight and often may gain weight
because of daytime tiredness and consequent decrease in physical activity (Phillips,
Kato, & Narkiewicz 2000). Furthermore, obese male patients with OSAHS have
significantly higher plasma leptin (leptin regulates appetite and might play a role in
the pathogenesis of obesity-related hypertension (Henriksen et al. 2000)) compared
with matched obese controls who were free of sleep apnoea (Phillips, Kato, &
Narkiewicz 2000). In another study, elevated leptin concentrations associated
positively with skinfold thickness, hip/waist ratio, serum low-density lipoprotein
cholesterol, and blood pressure in patients with sleep apnoea. In the same study, it
was found that leptin concentrations decreased after 6 months of CPAP therapy (Ip,
Lam, & Ho 2000).
1.7.3 Anatomical Factors
Retrognathia and micrognathia (congenital or acquired), including retroposition of
the maxilla and/or mandible (Mathur & Douglas 1995c) and also deviation of the
nasal septum all contribute to a reduction in upper airway size. Men and women with
OSAHS have a lower-set hyoid bone than do those without OSAHS (Mathur &
Douglas 1995c;Riha et al. 2005). In addition, enlarged tonsils and fat deposition in
the upper airway (see above) may also narrow the upper airway. The supine position
is associated with narrowing of the upper airway, perhaps owing to the tongue falling
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backward, and consequently the severity of sleep apnoea increases in the supine
posture (Douglas 2002b). Disorders such as acromegaly (Grunstein, Ho, & Sullivan
1991) and hypothyroidisim (Grunstein & Sullivan 1988) may reduce the upper
airway size owing to excessive tissue thickness and thereby increase sleep apnoea.
1.8 Consequences of OSAHS
1.8.1 Hypertension and Cardiovascular Complications
There is now robust evidence that OSAHS is associated with hypertension. This is
the main topic of this thesis and will be discussed in full in Chapter 2.
1.8.2 Pulmonary Haemodynamics Impairment
Haemodynamic consequences of OSAHS affecting the pulmonary circulation may
lead to the development of pulmonary hypertension (PH). Niijima et al. (Niijima et
al. 1999) evaluated 31 OSAHS patients with right cardiac catheterization and noted
that pulmonary artery vasculature tone increased during REM sleep, independent of
the degree of hypoxaemia, in patients with daytime pulmonary hypertension. The
pathogenesis of PH in OSAHS could be attributed to several factors including
hypoxia, hypercapnia and acidosis, neural reflexes and intrathoracic pressure.
Hypoxia is probably the most important factor, since pulmonary artery pressure is
increased by hypoxia (Cutaia & Rounds 1990). However, severe impairment of
pulmonary haemodynamics occurs only in subjects with concomitant lung disease or
morbid obesity (Kessler et al. 1996). OSAHS can also affect right ventricle (RV)
morphology and function. Noda et al. (Noda et al. 1995) found RV hypertrophy and
pulmonary hypertension in OSAHS subjects, in contrast to Sanner et al. (Sanner et
al. 1997), who did not find that RV dysfunction was related to PH. Treatment of the
apnoea could reverse the altered cardiopulmonary haemodynamics to some extent.
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Fletcher found a substantial decrease in pulmonary artery pressure and significant
improvement in right ventricular ejection fraction occurred in sleep apnoea patients,
with and without concurrent lung disease, after tracheostomy. Pulmonary vascular
resistance also decreased in these patients (Fletcher et al. 1987). There is no
randomised controlled study showing that long-term CPAP treatment can reverse
daytime pulmonary hypertension, although this is likely, but RV ejection fraction
may increase after long-term CPAP treatment (Nahmias, Lao, & Karetzky 2004).
More recently, it was found that severe OSAHS is independently associated with PH
in direct relationship with disease severity and presence of diastolic dysfunction.
Twelve weeks CPAP treatment reduced pulmonary systolic pressure (Arias et al.
2006).
1.8.3 Road Traffic Accidents
Patients with OSAHS are at a 1.3-7-fold greater risk of road traffic accidents (RTA)
than the general population. Epidemiological studies have shown that patients with
15 apnoea/hypopnoea per hour or more are at risk of having around seven times
more RTA than non-snoring normal subjects (Young et al. 1997). On direct
questioning, many patients will admit to falling asleep at the wheel and some to
having accidents or near accidents because of feeling sleepy while driving
(Engleman, Hirst, & Douglas 1997a). Furthermore, there is evidence from vigilance
tasks and driving simulators that driving performance is impaired in patients with
OSAHS, similar to that of sleep deprivation (George, Boudreau, & Smiley
1996a;George, Boudreau, & Smiley 1996b;Hack et al. 2001). In a case-controlled
study, Teran-Santos et al. (Teran-Santos, Jimenez-Gomez, & Cordero-Guevara 1999)
in Spain studied the presence of OSAHS in all drivers aged 30 to 70 who received
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emergency treatment after RTAs, and compared them with 152 age and sex-matched
control subjects. They found that the subjects with AHI greater than or equal to 10
had unadjusted odds ratio of 6.3 for having RTAs and, quite surprisingly, for those
with AHI greater than or equal to 5, the unadjusted odds ratio was 8.2. These
findings remained significant after adjusting for age, alcohol consumption,
medication use, visual refraction, BMI, driving history, and sleep schedule. Further
evidence to support the link between OSAHS and motor vehicle accidents is that
CPAP improves performance on vigilance tasks and the driving simulator and also
reduced the road accidents rate by at least 40% in OSAHS patients (George
2001;Krieger et al. 1997).
1.8.4 Cerebrovascular Disorder
Many patients with stroke have sleep apnoea, which might either be a risk factor or a
result of the cerebrovascular disease. Early epidemiological studies that examined the
relationship between OSAHS and cerebrovascular disease, using self-reported
snoring, show an association between snoring and stroke as an independent risk
factor even when adjusted for age, gender, and obesity. The strength of this
association is alleged to be similar to that for other risk factors of stroke, such as
hypertension, smoking, atrial fibrillation and high cholesterol (Koskenvuo et al.
1987;Partinen & Palomaki 1985). However, stroke might cause sleep apnoea, since
pharyngeal muscles can be affected in hemispheric stroke, and neurological
dysphagia is seen in 30-40% of stroke patients (Barer 1989) or ventilatory control
might be affected. A case-control study comparing 24 inpatients with recent stroke,
confirmed clinically and radiologically, with 27 healthy subjects matched for age and
gender (Dyke et al. 1996) with full polysomnography in all participants, reported
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increased sleep apnoeas and hypopnoeas in 19% of the control group and 71% of the
patients with stroke. The mean lowest arterial oxygen saturation level was 91% in the
control group and 85% in the stroke group, and the mean AHI was 4 for the healthy
individuals and 26 for the patients. Furthermore, obstructive apnoeas were more
common than central apnoeas or Cheyne-Stokes respiration. This study indicates that
OSAHS might be a consequence of stroke, although, in the absence of a study
evaluating sleep apnoea preceding the stroke, it is difficult to be certain that OSAHS
is a consequence of stroke. Nevertheless, a prospective study of 161 consecutive
patients with first episodes of Transient Ischemic Attack (TIA) or stroke followed for
3 months (Parra et al. 2000) showed that there were no significant differences in the
severity of sleep apnoea according to stroke subtype (TIA, ischemic or haemorrhagic
stroke) or the location. This study also found that the frequency of OSAH did not
significantly decline from the time immediately after the stroke to 3 months later,
which might indicate that sleep apnoea preceded the cerebrovascular events.
However, other studies have shown that sleep apnoea did improve with time and
with CPAP treatment (Sandberg et al. 2001a;Wessendorf et al. 2001), indicating that
OSAH is more likely to be in the main a consequence rather than a cause of stroke.
The presence of OSAHS after stroke is associated with a worse clinical outcome
including early neurological worsening, delirium, depressed mood, impaired
functional capacity, impaired cognition, and a longer period of hospitalization and
rehabilitation (Good et al. 1996;Spriggs et al. 1992). The effect of CPAP in stroke
prevention is not very clear, although its short-term effect after a stroke has been
shown in a randomized study in which depressive symptoms were reduced in
patients treated with nasal CPAP at 7 days and 28 days, compared with the untreated
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controls. There was no significant improvement in delirium, daily living activities, or
cognitive performance; while compliance for CPAP was about 50% only (Hui et al.
2002;Sandberg et al. 2001b;Wessendorf et al. 2001). Nevertheless, long-term
compliance for CPAP in stroke patients is not certain, especially for those with more
functional and cognitive disability (Sandberg et al. 2001a).
The pathophysiological mechanisms by which sleep apnoea could perhaps lead to the
development of stroke are still not very clear. However, during sleep apnoea,
hypoxaemia, hypercapnia, changes in intrathoracic pressure, and frequent sleep
arousal, may elicit autonomic, haemodynamic, coagulopathic, and vascular injury
processes that serve as plausible contributors to the development of stroke (Balfors &
Franklin 1994). An observational cohort study by Yaggi et al,(Yaggi et al. 2005)
found that obstructive sleep apnoea is an independent risk factor for stroke and
sudden death with hazard ratio of 1.12-3.48; P=0.004. There is significant increased
risk of stroke or death from any cause as a function of severity of OSAHS. The risk
of stroke or sudden death in sleep apnoea patients is three times that of controls.
1.8.5 Cognitive Function Impairment
One of the clinical features in patients with OSAHS is impairment of the cognitive
performance. Three-quarters of OSAHS patients reported difficulties at work and
reduced work efficiency (Kales et al. 1985). The impairment might affect attention,
concentration, vigilance, manual dexterity, visuomotor skills, memory, verbal
fluency, and executive function (Engleman & Douglas 1993a). In a disease specific
symptoms inventory, two-thirds of patients had memory disturbance and about 75%
reported problems with concentration (Flemons & Reimer 1998). The assessment of
cognitive performance in OSAHS can be conducted objectively, using different
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physiological tests either manually or by computer. Several epidemiological (Kim et
al. 1997;Redline et al. 1997) and clinical case-control studies (Bedard et al.
1991;Geenberg, Watson, & Deptula 1987) have been conducted to determine the
state of cognitive function in those with sleep apnoea. These studies suggest that
OSAHS of moderate severity could be associated with moderate to severe
impairments of cognitive performance, although cognitive impairment may not be
evident with mild sleep disordered breathing. Furthermore, studies have a shown
marked improvement in cognition after CPAP treatment in moderate and severe
OSAHS, but little change in cognition with CPAP in mild patients (Engleman et al.
1999f).
1.8.6 Quality of Life
Patients with OSAHS have a significantly impaired quality of life and social
functioning, and a high prevalence of minor psychiatric morbidity (Grunstein et al.
1995b;Kales et al. 1985). These problems might be related to excessive sleepiness,
low mood, motivation, and performance. One study suggested that more than two-
thirds of severe OSAHS patients had problems with their work and family
relationships (Kales et al. 1985). The Swedish epidemiological study (Grunstein et
al. 1995a) also assessed the quality of life and showed that symptomatic OSAHS
patients had a lower income, multiple divorce, and impaired work performance.
Associated with the impaired quality of life may be minor psychiatric disorders such
as anxiety and depressive disorders, which have been identified in approximately
one-third to half of patients with OSAHS (Douglas 1998b;Engleman et al.
1993;Engleman et al. 1994b;Engleman et al. 1999c). Recent studies on quality of life
have used generic scales to assess the functional limitations imposed by OSAHS.
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These scales include the Nottingham Health Profile (NHP): the medical outcomes
study Short Form-36 questionnaire (SF-36). There are also illness-specific scales
such as the Calgary sleep apnoea quality of life index (SAQLI), and the functional
outcomes of sleepiness questionnaire (FOSQ) (see Appendix). Research using
generic and illness specific-illness scales suggests that the quality of life in OSAHS
is reduced in aspects of both mental and physical functions. It has also been shown
that the quality of life improves in OSAHS after CPAP treatment (Engleman et al.
1994a;Engleman et al. 1999b). In randomized controlled trials of patients with
moderate to severe OSAHS, quality of life appears to improve with treatment as a
function of initial impairment, with worst affected scores showing the greatest
improvement (Engleman et al. 1999a;Jenkinson et al. 1999). In the randomized
controlled trial of Jenkinson et al. very large improvements were seen in vitality
score, with large effects on social function and moderate or small increments on
other subscale scores (Jenkinson et al. 1999).
1.8.7 Polycythaemia
OSAHS patients with a co-existing condition causing daytime hypoxaemia may
develop secondary polycythaemia. In a study of 624 patients (347 with an AHI > 10),
Hoffstein et al. (Hoffstein et al. 1994) found that haematocrit levels and white cell
counts increased minimally in patients with Sa02 < 85%, although there was no
difference in haemoglobin levels. In addition, haematocrit decreased after one night
of CPAP therapy, which might indicate a causal relationship between polycythaemia
and OSAHS. However, there is no evidence that patients with OSAHS have
increased erythropoietin levels (Pokala et al. 1995). The brief cyclical episodes of
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hypoxaemia, typical of sleep apnoea, may not be sufficient stimulus for
erythropoietin secretion (Goldman et al. 1991).
1.9 Diagnosis of Obstructive Apnoea/ Hypopnoea Syndrome
1.9.1 Clinical Symptoms
Daytime sleepiness is a cardinal feature of OSAS. This is often assessed by the
diagnosis requiring patients to have a score of more than 11 on the Epworth
Sleepiness Scale (see Appendix 1), which is the most widely used and best validated
scale (Johns 1991b). Its advantages include ease of administration and low cost. It
assesses the global level of sleepiness and is independent of short-term variations in
sleepiness with the time of day and inter-day variations (Johns 2005). The ESS aims
at measuring the general level of daytime sleepiness as a stable individual
characteristic and has satisfactory test-retest reliability (Johns 1992b). The ESS is
also able to discriminate between normal and pathological sleepiness (Johns 1994a).
The severity of sleepiness can be divided into three levels:
1- Mild: unwanted sleepiness occurs during activities that need little
attention such as reading, watching television or travelling as a
passenger.
2- Moderate: the individual tends to have involuntary sleep during
activities that require some attention such as during meetings or
presentations.
3- Severe: involuntary sleep occurs during activities that require active
attention such as during eating, walking, or driving, which may
produce marked impairment in social or occupational function (The
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Report of an American Academy of Sleep Medicine Task Force
1999).
Nocturnal features include snoring and witnessed apnoea (observed by the bed
partner). In addition, patients may complain of choking, restlessness, nocturia and
reflux (Senior et al. 2001). Other associated symptoms may include depression,
daytime fatigue, decrease of libido, and impaired concentration (Douglas 2002a).
1.9.2 Clinical Examination
Measurement of height and weight and calculation of body mass index should be
done for all patients with possible OSAHS who attend a sleep clinic. Many would
measure neck circumference, which was found to be increased (averaging 43 _+ 4.5
cm) in patients with OSAHS (Hoffstein & Szalai 1993). The upper airway should
also be examined to identify any structural abnormality that might cause upper
airway narrowing such as retrognathia, macroglossia and tonsillar hypertrophy. The
clinical assessment of the size of the upper airway was classified by Mallampati
(Mallampati et al. 1985) into four grades (Mallampati score) based on the visualizing
of the faucial pillars, soft plate and base of uvula:
Class 1: Entire tonsil clearly visible
Class 2: Upper half of tonsil fossa visible
Class 3: Soft and hard palate clearly visible
Class 4: only hard palate visible
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Class 1 Class 2 Class 3 Class 4
Figure 1.2 Classification of the Upper Airway after Mallampati (Mallampati 1983)
Obstructive sleep apnoea is associated with a higher Mallampati score (Hiremath et
al. 1998). Furthermore, the uvula should be assessed for size, length and height;
oedema and position. A low-lying palate and uvula are commonly seen in patients
with OSAHS. The nose should also be inspected for any previous fractures, polyps or
deviated septum as these may contribute to increased airway resistance and also for
mask fitting in case of CPAP use (Douglas 2002b).
1.9.3 Laboratory Assessment
Full-night polysomnography (figure 1.3) is indicated for patients suspected of having
sleep-related breathing disorders. Technically, polysomnography requires EEG,
EOG, chin EMG, airflow, arterial oximetry, respiratory effort, and ECG. Anterior
tibialis EMG is also useful to detect periodic leg movement, which might cause
sleepiness.
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Figure 1.3 Example of full polysomnography
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A limited sleep study, which is usually done at home, entails assessing some or all of
respiratory movement, airflow, desaturation by means of oximetry, and heart rate
without neurophysiological recording. There are several systems available and
practice in this field is changing very rapidly (Douglas 2002a). Limited studies are
usually done in the patient's home, to save sleep lab space and costs. Patients usually
apply the sensors by themselves after instruction from sleep technicians. Some
respiratory events occurring during wakefulness will be scored. However, limited
sleeps studies are cost-effective and do not affect subsequent CPAP use (Whittle et
al. 1997).
1.10 Treatment of OSAHS
1.10.1 General Measures
Overweight patients should be asked to lose weight, as weight reduction improves
OSAHS (Smith et al. 1985). Unfortunately, sustained weight loss is rarely achieved
by dieting alone (Pillar, Peled, & Lavie 1994). Weight reduction can be achieved by
dietary advice or surgery such as jejeuno-ilial bypass surgery, gastric banding or
gastroplasty. There are studies that have been conducted on the effects of surgical
weight loss on OSAHS in which significant changes in AHI, nocturnal Sa02 and
sleep integrity have been seen following surgery (Dhabuwala, Cannan, & Stubbs
2000;Pillar, Peled, & Lavie 1994;Strobel & Rosen 1996). However, these studies
lack adequate long-term assessment as well as control studies. Patients should also be
advised to avoid alcohol in the evening, and not to use sleeping tablets or sedatives,




Different agents have been tried as a treatment option for OSAHS; unfortunately,
however, there is no good evidence of benefit from any drug therapy.
Sex hormones. Progesterones are known to increase ventilatory drive and it has been
suggested that medroxyprogesterone could allow better matching of diaphragmatic
and upper airway tones (St John et al. 1986). Nevertheless, medroxyprogesterone had
no positive effect on male patients with OSAHS in a well-designed double-blind,
crossover trial (Cook, Benich, & Wooten 1989).
Acetazolamide inhibits carbonic anhydrase, producing a metabolic acidosis and an
increase in respiratory drive. In a randomized, controlled trial, acetazolamide reduced
the AHI by approximately half in 10 OSAHS patients, yet it did not improve arousal
frequency or daytime somnolence (Whyte et al. 1988). Many patients developed
adverse effects, causing withdrawal.
Serotonin agonists might be able, in theory, to increase upper airway dilating
muscle tone. It has been shown that fluoxetine was more effective than protriptyline
in reducing AHI, though with no reduction in daytime somnolence (Hanzel, Proia, &
Hudgel 1991). However, there are no well-designed placebo-controlled studies to
support its efficacy.
Physostigmine (PHYS) is an inhibitor of acetylcholinesterase activity. PHYS has a
central effect with the induction of REM sleep by shortening the time of REM sleep
onset and increasing the relative amount of REM sleep (Gillin et al. 1978). A
randomized controlled study found that PHYS might reduce AHI in patients with
moderate to severe OSAHS predominantly during REM sleep. However, the
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reduction in AHI was only 21.3% and the average increase in Sao2 was 8.7%
(Hedner et al. 2003).
Modafinil is a recently developed wakefulness-promoting, drug. Modafinil is
chemically unrelated to amphetamines and it acts on specific areas in the anterior
hypothalamus. This drug reduces persistent sleepiness in OSAHS patients complying
with CPAP therapy and it is licensed in the UK for this purpose (Pack et al. 2001).
However, its efficacy is limited and cost considerable. A randomized, double-blind,
placebo-controlled study showed that Modafinil had no effect on sleepiness as
measured by the ESS or the multiple sleep latency test compared with placebo in 30
OSAHS patients receiving effective CPAP therapy but still sleepy. However, a
significant improvement in alertness was found using the maintenance of
wakefulness test (p < 0.02) (Kingshott et al. 2001). CPAP use was significantly
reduced by Modafinil compared with placebo (p = 0.03) (Kingshott et al. 2001).
Nevertheless, Modafinil can be used as adjunct therapy for residual daytime
sleepiness in sleep apnoea patients receiving CPAP therapy (Schwartz et al. 2003).
Other drugs have been tried without promising results or in inadequately controlled
studies. These include theophylline, opioid antagonists, nicotine, antihypertensive
agents, and clonidine; and currently they are not considered as a realistic treatment
options for OSAHS.
1.10.1.2 Continuous Positive Airway Pressure (CPAP) therapy
CPAP was first described as a treatment for OSAHS in 1981 (Sullivan et al. 1981). It
is delivered via a well-fitted mask applied to the nose or nose and mouth. The mask
is attached to a machine that generates continuous pressurized air adjusted for the
individual patient. CPAP acts as a pneumatic splint preventing the airway from
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collapsing during sleep, thus reducing the apnoeas or hypopnoeas and subsequently
improving sleep structure. In randomized placebo-controlled studies, CPAP has been
shown to reduce sleepiness, improve quality of life (Douglas 1998c;Engleman et al.
1999d;Jenkinson et al. 1999), cognitive functions, mood disturbance (Douglas
1998a;Engleman et al. 1997a), driving performance (Krieger et al. 1997) and blood
pressure (Faccenda et al. 2001a). These data apply to symptomatic patients with AHI
more than 15. For symptomatic patients with AHI between 5 to 15 the benefit is not
clear. Although CPAP may produce symptomatic improvement in this group there
are only small improvements in cognitive function (Engleman et al. 1999e). In
addition, mild sleep apnoea patients (AHI < 15 and ESS <11) tend to use CPAP
relatively poorly with only 50% continuing to use it after 3 years (McArdle et al.
1999b) compared with > 90% in patients with severe OSAHS (AHI > 30 and ESS >
15) . Nevertheless, CPAP use must be monitored objectively in all OSAHS patients,
for patients tend to overestimate their use. The average CPAP run time in patient
groups tends to be approximately three to four hours a night, although it may go up
to five hours or more for regular CPAP clinic attendees (Engleman et al.
1997b;McArdle et al. 1999a). It is very important that patients receive adequate
education, preferably along with their partners, about the rationale for CPAP and the
need for long-term treatment. Optimal mask fitting with the most comfortable one is
crucial prior to starting CPAP therapy, since the treatment is fairly obtrusive and
these measures might improve CPAP usage and outcomes (Hoy et al. 1999).
The main side-effects of CPAP are nasal drying, stuffiness and rhinitis, which occur
in about 60% of CPAP users (Engleman et al. 1996a). These symptoms are mainly
due to mouth leaks causing high flows of cool air through the nose that can be
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reduced by chin straps, changing to a full facemask or by using heated humidifiers
(Massie et al. 1999;Richards et al. 1996). In addition, mask discomfort is a common
complaint that can be managed with good fit and by avoiding excessive tightening of
the straps. Abdominal bloating may also occur also, although it is rarely troublesome.
1.10.1.3 Mandibular Repositioning Splints (MRS)
Mandibular repositioning splints are designed to keep the lower jaw protruding
during sleep, thus preventing the tongue falling back and narrowing the throat.
Randomized placebo-controlled trials have shown that MRS use can decrease
snoring (Stradling et al. 1998), apnoeas and hypopnoeas and improve symptoms in
patients with mild OSAHS (Ferguson et al. 1996;Gotsopoulos et al. 2002;Mehta et
al. 2001) and can also reduce blood pressure in OSAHS over 4 weeks of therapy
(Gotsopoulos, Kelly, & Cistulli 2004). Nevertheless, it is less effective than CPAP in
the same patients (Barnes et al. 2004;Engleman et al. 2002). The main side-effects of
MRS include excessive salivation, mouth discomfort, crown displacement and
temporo-mandibular joint discomfort (Pantin, Hillman, & Tenant 1999). MRS is less
effective than 60% after 3 years. Reasons for stopping use include side-effects, social
circumstances, dental treatment, as well as lack of perceived efficacy (Izci et al.
2005;McGown et al. 2001). At present, MRS devices are considered a good second
line of treatment for patients with mild to moderate OSAHS who will not tolerate
CPAP.
1.10.1.4 Pacing
There are attempts to pace the upper airway muscles as a form of treatment in
OSAHS, such as pacing the tongue when upper airway obstruction occurs during
sleep (Eisele et al. 1997). Because of the technical challenges of the pacing and lack
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The most common surgical operation used in OSAHS is uvulopalato-pharyngoplasty
(U3P). The aim of the procedure is to widen the retropalatal airway by removing the
uvula and part of the soft palate combined with tensing the lateral pharyngeal walls.
This procedure can be done using different techniques, including scalpel cut, laser
(LAUP) or diathermy. U3P may improve symptoms and breathing pattern (Li et al.
2003;Sher, Schechtman, & Piccirillo 1996), although none of these studies had
adequate control groups and none was randomized. In addition, U3P is an invasive
procedure and causes complications such as bleeding, stenosis, voice change, and
velopharyngeal insufficiency that can make CPAP therapy difficult afterwards.
Death has also occasionally been reported (Sher, Schechtman, & Piccirillo 1996).
There are now attempts to improve the outcome of the procedure, such as using 3-
dimensional computed tomography (3-D CT) measurements in evaluating the
retropalatal space (Li et al. 2003) and also using modified (U3P) with extended
uvulopalatal flap with more promising results (Li et al. 2003;Li et al. 2005).
However, U3P results in decreased CPAP use by increasing mouth leak and reducing
the maximal level of pressure that can be tolerated (Mortimore et al. 1996) which is a
significant problem.
1.10.2.3 Other Upper Airway Surgery
1. Mandibular Maxillary Osteotomy (MMO)
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MMO is a form of advancement of the mandible and maxilla by cutting both
at an angle and rejoining them after sliding them forward (Hochban,
Brandenburg, & Peter 1994). It is major surgery and performed by a maxillo¬
facial surgeon. It has been shown in a controlled trial that MMO is as
effective as CPAP in normalizing the breathing pattern overnight and
improving both symptoms and daytime vigilance (Conradt et al. 1998).
However, there is as yet no clear indication about of when MMO should be
performed, although, in general, this procedure should be considered for non-
obese young patients and for patients with severe OSAHS who decline CPAP
therapy.
2. Other surgical procedures
There are other surgical procedures that can be employed in the management
of OSAHS, such as debulking the base of the tongue, using laser mid-line
glossectomy (Woodson & Fujita 1992), and advancing the insertion of the
tongue by advancing the genial tubercle of the mandible (Riley, Powell, &
Guilleminault 1994). These procedures are claimed to be effective in treating
OSAHS although further data are needed.
1.11 Conclusion
OSAHS is a multi-factorial disorder with many implications, which may require
more research work to understand its risk factors, pathogenesis, and association. It is
very important to diagnose OSAHS, since treatment can improve the quality of life
and prevent further complications. Although CPAP is the treatment of choice at
present, other treatments can also be used, such as adjuvant drug therapy or, as an
alternative, the surgical operations or using the MRS.
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Chapter 2
Sleep Disorder Breathing and Hypertension
2.1 Introduction
When this work was started, there was an evidence that patients with sleep apnoea
might be at increased risk of cardiovascular disease. Patients with sleep apnoea are
often hypertensive (Davies et al. 2000;Pedulla et al. 1995) and up to one-third of
hypertensive patients may have sleep apnoea (Berger, Somers, & Philips 2001).
Several cross-sectional studies have shown that the prevalence of hypertension
increases progressively with the severity of OSAHS (Lavie, Herer, & Hoffstein
2000;Nieto et al. 2000;Peppard et al. 2000). How hypertension is associated with
OSAHS is not fully understood. However, repetitive episodes of airway occlusion
during sleep, with consequent hypoxia, hypercapnia, dramatic changes in
intrathoracic pressure and repeated arousals, may provoke a number of autonomic,
haemodynamic, humoral and neuroendocrine responses. In this chapter, I will focus
mainly on the autonomic responses and, in particular, the baroreflex changes that
might occur in OSAHS patients. Other aspects of the possible vasculopathy in
OSAHS will also be briefly reviewed.
2.2 Epidemiology
OSAHS and hypertension are associated. OSAHS and hypertension have common
risk factors, such as obesity, alcohol intake, age, gender or exercise, which makes
causation impossible to prove, using epidemiology alone.
2.2.1 In the General Population
Early studies of the association between hypertension and snoring came from Norton
et al. and Koskenvuo et al., who found that snoring was a risk factor for hypertension
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(Koskenvuo et al. 1987;Norton & Dunn 1985a). Sleep apnoea was an independent
risk factor for the development of hypertension, similar to that of age and obesity
(Carlson et al. 1994). A large epidemiological study showed that sleep apnoea
significantly contributed to hypertension, independent of other risk factors (Lavie,
Herer, & Hoffstein 2000). Each apnoeic event per hour of sleep added 1% to the risk
of having hypertension. More evidence linking OSAHS with hypertension is
provided by the Wisconsin Sleep Cohort study, which showed a dose-response
association between OSAHS and de novo hypertension after 4 years of follow-up,
independent of confounding factors, although the number of new hypertensive
subjects was small (Peppard et al. 2000). In the original report, patients with an AHI
> 25 had a fivefold risk of hypertension (Hla et al. 1994). The increase in risk of
hypertension was greater in thinner patients who had abnormal breathing. After
correction for confounding factors, those with an AHI > 15 had a 2.9-fold greater
chance of developing hypertension in the following four years. A similar relationship
between OSAHS and hypertension was found in the Sleep Heart Health Study (Nieto
et al. 2000). In this study of 6,000 middle-aged and older adults, the prevalence of
hypertension (defined as a resting BP > 140/90 mmHg or the use of anti-hypertensive
drugs) increased progressively with the severity of OSAH. After adjusting for the
confounding factors, including obesity, the odds ratio in the group with severe
OSAHS (AHI > 30) was 1.37 compared with those with lowest AHI (< 1.5). A cross-
sectional study in a normal population by Bixler et al. also indicated an association
between hypertension and sleep apnoea independent of other risk factors. The
association was strongest in young subjects, and decreased with age (Bixler et al.
2000).
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2.2.2 In the Hypertensive Population
Epidemiological studies of hypertensive patients have also suggested an association
between sleep apnoea and hypertension. Hypertensive patients had a greater
prevalence of sleep apnoea than normotensive subjects (Worsnop et al. 1998). Grote
et al. found that OSAHS was a risk factor for poor blood pressure control in younger
hypertensive patients (Grote, Hedner, & Peter 2000). A greater prevalence of
obstructive sleep apnoea is found in adults with drug-resistant hypertension (BP >
140/90 who require a combination of three or more antihypertensive drugs) (Logan




In dogs, obstructive sleep apnoea leads to the development of sustained hypertension
(Brooks et al. 1997). Obstructive sleep apnoea (OSA) was produced in four dogs
using an occlusion valve attached to an endotracheal tube through which the dog
could breathe. Obstruction of the airway by the valve was controlled by telemetry of
ECG and EMG signals from the dog during a one- to three-month period. In the
same dogs, sleep fragmentation was also induced. Arterial blood pressure was
monitored for 12 hours every night. OSA caused a progressive increase in night-time
mean arterial BP in each of the four dogs. There was no difference between the
change in night-time BP caused by sleep fragmentation and that caused by OSA (p =
0.4). In contrast, the change in daytime BP caused by sleep fragmentation was
significantly less than the change during OSA (P = 0.001). There were no changes in
night-time or daytime heart rates during either OSA or sleep fragmentation. In
32
another dog study of chronic OSA by Parker et al. acute airway occlusion during
sleep increased LV afterload and decreased fractional shortening. Chronic OSA
caused a sustained decrease in LV systolic performance, caused either by systemic
hypertension and/or transient increases in LV afterload during episodes of airway
obstruction (Parker et al. 1999).
2-Human study
A case-control study found that patients with OSAHS had higher blood pressure than
matched control subjects. Diastolic blood pressure in patients with OSAHS was
significantly greater than controls during the daytime, night-time, and overall.
OSAHS patients also had significantly greater night-time systolic BP (p = 0.01),
although daytime and overall systolic blood pressure did not differ from control
subjects (Davies et al. 2000). Direct evidence that OSAHS causes hypertension is
provided by intervention studies, in which CPAP reduced BP (Faccenda et al. 2001c)
(see below).
2.3 OSAHS and Blood Pressure
In healthy subjects, blood pressure normally decreases by 10% to 15% from its
daytime value during sleep. This circadian drop in BP has been called dipping.
However, some patients with OSAHS do not show nocturnal dipping of BP and are
thus called nondippers (Pedulla et al. 1995). This may relate to apnoeas and
hypopnoeas, which cause repeated nocturnal increases in BP, which consequently
increase the mean sleeping BP (Pinto et al. 1993). The greatest pressure peaks occur
after apnoea and may be 100 mmHg above the baseline value (Narkiewicz & Somers
1997;Somers et al. 1995). These acute nocturnal changes may lead to persistent
daytime hypertension as a long-term consequence (Somers et al. 1995) with an
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increased risk of target organ damage (Palatini et al. 1992). In a case-control study,
sleep apnoea patients had significantly increased mean diastolic BP during both the
daytime and night-time, and systolic BP was higher among OSAHS patients at night
compared with controls. The nocturnal dip in BP was smaller in patients with OSAH
than in matched control subjects (Davies et al. 2000).
Hypoxia may explain partly these variations in BP in sleep apnoea patients. In
animals, repetitive episodic hypoxia causes diurnal elevation in BP in rats (Fletcher
et al. 1992). Similarly rises in daytime blood pressure follow induced apnoeas in
dogs and are probably related to hypoxaemia rather than arousal, because noise-
induced arousal does not cause daytime hypertension in the same dogs (Brooks et al.
1997). Increased sympathetic activation, perhaps induced by hypoxaemia, may be a
key factor in causing long-term BP changes (Lesske et al. 1997). However, other
factors may be implicated in the development of hypertension in OSAHS patients,
such as endothelial dysfunction, as discussed below.
2.4 Sympathetic Nervous System (SNS) in Hypertension
The sympathetic nervous system (SNS) has an integral role in the control of BP.
Increased sympathetic activity can increase blood pressure through a variety of
physiological and adaptive mechanisms. These include (1) increased vascular
resistance caused by the release of noradrenalin in different vascular beds; (2)
increased cardiac output; and (3) sodium and water retention by the activation of the
renin-angiotensin system (Abboud 1982). The development of hypertension is partly
due to abnormal renal excretory function, which is partly under the control of renal
sympathetic nerve activity (RSNA). The renal effects of increased RSNA include
increased renal tubular sodium reabsorption leading to renal sodium retention;
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decreased renal blood flow and glomerular filtration rate with renal vasoconstriction
and increased renal vascular resistance, and release of renin leading to the production
of angiotensin II (Abboud 1982). Young human subjects with borderline
hypertension have increased noradrenalin spillover from the kidney, which is an
index of RSNA (Esler et al. 2001). Single-fibre RSNA is significantly greater in
spontaneously hypertensive rats, than in normotensive Wistar-Kyoto rats (Thoren &
Ricksten 1979). RSNA is affected by the arterial baroreflex, which may cause the
immediate and sustained increase of arterial pressure. This is supported by studies of
chronic unloading of the carotid baroreceptors in mongrel dogs. Ligation of the
common carotid artery was used to cause baroreceptor unloading (Thrasher 2002).
This procedure caused an immediate and sustained increase in main arterial pressure,
an increase in heart rate and plasma renin activity, and a decrease in urinary sodium
excretion, reflecting sustained increases in sympathetic nerve activity to the heart and
kidneys (Thrasher 2003). Thus, progressive dysfunction of the arterial baroreflex
during the development of hypertension may contribute to the sustained increase in
activity of the sympathetic nervous system (including RSNA), and consequently
arterial pressure.
2.5 Sympathetic Activity in OSAHS Patients
2.5.1 During Sleep
In normal sleep, heart rate, blood pressure, and sympathetic nerve traffic usually
decrease (Somers et al. 1993). This reduction of sympathetic activity appears to
increase progressively from stage 1 to stage 4 sleep (Narkiewicz & Somers 1997).
However, during REM sleep, sympathetic activity increases, to as much as double
that of wakefulness (Somers et al. 1993). Blood pressure and heart rate during REM
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are variable, but average about the same as during wakefulness (Narkiewicz &
Somers 1997).
In contrast, sympathetic activity is increased during "sleep" in OSAHS patients and
the sympathetic and the haemodynamic state during "sleep" is determined primarily
by the duration and severity of apnoea rather than by the sleep stage itself (Somers et
al. 1995). Repetitive episodes of obstructive apnoea, hypoxia and hypercapnia
probably act through chemoreceptor reflexes and other mechanisms to increase
sympathetic drive (Morgan et al. 1995a). Resumption of breathing results in
increased venous return and increased cardiac output. This increased cardiac output
is delivered into a severely constricted peripheral vasculature, with surges in BP (see
above).
2.5.1.1 Effects of Arousal from Sleep on BP
Normal spontaneous arousals from sleep are associated with transient increases in
blood pressure, heart rate and ventilation (Horner 1996). These increases are caused
by changes in sympathetic activity caused by the arousal. In a study in dogs
(Schneider et al. 2000), ventricular stroke volume (SV) remained constant when
apnoea ended, if there was no arousal. However, with arousal from apnoeas, heart
rate and cardiac output increased, although SV decreased. Arousal increased the
systemic but not the pulmonary arterial pressure in response to obstructive apnoea.
The increase in systemic blood pressure was more marked during NREM sleep than
in REM sleep (Schneider et al. 2000). In a large population-based study, sleep
fragmentation index (SFI; calculated as the total number of awakenings/shifts to
stage 1 divided by the total sleep time per hour) was significantly associated with
systolic but not diastolic blood pressure during wakefulness in individuals with AHI
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< 1. However, sleep fragmentation and blood pressure were not associated in those
with AHI > 1 after controlling for the influence of the AHI. The author concluded
that sleep fragmentation was independently associated with a greater wakefulness
systolic blood pressure during wakefulness (Morrell et al. 2000). Noda et al. (Noda,
Yasuma, & Yokota 2000) found that end-apnoeic arousal and hypoxic asphyxia and
the subsequent sleep fragmentation might contribute to nocturnal and diurnal
elevation of BP. The rise in blood pressure with arousal might be caused by increase
in sympathetic activity. Sympathetic outflow remained elevated for a substantial
period even after a hypoxic stimulus was removed (Morgan et al. 1995b).
Nevertheless, it is unwise to conclude that sleep arousal is the sole contributor to
sustained hypertension in awake sleep apnoea patients. However, in patients with
higher AHI, sleep disruption may modulate the BP along with other effects such as
hypoxaemia and changes in intrathoracic pressure, which may overcome the effects
of arousal (Morrell et al. 2000).
2.5.2 During Wakefulness
Greater sympathetic activity in OSAHS patients may be present even during daytime
wakefulness, when subjects are breathing normally and both arterial oxygen and
carbon dioxide levels are normal (Hedner et al. 1988;Somers et al. 1995). Circulating
catecholamines (Marrone et al. 1993) and muscle sympathetic nerve activity
(Narkiewicz et al. 1998a) were greater in patients with OSAHS compared with
normal subjects, probably because of baroreflex dysfunction, chemoreflex excitation,
and endothelial dysfunction (see below). Greater sympathetic drive in these patients
may contribute, to a certain extent, to chronic elevated resting BP. The mechanism
underlying the sustained increase in sympathetic drive is not clear. Morgan et al.
37
suggested that combined hypoxia and hypercapnia evoke long-lasting sympathetic
activation (Morgan et al. 1995a). This may explain in part the increased daytime
sympathetic drive in OSAHS patients. However, repeated BP increases, acting via
the baroreceptors, may reset the baroreflex, permitting a higher level of sympathetic
activity and BP even during wakefulness. To understand the role of the
chemoreflexes and baroreflexes in BP control in OSAHS patients, I will discuss
these two aspects in detail below.
2.5.3 Chemoreflexes
The chemoreflexes are important and powerful modulators of sympathetic activation.
Hypoxia, which acts primarily on the peripheral chemoreceptors located in the
carotid bodies (Daly, Angell-James, & Eisner 1979), and hypercapnia, acting on the
central chemoreceptors located in the brain stem, trigger reflex increases in minute
ventilation as well as sympathetic activity. Patients with OSAHS have an enhanced
vascular response to hypoxia (Narkiewicz et al. 1998c). In a double-blind,
randomized, vehicle-controlled trial, it was found that MSNA and mean arterial
pressure were significantly reduced in OSAHS patients compared with control
subjects during chemoreflex deactivation by 100% oxygen (Narkiewicz et al. 1998c).
However, the enhancement of peripheral chemoreflexes are selective with
autonomic, haemodynamic and ventilatory responses in normotensive OSAHS
(Narkiewicz et al. 1999c). Furthermore, this enhancement of the reflex response to
hypoxia is not explained by obesity, since obese subjects who are otherwise healthy
with no OSAHS have chemoreflex responses similar to those seen in control subjects
(Narkiewicz et al. 1999a;Narkiewicz et al. 1999c). Nevertheless, obese patients had a
greater response to hypercapnia (Narkiewicz et al. 1999a). Both hypoxia and
38
hypercapnia have local vascular effects, causing vasodilation, which lowers the
blood pressure initially, which in turn increases sympathetic activity (3) and
catecholamine release (Shepard, Jr. 1990). During apnoea, sympathetic activity rises
gradually, reaching its peak at the end of the apnoea, when oxygen desaturation and
carbon dioxide retention are most marked (Somers et al. 1995). On release of the
airway obstruction and resumption of breathing, increased cardiac output, together
with the constricted peripheral vasculature, result in a marked increase in blood
pressure (Somers et al. 1993). There is also a carry-over effect to the tonic activation
of the peripheral chemoreceptors, even during normoxia, which may partly explain
the increased sympathetic activity during the daytime (see above).However a double-
blind study suggested that hyperoxia can suppress peripheral chemoreceptors in
OSAHS patients, shown by a decrease in blood pressure and slowing of heart rate
(Narkiewicz et al. 1998c).
2.6 Baroreflex Physiology
2.6.1 Arterial Baroreflex
The baroreceptor heart rate reflex, or baroreflex, is the fastest blood pressure
buffering mechanism (Guyton & Hall 2000). The arterial baroreflex seeks to regulate
the absolute blood pressure and to maintain the circulation to the brain and other
organs. Baroreceptors sense systemic blood pressure indirectly, by the stretch of
receptors in the walls of the carotid arteries and the aorta. A rise in blood pressure
elicits reflex parasympathetic activation and sympathetic inhibition with subsequent
decrease in heart rate (HR), cardiac contractility, vascular resistance, and venous
return. Conversely, a decrease in arterial pressure reduces baroreceptor afferent
discharge and triggers sympathetic stimulation with an increase in HR and peripheral
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vascular resistance, leading to an elevation of arterial pressure. In the following
section, I shall discuss briefly the basis of baroreflex regulation of arterial blood
pressure.
Mayer waves
Mayer waves are oscillations of arterial pressure occurring spontaneously in
conscious subjects at a frequency lower than respiration (0.1 Hz). These spontaneous
oscillations can be shown in experimental animals and humans, using spectral
analysis techniques. In one experiment on adult cats (Preiss & Polosa 1974), an
episode of Mayer waves was considered an oscillation of systemic arterial pressure
lasting for five minutes without attenuation. This oscillation is independent of and
slower than the rate of animal's respiratory centre activity. In addition, the arterial
pressure oscillation is associated with the simultaneous oscillation of sympathetic
neural activity. Preiss and Polosa found that Mayer waves were the result of the
activity of a central oscillator (Preiss & Polosa 1974). The Mayer waves persisted
even after systemic arterial pressure stabilization or decrease. However, some
authors consider that the baroreflex loop could be important in causing Mayer waves.
Arterial pressure oscillation is attenuated after surgical denervation of aortic and
carotid baroreceptors (Di Rienzo et al. 1991;Mancia et al. 1999). If the baroreflex
loop was interrupted in humans with the use of the alpha-adrenoreceptor antagonist;
phentolamine, Mayer waves and the oscillation of the sympathetic nervous system
were strongly depressed (van De et al. 2001). The amplitude of Mayer waves may
vary considerably within a particular individual over time (Janssen et al. 1997).
There appears to be a positive relationship between the amplitude of Mayer waves
and the strength of the corresponding sympathetic nervous system oscillations
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(Furlan et al. 2000), and these relationships have limited within-subject
reproducibility in the long term (Taylor et al. 1998), which may affect the
reproducibility of baroreflex measurements (see Chapter 8 on Reproducibility).
2.6.2 Cardiopulmonary Baroreflex
This baroreflex arc includes stretch fibres in the heart and lungs, which act as volume
sensors relaying information about the central blood volume to the brain stem, where
signals are integrated with those from arterial baroreflex to modulate sympathetic
outflow.
2.6.3 Physiological Influences on Baroreflex Function
1- Respiratory influence on baroreflex function
Respiration modulates cardiac autonomic regulation. Inspiration decreases and
expiration increases the cardiac vagal traffic caused by baroreflex activation.
Hyperventilation impairs the baroreflex influence of the heart rate (HR) and
sympathetic nerve traffic. Respiratory activity changes the membrane potentials of
preganglionic vagal and sympathetic motor neurons and continually modulates their
responsiveness to stimulatory inputs. This process is called respiratory gating and is
seen in the rhythmic fluctuation of R-R intervals (Ekberg 2003). This feature is
discussed in depth in Chapter 8 on Reproducibility.
2-Neurohumeral influences
Various hormones influence baroreflex function. Angiotensin IJ resets the baroreflex
function curve to a higher pressure independent of its effect on arterial pressure. In
contrast, vasopressin resets the baroreflex curve to a lower pressure. These actions
are mediated to some extent by the effect of these two circulating peptides on the
area postrema, a circumventricular region that lacks blood brain barrier and contains
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neurons that project to the vasomotor control centres (Guyton et al. 1972;Huang &
Leenen 1999).
3- Ageing
Ageing is associated with significant cardiovascular modifications, and arterial
baroreflex modulation of HR and sympathetic activity may decrease with advancing
age (Gribbin et al. 1971). Vascular compliance, which might decrease with age, may
decrease the baroreflex sensitivity (Gerritsen et al. 2000).
4-Physical Deconditioning
Orthostatic intolerance is the major cardiovascular effect of deconditioning after a
prolonged bed rest or microgravity in space flight, which might be caused by
autonomic dysfunction. Other factors such as hypovolaemia or vascular dysfunction
may also contribute to orthostatic intolerance (Moffitt et al. 1998). After head-down
bed rest for 14 days, baseline arterial baroreflex regulation of HR is reduced (Kamiya
et al. 2000b;Kamiya et al. 2000a).
5-Gender
There is a small difference between men and women in BRS. Huikuri et al. found
that middle-aged men have higher BRS values (10.5 ± 4.6 ms/mmHg) than middle-
aged women (8.0 ± 4.6 ms/mmHg) (Huikuri et al. 1996) and women receiving
hormonal replacement therapy (HRT) had higher BRS values that women without
HRT. However, younger women showed higher BRS during preovulation phase of
their menstrual cycle, compared with early follicular and midluteal phases but
similar to those of age- matched men (Tanaka et al. 2003), which could be attributed
to an effect of oestrogens (Liu, Kuo, & Yang 2003).
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2.6.4 Baroreflex and Hypertension
There is evidence that the cardiac baroreflex is impaired if blood pressure is
increased, in both humans (Floras et al. 1988;Siche et al. 1995) and animals
(Lantelme, Lo, & Sassard 1994). Floras et al. found that the arterial baroreflex could
buffer acute changes in blood pressure in subjects with WHO stage 1 hypertension.
However, this ability is weakened if the BRS is reduced. With the development of
clinically evident cardiac adaptation to hypertension (WHO stage 2), the contribution
of the arterial baroreflex to the regulation of blood pressure is no longer detectable
and the influence of cardiac and somatic afferents to reflex circulatory adjustment to
activity may predominate (Floras et al. 1988). Furthermore, Lantelme et al. found
that hypertensive rats have impaired cardiac baroreflex responses, characterized by a
range-independent decreased gain, which is not caused by cardiac hypertrophy
(Lantelme, Lo, & Sassard 1994). The impaired baroreflex may even precede the
development of hypertension. Baroreflex inhibition of muscle sympathetic nerve
activity is reduced in adolescents with a family history of hypertension, even when
they were normotensive, which may lead to the development of hypertension by
increasing sympathetic vasomotor tone (Yamada et al. 1988). This could also be a
factor in hypertension in OSAHS patients, although there is no evidence for this so
far.
2.6.4 Baroreflex in Sleep Apnoea
Patients with OSAHS have baroreflex dysfunction. Narkiewicz et al, used
phenylephrine to activate baroreceptors and nitroprusside to deactivate them.
Normotensive patients with OSAHS had an impaired response to baroreceptor
deactivation but not to baroreceptor activation. They suggested that the reduced
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baroreflex sympathetic modulation in patients with sleep apnoea was not
accompanied by any impairment of baroreflex control of heart rate (Narkiewicz et al.
1998b). In addition OSAH patients have impaired baroreflex responses to a
hypotensive stimulus (Carlson et al. 1996). Furthermore, it was found by using
sequence method analysis (Bonsignore et al. 2002;Tkacova et al. 2000), that
baroreflexes are impaired in OSAHS patients compared with healthy controls.
2.7 Effect of treating Sleep Apnoea on Sympathetic activity and BP
As discussed in Chapter 1, treating of sleep apnoea improves symptoms. In addition
to symptoms, CPAP treatment may also reduce sympathetic activity. Nasal CPAP
was found to reduce catecholamines (Jennum et al. 1989). Somers et al. found that
CPAP treatment caused an acute and marked reduction in nocturnal sympathetic
nerve traffic (Somers et al. 1995). However, CPAP does not reduce daytime blood
pressure acutely, although it significantly reduces the large oscillations in blood
pressure seen overnight in patients with untreated sleep apnoea (Ali et al. 1992).
Nevertheless, a small fall in night-time systolic BP was seen in OSAH patients after
2 weeks of treatment (Davies et al. 1994), with some improvement in daytime mean
arterial blood pressure in non-dippers after 3 weeks of CPAP treatment compared
with placebo (Engleman et al. 1996b). However, when effective CPAP treatment was
given for a longer period (8 weeks) in a before-and-after non-placebo controlled
design, there was a significant fall in both systolic and diastolic BP, independent of
changes in body weight (Wilcox et al. 1993). Thus, long-term treatment with CPAP
may be needed to attenuate sympathetic activation and consequently reduce BP. This
idea is supported by the findings that CPAP treatment reduced the muscle
sympathetic nerve activity (MSNA) in otherwise healthy OSAHS patients, although
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the reduction was evident only after one and a half years of treatment (Narkiewicz et
al. 1999b). Furthermore, in the only randomized placebo-controlled crossover study
published before the work on this thesis started, Faccenda et al. found that CPAP
therapy reduced 24-hour diastolic blood pressure in comparison with the placebo,
although the overall reduction was small, averaging 1.5 mmHg over the 24 hours.
The decrease was greater during the early morning period, that is, 2:00 a.m. As
predicted a priori, the decrease was greater in those with more nocturnal hypoxaemia
(> 20% desaturations/hour) (Faccenda et al. 2001b).
2.8 Heart Rate Variability (HRV)
The beat of the healthy heart is not regular. It varies as a result of many factors,
including exercise and physical and mental stress. In addition, the intervals between
normal sinus beats vary periodically because of respiration, blood pressure regulation
(see above), thermoregulation, actions of the renin-angiotensin system, and circadian
rhythms (Stein et al. 1994). HRV can be measured by a non-invasive method of
power spectral density (PSD) analysis. PSD describes how the energy (or variance)
of a signal or a time series is distributed with frequency. There are two ways to
measure the HRV, the time domain and the frequency domain.
Time domain indices use analysis of interbeat intervals or a comparison of the
lengths of adjacent cycles, in relation to time. Such indices include the standard
deviation of all normal R-R intervals and the standard deviation of the mean of the 5-
minute intervals, averaged over a 24-hour period. A geometric approach to
quantifying inter-beat interval-based HRV entails measuring the baseline width (in
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Figure 2.1 Time domain of the heart rate variability. Normal R-R intervals are all
intervals between adjacent QRS complexes resulting from sinus node
depolarization.
Adapted from "Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology", Circulation (1996),93:1043-
1065).
This method has the advantage of being less dependent on the accurate classification
of individual beats. The second class of time domain variables is based on
comparisons of lengths of the adjacent cycles, including the proportion of the
adjacent cycles that are > 50 msec apart, measured as a percentage, and the root
mean square successive differences. These variables are virtually independent of
long-term trends and predominantly reflect vagal tone.
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The frequency domain gives information about the amount of overall variance in
heart rate resulting from periodic oscillations of heart rate at various frequencies.
REST TILT
Figure 2.2 Frequency domain of the heart rate variability in two different positions,
adapted from "Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology", Circulation (1996),93:1043-
1065).
The variance of the heart rate is referred to as 'power' in a portion of the total
spectrum and is measured in milliseconds squared. The power spectrum has been
classified into three bands: high frequency power (HF), which is parasympathetically
mediated and represents mainly the respiratory variation; low frequency power (LF),
which is modulated by both the sympathetic and parasympathetic nervous systems
and strongly affected by the oscillatory rhythm of the baroreceptors (Bigger et al.
47
1992;Yu & Lumbers 2000); and very low frequency power (VLF), which may
represent the influence of the thermoregulation, peripheral vasomotor, or renin-
angiotensin systems. The total power (TP) is the sum of all these three frequencies
(see above).
Time and frequency domain measures of HRV are closely related, since for every
frequency domain measure, there is a time domain measure that is strongly correlated
with it. Indices of HRV have been shown to be stable, at least over a 30- to 65-day
interval, and there is no placebo effect on HRV (Kleiger et al. 1991).Thus, the
measurement of HRV is an excellent tool for studying autonomic input to the heart (
1996a)
2.9 OSAHS and Endothelial Function
2.9.1 Introduction
The endothelium is the cell layer lining the blood vessels. It is one cell thick and
senses changes in haemodynamic states (Raitakari & Celermajer 2000). The
endothelium responds to physical and chemical stimuli by synthesis or release of
substances such as nitric oxide (NO), prostacyclin, endothelins, endothelial cell
growth factors, interleukins, adhesion molecules, and fibrinolytic factors (Jaffe
1987). It controls thrombosis and thrombolysis, platelet and leukocyte interactions
with the vessel wall, and regulation of vascular tone and growth that play a very
important role in cardiovascular control. The endothelium has anticoagulant,
antiplatelet, and fibrinolytic properties. Endothelial cells are the major sites for
anticoagulant reactions involving thrombin. Platelet adhesion to endothelial cells is
markedly inhibited by the endothelium-derived arachidonic acid metabolite,
prostacyclin. The same stimuli that activate platelets, such as thrombin, also act to
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release prostacyclin and tissue-type plasminogen activator (TPA) from the
endothelium, which allows the normal endothelium to limit the extent of platelet plug
formation. The endothelium also controls underlying smooth muscle tone in response
to certain substances. These substances include endothelium-derived relaxing factor
(EDRF), mediated by NO, acetylcholine, endothelin, and substance P (Jaffe
1987;Vanhoutte 1989).
2.9.2 Nitric Oxide (NO)
Nitric oxide is a gas with a half-life of several seconds in biological tissues. It is
synthesized from L-arginine by an enzyme, NO synthase (NOS) (Palmer, Ferrige, &
Moncada 1987). Three distinct isoforms of NOS have been identified. Two of these
are constitutively expressed: endothelial NOS (eNOS), and neuronal (nNOS). The
third iso-form is inducible NOS (iNOS) and is regulated by cytokine stimulation
(Nathan & Xie 1994). NO, a potent inorganic vasodilator, acts of blood vessels to
maintain a low vascular tone at rest in both the systemic and pulmonary circulation
(Faller 1999). It inhibits platelet aggregation and adhesion as well as smooth muscle
fibroblast mitogenesis (Garg & Hassid 1989). In addition, NO plays an important
role in vascular growth, leukocyte adhesion, immunological regulation, metabolism
of circulating amines, lipoprotein metabolism, and integration and transduction of
blood-borne signals (Riatakari & Celermajer 2000).
NO transmits its message by activation of soluble guanylyl cyclase, which then
produces cyclic GMP (cGMP). cGMP appears to be the second messenger
responsible for mediating vasorelaxation and antiplatelet functions (Nathan & Xie
1994). NO can also act directly on calcium-dependent potassium channels, causing
relaxation of smooth muscle. The vascular effect of NO is confined not only to the
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smooth muscle cell, but may also include promotion of endothelial cell proliferation,
protection of endothelial cells from apoptosis, and inhibition of adherence of
inflammatory cells (Furchgott & Zawadzki 1980). NO has been implicated in the
pathogenesis of many cardiovascular diseases, including atherosclerosis,
hypertension, intimal hyperplasia, and aneurysmal disease (Rubanyi 1993). This
section will examine mainly atherosclerosis and hypertension as the main focus of
this thesis.
2.9.2.1 Atherosclerosis and NO
Disturbed endothelial function may be important in cardiovascular disease.
Atherosclerosis results from excessive inflammatory and fibroproliferative responses
to vascular insults. The earliest change in the vessel wall is the formation of the fatty
streak and monocyte adhesion (Gerrity 1981). Patients with developing
atherosclerosis have reduced NO bioavailability in both the peripheral and coronary
vasculature (Rubanyi 1993). The importance of NO in atherogenesis was suggested
in mice deficient in apolipoprotein E (apo E), in which atherosclerotic lesions
developed spontaneously when eNOS was deleted (Barbato & Tzeng 2004;Bocksch
et al. 2001;Rubanyi 1993). Specific factors can alter the production of NO and
therefore influence the progression of atherosclerosis. BH4 is a necessary cofactor
for the proper functioning of all NO enzymes. When it is in short supply within the
cell, NOS uncouples and behaves as an NADPH oxidase, leading to the production
of superoxide rather than NO (Kitamoto et al. 2000). Hypercholesterolaemia and
hyperlipidaemia mediate endothelial dysfunction, in part by consuming NO and
forming reactive oxygen species and consequently contribute to the atherosclerotic
plaque formation (Ross 2004).
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2.9.2.2 The Role of Hypoxia in NO Production
Hypoxia has been associated with both the upregulation (Justice, Tanner, & Myers
2000;Resta et al. 1999) and downregulation (Quinlan et al. 2000) of eNOS
expression. It seems that NO regulation varies among vascular beds as well as
between species (Tai, Robb, & Marsden 2003). In vivo, hypoxia induces upregulation
of eNOS gene expression and consequently NO production (Hoffman, Gloe, & Pohl
2001;Thompson et al. 2000). In a study assessing the cell regulation of NO
production during hypoxia in porcine coronary microvessels and epicardial arteries,
hypoxia caused a time-dependent increase in eNOS protein when compared with
cells grown under conditions of normoxia. The NO production was markedly
increased after 30 minutes of exposure to low oxygen (Justice, Tanner, & Myers
2000). In contrast, other studies have shown that eNOS is downregulated by
prolonged hypoxia in human or bovine cultured endothelial cells (Phelan & Faller
1996). Faller et al. found that low oxygen tension (P02 = 20 - 40 mmHg) results in a
profound decrease in the transcript of eNOS, a corresponding fall in eNOS protein
levels, and co-ordinated impairment of production of NO in response to stimulators
of eNOS (Faller 1999). In another study, using rat pulmonary artery, both acute and
chronic hypoxia selectively attenuated pulmonary endothelial NO production (Shaul,
Wells, & Horning 1993). It is perhaps not surprising that endothelial cells from
various vascular beds should respond to hypoxia differently, depending on the
specific in vivo and in vitro milieus, as well as the chronicity and severity of the
hypoxic exposure (Tai, Robb, & Marsden 2003).
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2.9.2.3 NO and Hypertension (Endothelial dysfunction)
Endothelial dysfunction is a reversible change in endothelial cells, which may result
from impairment in NO availability. Thus, endothelial dysfunction is distinguished
from endothelial damage, which is represented by the anatomical disruption of the
endothelium. Inhibition of NO production produces hypertension in animals and
humans. In animal models, eNOS knockout mice developed mild to moderate
hypertension, with blood pressure levels 20 mmHg higher than in normal controls
(Huang et al. 1995). When normotensive mice were engineered to overexpress
eNOS, their mean BP levels were 18 mmHg lower than normal (Ohashi, Kawashima,
& Hirata 1998). In humans, blocking of eNOS by methylated arginine caused a
marked and dose-dependent elevation of BP, suggesting that production of NO is one
of the most important factors in BP regulation. Furthermore, endothelial dysfunction
associated with essential hypertension has been documented in peripheral and
coronary macro- and microcirculation and in renal circulation. The mechanism
responsible for this alteration appears to be the activation of an alternative pathway
involving cyclo-oxygenase, which reduces the NO availability through production of
oxidative stress (Katusic & Vanhoutte 1989;Taddei et al. 2001). The NO-system may
interact with other peptides such as endothelin-1 (see below) to regulate the vascular
tone (Schiffrin 1999a). NO inhibits the production and vasoconstrictor activity of
ET-1, which was found to be impaired in essential hypertension (Taddei et al. 1999).
2.9.2.4 NOS inhibitors
Nitric oxide synthase can be blocked by L-arginine analogues or the endogenous
competitive inhibitor, asymmetric dimethylarginine (ADMA) and by NOS
antagonists, such as N-nitro-L-arginine methylester (L-NAME) and NG-
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monomethyl-L-arginine (L-NMMA). It was found that these substances can inhibit
NO production and consequently endothelial cell proliferation (Babaei et al. 1998).
ADMA is a naturally occurring amino acid that circulates in plasma, is excreted in
urine, and is found in tissues and cells (Vallance et al. 1992a;Vallance et al. 1992b).
It has aroused interest because it inhibits nitric oxide synthase (NOS) and therefore
can cause considerable biological effects, particularly on the cardiovascular system.
Several recent studies have suggested that plasma concentrations of ADMA provide
a marker of risk for endothelial dysfunction and cardiovascular disease (Cooke
2000). ADMA inhibits all three isoforms of NOS and is approximately equipotent
with L-NMMA (MacAllister, Whitley, & Vallance 1994). It is a non-selective
inhibitor of NOS, causing elevation of blood pressure, vasoconstriction and impaired
endothelium-dependent relaxation, and increases endothelial cell adhesiveness
(Achan et al. 2003). Furthermore, there is evidence that basal NO is reduced in
hypertension and that the vasoconstrictor response to L-NMMA is reduced in
untreated hypertension (Calver et al. 1992). Recently, a study showed that OSAHS
may be associated with an elevated level of ADMA, which could be reversed by
CPAP therapy (Ohike et al. 2005).
2.9.3 Endothelin-1
Endothelins are 21-amino-acid peptides encoded by three genes, and produced by the
endothelium of blood vessels and also in many other tissues (Schiffrin
1999b;Schiffrin 2001). Endothelin-l(ET-l) is an endothelium-derived peptide with
powerful vasoconstrictor and mitogenic properties, which is a paracrine or autocrine
regulator of vascular tone (Schiffrin 2001;Yanagisawa et al. 1988). It has two
receptors, ETA and ETB, and acts on adjacent endothelial or smooth muscle cells.
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ET-1 has a short half-life, because it is rapidly cleared from the circulation, yet it has
a sustained effect on vascular tone. Physiological low oxygen tensions (P02 <
30mmHg) increase endothelin-1 secretion from cultured human endothelial cells
four- to eightfold above the secretion rate at ambient oxygen tension (Faller 1999). In
addition, hypoxia increases endothelin-1 transcript within 30 minutes of exposure
and persists for 48 hours, although this is reversible after re-exposure to normoxia
(Kourembanas et al. 1991). Increased levels of endothelin-1 have been demonstrated
in conditions associated with endothelial dysfunction, such as atherosclerosis,
hypercholesterolaemia (Haak et al. 1994), and cigarette smoking (Haak et al. 2004).
In human essential hypertension, circulating levels of ET-1 have been reported to be
elevated by some, but not all investigators. ET-1 is overexpressed in African-
American hypertensive patients compared with white Caucasian patients (Ergul et al.
1996). Schiffrin et al. have found enhanced expression of ET-1 gene in resistance
arteries in severe human essential hypertension (Schiffrin 1999b). Another study
found that salt-depleted, salt-sensitive hypertensive patients with blunted renin
responses had enhanced catecholamine-stimulated endothelin levels (Elijovich et al.
2001).
The role of ET-1 in the development of hypertension in OSAHS patients is not clear.
It has been suggested that ET-1 is not elevated in these patients (Grimpen et al.
2000), in contrast with earlier findings by Phillips et al. (Philips et al. 1999), who
found that sleep apnoea elicits increases in blood pressure and endothelin-1, with a
decrease in both after overnight CPAP treatment. However, it would be very difficult
to be certain about these findings since ET-1 is rapidly and locally degraded.
2.9.4 Tissue Plasminogen Activator (TPA)
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Tissue plasminogen activator (TPA) is a protein released by endothelial cells. It
activates the reaction where plasminogen is converted to plasmin. Plasmin is a potent
fibrinolytic enzyme that degrades all proteins. TPA regulates the fibrinolytic activity
of blood in balance with another protein called plasminogen activator inhibitor-1
(PAI-1). PAI-1 is also produced by endothelial cells and helps in the regulation of
fibrinolysis, serving as the primary inhibitor of TPA (Raitakari & Celermajer 2000).
PAI-1 could be enhanced by low oxygen tension in contrast to TPA, which is
decreased by hypoxia (Pinsky et al. 1998). This mechanism plays an important role
in the suppression of fibrinolysis. In prospective studies, high concentrations of TPA
antigen in apparently healthy men may be associated with an increased risk of
subsequent myocardial infarction and stroke (Ridker et al. 1994). So far, few studies
have found a relationship between sleep apnoea and fibrinolytic activity.
Nevertheless, Rangemark et al. found that PAI-1 was greater in OSAHS patients
compared with healthy controls. They concluded that low fibrinolytic activity may
represent a confounding pathophysiological mechanism behind the high incidence of
myocardial infarction and stroke in sleep apnoea patients (Rangemark et al. 1995).
2.10 Conclusion
Thus, when the present investigations were being designed, evidence was
accumulating that OSAHS was associated with hypertension. Some comparative data
also suggested that baroreceptor function might be abnormal in patients with
OSAHS, although no randomized placebo-controlled studies of the effect of the
treatment of OSAHS on baroreceptor or endothelial function had been conducted.
Thus, studies were designed to address these issues.
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Chapter 3
Methodology of Measurement in Baroreflex Study
3.1Introduction
The data reviewed in Chapter 2 show that OSAHS is associated with altered
baroreceptor (Tkacova et al. 2000). However, they are epidemiological or before-
and-after treatment studies which cannot exclude other reasons for the association.
To determine whether OSAHS caused altered baroreceptor and whether this was
reversed by effective treatment, we performed a randomized placebo controlled trial
of CPAP therapy on baroreceptor in patients with OSAHS.
3.2 Methods of Baroreflex Measurement
In humans when blood pressure increases, there is a linear relationship between the
systolic blood pressure of each cardiac cycle and the subsequent pulse interval
(Pickering et al. 1972).The assessment of this relationship assumes a positive
correlation between a stimulus and a response, in this case, a change in blood
pressure and a change in the pulse interval (PI). It therefore reflects the ability to
alter vagal activity in relation to the blood pressure in a reciprocal manner. BRS is
diminished in several diseases, most notably hypertension (see Chapter2).
The measure of an intact baroreflex is the degree of change in the heart rate or
sympathetic stimulation for a given unit change in blood pressure (Bertinieri et al.
1985a). It can be quantified as the response of the cardiovascular system to the
application of an external stimulus, mechanical or pharmacological (La Rovere et al.
1998) in standardized conditions. However, there is an alternative way of evaluating
baroreflex modulation, by identifying spontaneous episodes of consecutive beats in
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which progressive increases or decreases in systolic blood pressure (SBP) are
followed by concordant R-R interval (RRI) changes (Bertinieri et al. 1985a). These
sequences have been shown specifically to reflect the baroreflex activity, hence their
relationship is used as an index of the sensitivity of the cardiac baroreflex (Parati, Di
Rienzo, & Mancia 2000;Parlow et al. 1995).
These sequences, in physiological conditions, are often interspersed with SBP
changes that are not coupled with reflex changes in R-R modulation. A new index
has been proposed to quantify baroreflex activation in modulating HR, the baroreflex
effective index. The arterial baroreflex induces beat-to-beat changes in pulse interval
in response to only around 21% of all the ramps in blood pressure (Di Rienzo et al.
2001). Baroreflex effective index quantifies the number of times the baroreflex is
clearly effective in driving the sinus node, whereas baroreflex sensitivity quantifies
the power of the reflex when this drive is effective (Di Rienzo et al. 2001).
Baroreflex sensitivity can also be quantified by spectral analysis, which is expressed
by the gain of the transfer function relating changes in blood pressure to coherent
changes in the R-R interval. This approach is based on the coherent relationship
between the SBP and R-R interval, which oscillate in the same frequencies in the
power spectrum, controlled by the baroreflex. De Boer and colleagues indicated that
this frequency region lies between 0.04 and 0.35 Hz (de Boer, Karemaker, &
Strackee 1985b). This region is divided into very low frequency (VLF), low
frequency (LF) - which avoid the possible influence of respiration - or high
frequency (HF) region, which is more driven by respiration (de Boer, Karemaker, &
Strackee 1985a). In a simplified approach, BRS can be determined by power spectral
analysis of heart rate period (1/HR) and BP using Fast Fourier Transformation (FFT)
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and expressed as the square root of the total power of the pulse interval frequency
divided by the total Power of the BP frequency, which is known as the alpha
coefficient
BRS= V (power R-Interval/ power SBP).
A characteristic of the alpha approach is that it models the BP-RRI relationship by
assuming that all the RRI power in the considered frequency band is generated by the
baroreflex. For statistical reasons, it is accepted that this is correct if the SPB-PI
coherence in the frequency band considered for the estimate is > 0.5 (Pagani et al.
1988). These methods for computing baroreflex gain assume linearity of the
relationship between changes in blood pressure and R-R interval, which is defined as
the interval between adjacent normal QRS complexes resulting from sinus node
depolarization ( 1996b).
Respiration modulates the influence of the baroreflex on cardiac vagal motor
neurons: inspiration decreases and expiration enhances the cardiac vagal responses to
baroreflex activation (Eckberg & Orshan 1977). Hyperventilation impairs baroreflex
modulation of HR and sympathetic nerve traffic, and increased BP during
hyperventilation does not elicit any reduction in heart rate (Van De Borne et al.
2000). A change in the respiratory pattern might itself affect respiratory sinus




Consecutive patients who attended the Sleep Centre at Edinburgh Royal Infirmary
and who met the inclusion criteria were approached. Patients were contacted in
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person at the Centre, by telephone, or by writing to them, explaining the objectives of
the study and giving an information sheet. If the patient agreed, he or she was
randomized for treatment order, using a balanced block design, and a date sent for
the CPAP titration study.
Patients were told that the study was to compare two different potential treatments
for OSAHS, one was standard treatment, and the other was new. The standard
treatment was CPAP and the new treatment was treatment with capsules. They were
told that the capsules might affect upper airway tone and therefore reduce the number
of breathing pauses. Thus, the placebo was actively sold to our patients as a possible
active treatment. Patients were told that we wanted to look at the effects of both
treatments on their blood pressure in a crossover design. This design had the
approval of the Lothian Ethics of Medical Research Committee (See appendix 3).




1. AHI > 15 by full polysomnography or apnoea/hypopnoea per hour > 25 with
limited sleep study.
2. Epworth sleepiness scale >11
3. Aged between 18 and 75 years
Exclusion criteria
1. Living > 50 miles from the sleep centre
2. Taking any medication that affects blood pressure or might augment the
autonomic nervous system, including all anti-hypertensive drugs, cardiac
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(anti-anginal and heart failure) drugs, anti-depressant drugs, anti-psychotic
drugs, and steroids.
3. Any co-existing medical disorder that might affect blood pressure, for
example, diabetes.
4. Patients with cardiopulmonary diseases, for example, COPD, IHD, CHF or
severe asthma.
5. Driving Problems as a result of sleep apnoea (to avoid delaying effective
treatment).
All patients gave written informed consent to participate in the study, which was
approved by the Lothian Ethics of Medical Research Committee.
3.4 Screening
The main recruitment was by identifying patients at the Friday clinical case review
meeting of the department of sleep medicine and directly from the sleep clinic. The
screening process was performed by reviewing patients' case notes, referral letters
and the sleep questionnaires for patients and their bed partners followed by direct
questioning of patients about their past medical history. Chapter 4 gives details of the
screening results.
3.5 Desaturation index
From diagnostic polysomnography, the desaturation index (DI) was usually
calculated. Each PSG trace is reviewed manually and any parts with oxygen
saturation artefact edited out. DI was also calculated from the limited home sleep
study. The number of 4% oxygen desaturations is counted during the total sleep time
(wake periods were excluded). This total number was then divided by the total sleep
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time in minutes and multiplied by 60, giving the number of events per hour slept,
which is known as the desaturation index.
3.5.1 Measurement
Non-invasive technologies allow the continuous monitoring of oxygen saturation of
arterial blood (Sa02). Pulse oximeters use spectrophotoelectrical principles to
determine Sa02 from a two-wavelength light transmitter and receiver placed on
either side of the pulsating vascular bed. These devices are sensitive only to tissues
that pulsate. The sites of monitoring may include finger, ear and nose, which are all
recommended for measurement. In the sleep laboratory, the finger oximeter is mainly
used as part of a full polysomnography or limited home sleep study. The finger
should be kept straight, because significant bending of the digit can restrict the
ability of the devices to detect pulsatile flow, the absence of which precludes Sa02
determination.
3.5.2 Body Measurements
Body length measurements were made using a dressmaker's standard measuring
tape. The waist was measured at the umbilicus, the hips were measured at the level of
the iliac crests, and the neck was measured at the level of the crico-thyroid
membrane. Height was recorded from a fixed standard scale, to allow calculation of
body mass index (BMI = weight/height2 in kg/m2). Weight was measured using the
standard Sleep Centre scales (Seca, Germany), which are calibrated annually.
Measurements were recorded in centimetres (cm) and kilograms (kg) respectively.
Patients were weighed on each visit to ensure that there was no important change in
their weight during the study.
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3.5.3 Ambulatory Blood Pressure Monitoring (ABPM)
ABPM was performed using a lightweight microprocessor, which is carried on a belt
or shoulder strap, connecting to the arm cuff via a rubber hose (Ultralite ABPM,
90217, Space Labs Medical Ltd). The ABP monitor measures 2.8 x 11.4 x 8.6 cm
and weighs 347g. It has a four-digit liquid crystal display on the front panel, a
manual start/stop button, and attachment for the BP cuff. The rear panel contains a
serial communications port and the on/off switch. The data can be transferred to a
personal computer via a PC interface for formal analysis. The monitors are carried in
pouches, which are worn with either a belt or a shoulder strap. The monitors can be
programmed to carry out various functions such as displaying cuff pressure at each
bleed step, and displaying systolic, diastolic, mean arterial pressure and heart rate at
the end of each cuff deflation. They continue to bleed to 40 mmHg rather than
stopping at the diastolic value. Although they can bleep before and after each
recording is taken, the bleep was disabled during this study. The machine takes
Korotkoff sound one for the systolic and five for the diastolic pressure. The monitor
bleeds air in discrete steps (approx. 4 mmHg), and uses the oscillometric method of
BP determination. The monitor measurement ranges are heart rate 40-180 beats per
minute; systolic BP 70-280 mmHg; diastolic BP 40-200 mmHg; and mean arterial
BP 60-240 mmHg. The microprocessor can be programmed to take recordings at
intervals of 6 to 120 minutes. In this study, the monitor was programmed to record at
intervals of 30 minutes for 48 hours, day and night. It takes approximately 30-50
seconds to make a recording. After any failed attempt, the monitor is programmed to
try a further recording one minute later. The cuff pressure inflates to 170 mmHg
initially, then to 30 mmHg above the previous systolic recording. The
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microprocessor is programmed to distinguish between pressure signals, patient
movement and respiratory artefact. The pressure transducer channel automatically
zeros before taking a recording. The cuff is inflated with an automatic pump, and the
bleed rate is also controlled via the microprocessor. The device contains a real-time
clock, which is recalibrated with each monitor initialization. The monitor is
initialized before being fitted to each patient. This ensures that the time clock is
correct and allows the patient's identification data to be stored with the collected
data. The microprocessor auto-edits aberrant results. For safety, the measurement
cycle is limited to 180 seconds, and the absolute maximum pressure of the cuff is
310 mmHg.
The patient was fitted with a cuff of appropriate size to the non-dominant upper arm
with appropriate instructions on how to readjust the cuff when necessary. Patients
were asked to continue their normal daily activities and to record these in a diary.
The monitor recorded systolic BP (SBP), diastolic BP (DBP), heart rate (HR) and the
mean arterial pressure (MAP).
3.6 Measures of Daytime Sleepiness
3.6.1 Epworth Sleepiness Scale
Appendix 1
The Epworth sleepiness scale (ESS) is a self-administered eight-item questionnaire
(Johns 1991a) that was developed as a tool to measure subjective sleepiness in
adults. The scale has been found to be a reliable for measuring persistent daytime
sleepiness (Johns 1992a) and can show differences with treatment and time
(Hardinge, Pitson, & Stradling 1995). It does not, however, differentiate between
different causes of sleepiness (Johns 1993;Johns 1994b). The patients were asked to
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score themselves on a self-rating scale totalled from 8 ratings of 0-3, each depending
on how easily they would fall asleep in a specific situation. The overall score ranges
from 0-24: the higher the score, the sleepier the individual. All the patients were







Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic
3.6.2 FOSQ (Functional Outcomes of Sleep Questionnaire)
Appendix 2
This is a sleep specific questionnaire developed to reflect the impact of sleep
disorders and excessive sleepiness on the activities of daily life. It is a self-
administered questionnaire consisting of 30 questions, focusing on five different
aspects: general productivity, social outcomes, activity level, vigilance, sexual
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relationships, and intimacy. The optional questions on intimacy and sexual
relationships were excluded in this study as is our custom (Faccenda 2000;Teixeira,
Faccenda, & Douglas 2004). The questionnaire consists of 26 questions, each with a
four-point scale. The results are processed to give a mean-weighted item score for
each of the four sub-groups, which when added, produce a global score. The lower
the score, the more dysfunctional is the individual secondary to sleepiness. This
questionnaire has been validated for use with OSAHS patients and control population
and can be used to determine how disorders of excessive sleepiness affect patients'
abilities to conduct normal activities and the extent to which these abilities are
improved by effective treatment of sleep disorders (Weaver et al. 1997). At the end
of each treatment FOSQ were scored and all the data were analysed with SPSS.
3.8 CPAP Night
All patients underwent a CPAP titration study, regardless of their subsequent
treatment randomization, which was in random order done by a third person. Before
the CPAP night, patients were usually educated about sleep apnoea/hypopnoea
syndrome and CPAP treatment. This teaching was usually done on their baseline
visit. They were fitted with an appropriate CPAP mask and then had a 20-minute
CPAP trial in a darkened room. This mini-trial provided the patient with an
opportunity to ensure that the mask fitted correctly and gave him or her the feeling of
positive pressure treatment before the overnight titration study.
Titration was conducted using either Autoset or Autoset T CPAP machines (ResMed,
Australia) under the supervision of experienced specialist sleep nurses. Titration
usually commenced between 10:30 and 11:00 p.m. and ended around 7:00 a.m. the
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next morning. The Autoset machine was downloaded and the 95th centile pressure
was usually taken.
3.9 Treatment
Patients were randomized to receive either CPAP or placebo for one month in a
crossover study.
3.9.1 CPAP
Following the CPAP titration night, a fixed-pressure CPAP machine with memory
(ResMed or O'Sullivan) had been initialized to the 95th centile CPAP pressure.
Patients were taught how to use the machine and the mask. Patients were given a
number to call if they had any problem during the month and they were contacted
once. On a few (5) occasions, some patients had a home visit to change mask. At the
end of the treatment trial, the CPAP machine memory was downloaded and this
provided data on night-to-night use and the overall compliance.
3.9.2 Placebo
The study used a crossover design to assess effects of CPAP on blood pressure and
baroreflex. CPAP was compared with oral treatment with capsules. Patients were
told that these capsules might improve the upper airway tone. When this study was
started, "sham" CPAP had not been fully developed and tested and there were
concerns about its effect on sleep disruption and oxygenation. An oral placebo has
been used in previous OSAHS studies. These studies were mainly testing blood
pressure changes (Faccenda et al. 2001c) and daytime function (Engleman et al.
1998). The placebo was given in a sealed white medicine bottle containing 35 white
capsules labelled "trial medication". Patients were instructed to take one capsule with
water before going to bed. They were also given a contact number to call if they had
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any problems during the month. I usually asked the patients to bring back any
remaining capsules as an indication of compliance.
3.10 The Protocol
All patients underwent a full night in the sleep laboratory for CPAP titration study,
using an automated pressure setting device (as described above). The following
morning, the patient was randomized by a research nurse using a balanced block
design to receive either CPAP or an oral capsule for the first limb, and crossed over
after a month to the alternative treatment for the second limb. The patients were told
that the capsules might improve the tone in the upper airway. The CPAP units used
for home therapy were Sullivan V Elites (ResMed Australia). At the end of the
treatment period, data were downloaded to obtain a real-time record of the time when
the patient was using the device at the appropriate pressure (the compliance). The
patients were fitted with the ambulatory blood pressure monitor for 48 hours at the
end of each limb. The monitors were fitted at around 6 p.m. in all patients, and
programmed to measure blood pressure every 30 minutes for 48 hours. Patients were
asked to abstain from caffeine-containing products for the whole 48 hours. Data of
the first 24 hours were discarded to allow for acclimatization, and the analysis was
performed only on the second 24 hours of monitoring. Thus, data was accumulated
during 27 days from commencing that treatment, so that the risk of carry-over effects
of the other treatment was reduced. All the data were manually checked for artefacts
by an independent observer, who did not know the treatment status of the patient. At
the end of each treatment period, the patient was invited for the baroreflex sensitivity
test. Weight and height were measured to allow the calculation of the body mass
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index (kg/m2). The ESS and FOSQ were completed at the start of the study and at
the end of each limb.
3.11 The Measurement of Baroreflex Sensitivity
3.11.1 Finapres
General principles and theory of the technique
A method of non-invasively measuring the complete arterial waveform was
developed by Dr Jan Penaz. The technique uses the concept that if an externally
applied pressure (via bladder in the cuff) is equal to the arterial pressure at all times
(instantaneously), the arterial walls will be unloaded (zero transmural pressure) and
the arteries will not change in size. Since the arteries under the cuff are not changing
in size, the blood volume, which is only contained in the arteries at these pressures,
will not change, so the photoplethysmogram will be constant at some value.
The measurement technique works by taking the above concept in reverse. First, the
constant blood volume has to be determined, as represented by the
photoplethysmogram, which becomes a "set point" for a servo loop. It means that as
the measured photoplethysmogram varies from the set point, so the servo valve is
driven to increase or decrease the cuff pressure as required to maintain the measured
photoplethysmogram at the set point value. The pressure in the cuff will be driven to
equal the arterial pressure throughout each pressure cycle. This cuff pressure can be
measured with an electronic pressure transducer and the resulting signal displayed as
the arterial pressure. Setting and maintaining the set point is critical for an accurate
blood pressure measurement by this technique. The Finapres blood pressure monitor
uses two methods to determine the set point. The first method, known as the start-up
adjustment, is an automated process similar to what Dr Penaz did manually, and is
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used to establish an initial approximate set point. The second method, known as the
servo self-adjustment, provides fine-tuning of the set point and corrects for slow
moving physiological changes occurring in the finger and arteries under the cuff.
The Finapres is an accurate method of monitoring short-term changes in BP (Silke &
McAuley 1998), and can track the changes that occur during the Valsalva (Singer et
al. 2001;Tank et al. 2001) and Mueller manoeuvres, atrial fibrillation (van den Berg
et al. 2001), and OSAHS (Tkacova et al. 2000). Digital arterial pressure, however,
differs from brachial artery pressure because of the hydrostatic effects of the hand
position, and the normal changes in the BP along the vascular tree. Thus, the
plethysmographic volume clamp is best used as an index of change in BP rather than
of absolute pressure. Furthermore, the Finapres derived pressure has been shown to
correlate well (r = 0.96) with invasive intra-arterial blood pressure monitoring during
anaesthesia (Huang et al. 2000).
Description
I used the Finapres monitor (Ohmeda, USA) figure 3.2 that uses Penaz principle. It
provides continuous measurement of finger arterial pressure. It has a diagonal shape
with a screen that displays measurements. It has also four soft keys by which the
operator can change the displayed page. These keys give control on other functions
such as alarm, and calibration.
Cuff Application
This device uses a pneumatic servo-controlled cuff, which is inflated to keep the
infrared absorption in the finger constant by the correction of a photoplethysmogram.
The infrared absorption in the finger alters owing to the variation in blood volume in
the finger; changes in cuff pressure are therefore required to keep the
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photoplethysmogram constant, and these reflect changes in the intra-vascular
pressure. The cuff must be properly applied to achieve accurate and stable blood
pressure measurements. The middle finger is the one preferred for the cuff, although
other fingers can be used if no pulse can be obtained from the middle one.
3.11.2 Procedure of monitoring
An appropriately-sized cuff was attached to the middle finger of the left hand.
Patients were allowed to acclimatize with the equipment running, and rested
unstimulated for 30 minutes before any recordings are made. The patient's hand was
at the level of the heart, and the patient was instructed not to move the hand or the
finger with cuff while recording. The servo-self adjust (in-built calibration mode)
was disabled on the Finapres device during each 5-minute test run. It was then
reactivated. If there was more than a 5 mmHg difference in the readings, the test was
re-run. Data for the whole time were recorded; however, the analysis was conducted
only of the five-minute time blocks. Three sets of recordings, lasting 5 minutes each,
were taken for every patient during both visits.
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Figure 3.1 Example of BRS testing
71
Figure 3.2 Finapres apparatus
3.12 Baroreceptor Reflex Sensitivity
The patients were asked to abstain from alcohol, smoking and caffeine for a
minimum of 12 hours prior to attending for the study. All baroreceptor studies were
performed between 8 a.m. and 12 p.m. The patients lay supine in a quiet, dimly lit
soundproofed room and were left unstimulated. Electrocardiographic recordings
were taken from chest leadll. The skin was prepared using an exfoliating gel and
wiped with alcohol to ensure good contact before the electrodes were placed. Beat-
by-beat blood pressure was recorded using the Finapres. Data from the ECG and
Finapres were recorded on a PC, using a special montage in the Compumedics
software, in which there were two recording channels, one for the ECG and another
one for the Finapres. Data from these files were backed up onto optical disks.
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Figure 3.3 Example of baroreflex recording. The upper tracing represents two ECG
chest leads and lower tracing is the pulse pressure measured by the Finapres.
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3.13 Controls
Ten healthy subjects were recruited as controls for the baroreceptor sensitivity test.
Recruitment was done by advertising in the University of Edinburgh and Edinburgh
Royal Infirmary e-mail and messenger system. OSAHS was excluded by using a
sleep questionnaire for the participants and his/ her partner with ESS < 5. Loud
snorers were also excluded. The rest of the exclusion criteria were the same as above
(Section 3.3.2). The BRS study was done once for each subjects and blood pressure
was measured twice. The rest of the procedure was as above (Sections 3.8 & 3.9).
3.14 Data Analysis
The Finapres data were moved to an EDF file and then processed by a custom-
written programme. The programme was written by a computer expert to analyse
baroreceptor sensitivity, using both the sequential analysis method and the spectral
analysis method.
3.14.1Sequence Method
The programme computed the linear regression between the sequences of systolic
blood pressure values and the related pulse intervals which had a coefficient of
determination (r2) of the regression greater than 0.85. The programme determined the
difference between each two consecutive systolic blood pressure and pulse intervals.
It identified sequences with following characteristics:
systolic blood pressure increased by at least 1 mmHg in each of three or more blood
pressure waves, and pulse interval increased by at least 4ms/beat in each of three or
more cycles; and (2) systolic blood pressure fell by at least 1 mmHg during each of
three or more blood pressure waves, and pulse interval decreased by at least 4
ms/beat (Bertinieri et al. 1988).
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3.14.2 Spectral analysis method
Power spectral analysis is a frequency domain technique that enables the cross
spectrum between BP and pulse interval to be quantified in amplitude or gain, phase
and coherence. Power spectral analysis was performed on the R-R interval and SBP
data, using an autoregressive algorithm. The following components were considered:
• Very low frequency (VLF) in the band below 0.04,
• Low-frequency (LF) power in the 0.04-0.15 Hz band, and
• High frequency (HF) power in the 0.15-0.4 band.
Coherence between the R-R interval and SBP was assessed by cross-spectral
analysis. If it was more than 0.5, then power spectral analysis was performed on the
RR interval and SBP data using autoregression. The alpha index was computed as
the square root of the quotient of the R-R interval and SBP spectral powers in the LF
and VLF bands.
Before starting the analysis, the calibration and the start and end time of each five-
minute block were determined. The analysis was then done in two stages. First, any
ectopic beats and artefacts were removed. Then each five-minute block of recording
was analysed using the two methods. Then, all three 5-minute blocks of one visit
were added together and the average was taken. The data were then saved in a text
file before moving it to Excel, where further analysis was performed, and the data
were transferred to SPSS for Windows for final analysis.
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Figure 3.4 Processing of the ECG and pulse pressure with sequential analysis in which
there is coordination between R- and the following systolic peak.
3.15 Measurement of Proteinuria and Creatininuria
3.15.1 Introduction
Normal subjects excrete less than 150 mg of protein per day in the urine
(Cunningham 2002) and, with exception of orthostatic proteinuria, levels above this
imply disease of the kidney or urinary tract. It has been recognized in recent times
that even slight increases in the urinary albumin excretion can be a valid predictor of
premature morbidity and mortality from cardiovascular diseases (Schrader et al.
2006;Wang et al. 2006). In addition, increases in albumin excretion are an early
marker of nephropathy in patients with hypertension.
3.15.2 Mechanisms of Proteinuria
Normal barriers to protein filtration are present in the glomerulus, which consists of
unique capillaries that are permeable to fluid and small solutes but effective barriers
to plasma proteins. The adjacent basement membrane and visceral epithelial cells are
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covered with negatively charged heparan sulfate proteoglycans (Kanwar 1984).
Proteins cross to the glomerular fluid in inverse proportion to their size and negative
charge. Proteins with a molecular weight of less than 20,000 pass easily across the
glomerular capillary wall (Larson 1994). Conversely, albumin, with a molecular
weight of 65,000 Daltons and a negative charge, cannot normally pass. The smaller
proteins that do pass are largely reabsorbed at the proximal tubule, and only small
amounts are excreted. The pathophysiological mechanisms of proteinuria can be
classified as glomerular, tubular or overflow. Glomerular disease is the most
common cause of pathological proteinuria (Stone 1989). Several glomerular
abnormalities alter the permeability of the glomerular basement membrane, resulting
in urinary loss of albumin and immunoglobulins (Abuelo 1983). Glomerular
malfunction can cause large protein losses; urinary excretion of more than 2 g per 24
hours is usually a result of glomerular disease (Larson 1994).
3.15.3 Measurement of Proteinuria
Traditionally, proteinuria is measured using 24-hour urine collections and expressed
as grams per day (g/day). This has the advantage of averaging out protein excretion
and is not therefore affected by normal diurnal variation in protein excretion. Testing
spot urine samples for protein has been introduced to overcome the inherent
problems of patient accuracy and reliability with 24-hour urine collections. The
urinary albumin concentration is measured by radioimmunoassay. Under resting
conditions, urinary creatinine excretion is relatively constant throughout the day.
Thus to overcome the problems of timing of urinary collections, proteinuria in spot
urine samples is expressed as the albumin: creatinine ratio.
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3.15.4 Microalbuminuria
Dipstick analysis is used in most outpatient, and sometimes in inpatient settings, to
measure semiquantitatively the urine protein concentration. Dipsticks can detect a
protein content of > 200 pg/min and they react primarily to albumin, being relatively
insensitive to globulins and Bence-Jones proteins. In the urine, albumin is normally
present in concentrations of < 20 pg/min, and the range of 20-200 pg/min is referred
to as microalbuminuria, which is therefore by definition not picked up by dipstick
testing (Beetham & Cattell 1993). Microalbuminuria is therefore defined as a urinary
albumin excretion rate of 20-200 pg/min. The albumin excretion rate (AER) is
around 25 per cent higher during the day than at night. There is a good correlation
between the morning AER and the albumin: creatinine ratio in the first urine sample
of the morning. The advantage of spot urine samples is that almost all patients can
provide a sample when they attend the clinic (the Sleep centre in our case). Provided
that each urine sample is taken at the same time, and the patient's dietary intake is
largely constant, then these samples are very useful in assessing patients over time.
The advantage of measuring the albumin :creatinine ratio is that it eliminates the
timing of urinary samples, which is important in calculating the albumin excretion
rate. Microalbuminuria can be used as a predictor of cardiovascular events in diabetic
as well as hypertensive and cardiac failure patients (Rowley et al. 2000;Wardle
1982). Similarly, microalbuminuria may occur in healthy subjects after exercise and
during normal pregnancy (Davenport 2003).
3.15.3 Proteinuria in OSAHS patients
Few studies have investigated the relationship between OSAHS and proteinuria.
Earlier studies have shown that proteinuria is not uncommon in obese patients with
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OSAHS and that this could be reversible (Sklar & Chaudhary 1988;Sklar,
Chaudhary, & Harp 1989). However, more recent studies have reported that
proteinuria is weakly associated with OSAHS (Casserly et al. 2001;Chaudhary,
Rehman, & Brown 1995;Iliescu et al. 2001)
3.15.4 Methods and Samples
Patients were asked to give a spot urine sample, in a standard urine container used by
the Royal Infirmary of Edinburgh, on three different occasions: baseline, after CPAP
and after placebo, morning time (09:00-10:00). The sample was processed in the
biochemistry laboratory by experienced technicians, who performed a
radioimmunoassay to determine the concentration of albumin and creatinine in the
sample so that a ratio of albumin to creatinine excretion could be derived.
3.16 Statistics
I used Microsoft Office Excel (Microsoft Office Excel 2003) to do the primary
analysis of the 24 hours ambulatory blood pressure values. The recording was
divided in to 6 time intervals before exporting the data into SPSS for comparative
testing. Excel was also used to draw graphs and for preliminary calculation of
spectral and sequence analysis.
I used SPSS (SPSS version 12.0 for Windows) to carry out analysis of variance for
the treatment comparison.
3.16.1 Statistical Tests used in this Thesis
The paired-Sample T Test was used to compare two variables for a single case. It
computes the differences between values of the two variables for each case and tests
whether the average differs from zero.
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The Wilcoxon signed-rank test considers information about both the sign of the
differences and the magnitude of the differences between pairs. It was used to test
data that were not normally distributed.
The Independent-Samples T Test procedure compares means for two groups of
cases. Ideally, for this test, the subjects should be randomly assigned to two groups,
so that any difference in response is due to the treatment (or control) and not to other
factors. Furthermore, in this analysis, we assumed non-equal variance
The One-Way ANOVA procedure considers a quantitative dependent variable
affected by a single factor (independent) variable. Analysis of variance is used to test
the hypothesis that several means are equal.
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Chapter 4
Results: Treatment Effect on Blood Pressure
4.1 Introduction
Ambulatory blood pressure was measured as part of the main study, which also
included an assessment of sleepiness, baroreflex measurement, and measurement of
microalbuminuria. There was no power calculation performed and these are small
numbers and therefore this has a bearing on the validity of the results.
4.2 Preliminary results
Ninety consecutive patients were invited to participate in this study, of whom
35accepted the invitation. Of the 55 patients who declined to participate, most did so
because of work commitments, the remainder for social and personal reasons. Of the
35 patients who agreed to participate, 29 completed the study: 24 males and 5
females. Three patients withdrew at the beginning of the study because of work
commitments and personal reasons; one withdrew during placebo treatment and 2
during CPAP treatment. In addition, 10 healthy control subjects (8 males and 2
females) were also studied to measure baroreflexes only.
4.3 Patients' Screening
For the baroreflex study, I screened 705 patients who attended the Sleep Laboratory
at the Royal Infirmary of Edinburgh from November 2000 to October 2002. Only 90
patients were eligible and contacted and Figure 4.1 gives details of the screening
process.
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Figure 4.1 Patients screening results
The diagram shows that patient selection resulted in many patients being rejected, so
that only 4.1% of the original number of patients took part in the study. Most of the
patients were excluded because of co-morbidity. Hypertension and cardiac causes
excluded about 17% of the total screened patients. Distance was another important
reason for excluding patients from participation, since they had to be visited at least
twice during the study and to come to Edinburgh at least 3 times. Sleepiness while
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twice during the study and to come to Edinburgh at least 3 times. Sleepiness while
driving was another major exclusion reason, since it was not ethical to include these
patients because the placebo treatment could have exposed the patient to the risk of
an accident. Other factors that affected the recruitment were that around 17% of the
patients were booked for half-and-half clinical / CPAP titration and proceeded
immediately to CPAP therapy. It was not ethical to delay their treatment. Finally,
some patients were involved in other research studies.
4.4 Demographics
The demographics of the patients who completed the study are included in Table 4.1.
Participants were compared with a random sample of 100 excluded patients, using
the Student T- test.
Table 4.1 Demographics of participants and a random sample of 100 excluded subjects
Participants Excluded P-value
2-tailedMean S.D. Mean S.D.
Age (yrs) 50 9 52 10 0.3
BMI (kg/m2) 33.8 6.6 32.9 7.7 0,6
ESS 13 5 15 5 0.2
Waist (cm) 110.3 17.3
Hip (cm) 116.3 14.3
Neck (cm) 42.8 3.8
SBP (mmHg) 133 19
DBP (mmHg) 85 13
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There was no significant difference between participants and excluded patients in
age, BMI and ESS (P>0.2). Other patients' characteristics were calculated by non-
parametric measures because the data were not normally distributed.
Table 4.2 non-parametric measures
4%
Desaturation
4%Desatuarion index CPAP Use
AHI Dips (dips/hours) (hours/night)
N Valid 29 26 26 29
Missing 0 3 3 0
Median 44.3 97.0 19 4
Percentiles 25 31 27.5 4.1 2
50 44.3 97.0 19 4
75 59.4 202.3 38 6
4.5 Apnoea/Hypopnoea Index and Desaturation
Table 4.2 indicates that the median of AH1 was 44.3. The median 4% desaturation
index was 19 (dips/hour). As expected, there was a significant correlation between
the AH1 and the desaturation index (P < 0.0001).
4.6 CPAP Use
The median use of CPAP was 4 hours/night. Furthermore, there was no significant
order effect of CPAP use. The mean use of patients starting with CPAP was 4.5
hours/night, and for those started with placebo, the mean was 3.4 hours/night.
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4.7 24-hour Blood Pressure Results
4.7.1 Results of Intention to Treat Analysis
The result of data analysis was performed as intention to treat, irrespective of the
compliance with treatment.
Table 4.3 24-hour Blood Pressure results of intention to treat analysis.
CPAP Placebo P-value
t-testMean S.D. Mean S.D.
SBP (mmHg) 129 17 128 17 0.4
DBP
(mmHg)
79 10 79 11 0.8
MAP
(mmHg)
96 12 96 13 0.7
HR
(bpm)
79 11 79 12 0.97
There was no significant difference in blood pressure in any parameters between the
two treatments. The data were re-examined including only patients with more than
ten 4% 02 desaturations/hour and CPAP usage > 4 hours per night (n=10). In this
analysis, we obtained the results as shown in Table 4.4.
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Table 4.4 24-hour blood pressure subanalysis results
CPAP Placebo P-Value
t-testMean S.D. Mean S.D.
SBP
mmHg
131 14 131 13 0.94
DBP
mmHg
81 10 82 9 0.63
MAP
mmHg
98 10 99 11 0.68
HR
bpm
81 13 81 11 0.95
4.7. Diurnal changes in BP
Intention to treat analysis
Number of patients 29
Statistics
Blood pressure readings were grouped into six time intervals from 18:00 to 18:00 the
following day. Comparison of the blood pressure values between treatments was





i 1 1 1 r
18:00-21:30 22:00-01:30 02:00-05:30 06:00-09:30 10:00-13:30 14:00-17:30
Time intervals (Hours)
Figure 4.2 Diurnal changes in systolic BP and the effect of CPAP and Placebo treatments
I performed univariate analysis of variance for the diastolic blood pressure with the
following results:
88
Table 4.5 ANOVA results of Diastolic BP
Dependent Variable: diastolic BP
Source Type III Sum of Squares df Mean Square F Sig.
Corrected Model 10355.6(a) 11 941.4 5.557 0.00
Intercept 2192170.3 1 2192170.3 12940.3 0.00
Treatment 212.4 1 212.4 1.3 0.3
Time 9999.8 5 1999.96 11.8 0.00
Treatment * Time 141.5 5 28.3 .2 0.97
Error 55903.8 330 169.4
Total 2259862.0 342
Corrected Total 66259.4 341
a R Squared = 0.156 (Adjusted R Squared = 0.128)
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Figure 4.4 Diurnal changes in mean BP and the effect of CPAP and Placebo treatments
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Figure 4.5 Diurnal changes in Heart Rate and the effect of CPAP and Placebo treatments
4.7.4 Diurnal Changes with Desaturation Index >10 and CPAP Use > 4
hours
With sub-analysis of 24-hr BP monitoring, n = 10 in CPAP treatment and 9 in
placebo patients
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Table 4.6 Diastolic BP Univariate ANOVA-subanalysis
Tests of Between-Subjects Effects
Dependent Variable: diastolic BP
Source Type III Sum of Squares df Mean Square F Sig.
Corrected Model 1822.6(a) 11 165.7 1.5 0.1
Intercept 635864.3 1 635864.3 5865.6 0.00
Treatment 157.6 1 157.6 1.4 0.2
Time 1608.8 5 321.8 2.96 0.02
Treatment * Time 56.2 5 11.2 .1 0.99
Error 9106.1 84 108.4
Total 646793.0 96
Corrected Total 10928.7 95
a R Squared = 0.167 (Adjusted R Squared = 0.058)
Univariate ANOVA was performed with diastolic BP with no significant difference
between CPAP and placebo treatment.
4.8 Linear Regression Analysis
The relationship between heart rate and desaturation index in patients treated with
placebo was investigated with linear regression analysis. The correlation between
heart rate and desaturation is significant in the period between (22:00-1:30) (R =
0.45, P = 0.02), and between 2:00-5:30 with R = 0.4, P = 0.04. The HR was
positively correlated with desaturation index in these two periods, that is, HR
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Figure 4.6 Heart rate (22:00-01:30)
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Desaturation index
Figure 4.7 Heart rate (02:00-05:30)
4.9 Conclusion and discussion
There was no significant difference between CPAP and placebo treatment in all
blood pressure measurements (p>0.4) in either intention to treat analysis or in the a
priori sub-analyses of the compliant subjects or those with more than ten 4%
desaturations per hour. Similarly, when the data were analysed by time of the day,
there was no significant difference between the results after CPAP or placebo.
Univariate ANOVA of Diastolic BP did not show any significant difference between
CPAP and placebo in either intension to treat analysis nor in a priori sub-analysis of
the patients who had severe AHI and were compliant. The regression analysis
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indicates that hypoxaemia is a significant predictor for heart rate in OSAHS patients
(p=0.02 & p=.04, r= 0.46 & 0.41 respectively) during the night-time (22:00-05:00).
These findings suggest that hypoxaemia during sleep may have an effect on
sympathetic activation of the heart (Narkiewicz et al. 1998c) which might lead to an
increase in blood pressure. However, the correlation is weak and this study did not
show any correlation between desaturation and any other measures of blood pressure.
An alternative explanation for the relationship between hypoxaemia and heart rate
would be that hypoxaemia contributed to arousal and thus indirectly increased
sympathetic tone. The data in this study cannot distinguish between these two
possible explanations.
As I discussed in chapter two, nasal CPAP treatment can reduce mean blood
pressure. A non-randomised non controlled study suggested that one week of CPAP
treatment reduced daytime and nocturnal blood pressure (Dimsdale, Loredo, &
Profant 2000). A randomised crossover study found that one month of CPAP
treatment reduced 24-hour diastolic blood pressure (Faccenda et al. 2001c), with
greatest fall occurring between 2:00 am and 9:59 am (p=0.03). The reduction was
more evident in patients with more oxygen desaturation and with CPAP use more
than or equal 3.5 hours/night (see chapter 2 and chapter 12). In a randomised parallel
study, nasal CPAP reduced mean ambulatory blood pressure by 2.5 mmHg.
(Pepperell et al. 2002) The reduction in mean blood pressure was dependent on
average nightly CPAP use and on 4% desaturation dips. Mean blood pressure fell by
4.9 mmHg in patients who used CPAP for longer than five hours, compared with no
change in those who used CPAP for less than five hours. Patients whose blood
pressure fell with CPAP had had more than 33 falls in arterial oxygen saturation of
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greater than 4% every hour. In our study, we found that the median CPAP use was
only four hours per night and the median 4% desaturation index was 19. These two
factors may perhaps contribute to the lack of significant difference between CPAP
and oral placebo treatments. In another study, ambulatory blood pressure was
measured using finger Portapres for 20 hours (Becker et al. 2003). Here, 5.5 hours
per night of CPAP use reduced mean blood pressure by 9.9 mmHg after 9 weeks of
treatment. Our study only tested the effect of one month of CPAP treatment. A
parallel, randomised, placebo-controlled trial (Campos-Rodriguez et al. 2006)
showed that four weeks of CPAP therapy did not reduce blood pressure in
hypertensive OSAHS patients who were undergoing antihypertensive treatment. The
author concluded that four months of CPAP therapy was not enough to reduce the





Patients' sleepiness was assessed throughout the study by means of the Epworth
sleepiness scale (ESS) and the functional outcome of sleep questionnaire (FOSQ).
All patients (n =29) completed the questionnaires on three different occasions: at the
time of recruitment, and the end of each treatment period to assess the patients'
sleepiness and response to treatment. Each questionnaire required 5 minutes to
complete. . The mean baseline ESS was 13 ± 5. Other demographic details of the
subjects have been discussed in Chapter 4.
5.2 Effect of Treatment
The ESS data show that patients improved with CPAP compared with placebo
treatment (P =0.02, Paired t-test was used to calculate for the P value because it was
a crossover trial) (Table 5.1, Figure 5.1)
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Table 5.1 CPAP effect on ESS
CPAP Placebo P-Value
Mean S.D. Mean S.D.




Figure 5.1 comparisons of baseline and CPAP and placebo effect on ESS
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5.3 Treatment Effect on FOSQ
The effect of CPAP on total FOSQ score was not significant in comparison with
placebo (P > 0.05). None of the four categories of FOSQ questionnaire was improved
by CPAP treatment. There was no significant difference with any of the groups (P >
0.2) in all cases.
Table 5.2 Treatment effect on FOSQ
variable Baseline CPAP placebo CPAP v
Placebo
p-value
Mean S.D. Mean S.D. Mean S.D.
FOSQ- GP 3.1 0.06 3.3 0.6 3.2 0.6 0.96
FOSQ-SO 3.1 0.9 3.3 0.8 3.3 0.9 0.5
FOSQ-AL 2.6 0.7 2.9 0.7 2.9 0.7 0.7
FOSQ-VG 2.6 0.8 3.0 0.7 2.8 0.6 0.2
FOSQ-total 11.4 2.6 12.5 2.5 12.2 2.6 0.96
Figure 5.2 summarizes the treatment effect between CPAP and placebo on total
FOSQ scores, which also indicate that there was no significant difference, between
CPAP (mean 12.5 ± 2.5) and placebo (12.2 ± 2.6), treatment compared with

















Figure 5.2 Treatment effect on FOSQ total score
5.4 Conclusion
We found that patients' subjective sleepiness determined by the ESS questionnaire
improved after CPAP treatment (P=0.02). This result supports numerous other
studies where OSAHS patients improve symptomatically with CPAP treatment
(Engleman et al. 1994c;Engleman et al. 1997c;Hardinge, Pitson, & Stradling
1995;Jenkinson et al. 1999;Monasterio et al. 2001;Montserrat et al. 2001). However,
the FOSQ results did not change after CPAP. This suggests the FOSQ may be a less







(mean 11.2 ± 2.6). This could limit the symptomatic improvement possible with
CPAP. The relatively small number of subjects and thus low power may have also
contributed to this negative finding. In a study of 48 patients by Engleman et al
showed that ESS score was significantly reduced by CPAP treatment. FOSQ score
was also improved with CPAP. (Engleman et al. 2002). Relatively low CPAP
compliance may also contribute to the negative result of the FOSQ. Another study by
Montserrat et al.(Montserrat et al. 2001) showed that OSAHS patients significantly
improved after six weeks of CPAP treatment compared with sham CPAP. CPAP
reduced ESS score significantly but not the total FOSQ score. However, there was
significant difference in general productivity and vigilance. In another study
(Monasterio et al. 2001), CPAP did not significantly improve FOSQ score in mild
sleep apnoea patients after three months of treatment with trend of significance after
six month. Nevertheless, CPAP reduced symptoms of sleep apnoea. The baseline
score of FOSQ and ESS was 101 and 12.1 respectively. These results indicate that
total FOSQ score may not improve statistically with short-term CPAP use (one
month in our study), and longer period with good compliance of treatment is required
to show the difference.
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Chapter 6
Effect of CPAP Treatment on Baroreflex Sensitivity (BRS)
6.1 Introduction
The main aim of this thesis is to investigate the treatment effect of OSAHS on
baroreflex sensitivity (BRS). When this study was started, studies indicated that BRS
was impaired in OSAHS (Carlson et al. 1996;Tkacova et al. 2000), although none
were adequately controlled. Thus, we investigated the effect of CPAP treatment on
BRS in patients with OSAHS, using non-invasive methods.
6.2 Comparison between Patients and Controls
6.2.1 Demographics of subjects
We studied 29 patients with OSAHS (24 males and 5 females) and 10 controls (8
males and 2 females) whose characteristics were:
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Table 6.1 Demographics of patients and controls
OSAHS patients Controls P-Value
t-testMean S.D. Mean S.D.
Age (yrs) 50 9 45 12 0.3
BMI (kg/m2) 33.8 6.6 26.9 5.3 0.1
Waist (cm) 110.3 17.3 98.1 21.5 0.9
Hip (cm) 116.3 14.3 103.9 13.5 0.3
Hip/waist 1.1 0.11 1.1 0.14 0.8
Neck (cm) 42.8 3.8 39.1 6.6 0.7
SBP (mmHg) 133 19 112 11 0.2
DBP (mmHg) 85 13 75 8 0.9
ESS 13 5 5 2 0.03
There was no significant difference between patients (n = 29) and controls (n = 10)
in any of these characteristics (Student t test) except that the controls had
significantly lower Epworth sleepiness scores compared with the OSAHS patients (P
= 0.03). However, the patients tended to have higher, though not significant, BMIs
than the controls. There was no significant difference in hip/ waist ratio between the
two groups. There were 10 smokers among patients and only one smoker among
control subjects.
6.3 Comparison of BRS between Patients and Controls
Table 6.2 demonstrates that although control subjects tended to have higher BRS
values than patients there was no significant difference between the two groups in
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any of the measures of BRS (P=0.2, Student t test). Nevertheless, Figure 6.1 and
figure 6.2 show the BRS values in patients and controls.
Table 6.2 Statistics: BRS measurements of patients and controls
Controls Patients P-Value
Mean S.D Mean S.D. 2-tailed
BRS ( sequential analysis) (ms/mmHg) 8.2 5.2 5.5 4.4 0.2
VLFBRS (ms/mmHg) 3.7 1.8 3.5 2.3 0.9
LFBRS (ms/mmHg) 7.3 4.1 6.5 5.8 0.7
HFBRS (ms/mmHg) 14.3 9.2 9.5 9.3 0.2
























Figure 6.2 Spectral analysis of BRS in OSAHS patients and healthy controls
6.4 Effect of Treatment on BRS
There was no significant difference between the effect of CPAP and the placebo in
this study. The initial calculation was done for all the patients who completed the
study, that is, 24 males and 5 females. As shown in Table 6.3, there was no
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significant difference between CPAP and the placebo in this study in any of the
variables (P > 0.1).
Table 6.3 Treatment effect on BRS for all cases
CPAP Placebo P-Value
Median Range Median Range
BRS(ms/mmHg)
(Sequence analysis)
4.8 1.7-14.7 4.2 2.0-25.6 0.9
VLFBRS (ms/mmHg) 2.5 1.5-5.8 3.1 1.4-13.5 0.5
LFBRS (ms/mmHg) 4.9 1.6-15.7 5.5 2.2-34.2 0.1
HFBRS (ms/mmHg) 6.5 1.9-24.3 6.0 1.6-49.2 0.97
Alpha BRS (ms/mmHg) 5.9 1.8-20.0 6.2 2.2-41.7 0.7
The Wilcoxon test was used to calculate these P values as the data were not normally
distributed. In the a priori selected cases in which the 4% DI was more than 10 and
CPAP usage was more than 4 hours/night (ten subjects), the BRS and other variables
did not differ significantly between CPAP and the placebo either, as shown in Table
6.4.
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Table 6.4 Subanalysis of BRS (4% Dl > 10 & CPAP use > 3.9)
CPAP Placebo P-Value
Median Range Median Range
BRS (ms/mmHg) 5.0 1.7-6.6 4.2 2.0-9.1 0.8
VLFBRS (ms/mmHg) 2.3 1.6-4.1 3.0 1.5-4.5 0.2
LFBRS (ms/mmHg) 5.1 3.3-7.5 5.9 2.8-7.7 0.2
HFRS (ms/mmHg) 7.7 2.1-22.2 6.8 1.6-16.3 0.1
Alpha BRS (ms/mmHg) 7.0 2.7-13.6 6.4 2.2-11.0 0.6
The non-parametric Wilcoxon Test was used to calculate the P-Value
The graphs in Figure 6.3 show that there was no significant difference between





















































Figure 6.3 Treatment effect on BRS of OSAHS patients.
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6.5 Conclusions
We found no significant difference between OSAHS patients and healthy subjects in
the sequential domain analysis as well as the frequency domains of baroreceptor
sensitivity (P > 0.2). This does not support other studies using similar comparisons,
such as a study by Carlson et al. who found that baroreflex sensitivity is depressed in
OSAHS patients compared with healthy controls (Carlson et al. 1996). They used a
different technique to evaluate the baroreflex sensitivity. They quantified baroreflex
sensitivity by changes in RR-interval and muscle sympathetic nerve activity, evoked
by a reduction of blood pressure by sodium nitroprusside. Furthermore, in the present
study, none of the baroreceptor sensitivity indices changed after CPAP therapy, even
when data were analysed on the basis of a priori criteria designed to select a sub¬
group most likely to show changes by excluding the less-compliant and non-
desaturating patients. The lack of changes in OSAHS patients either in comparison
with normals or with CPAP might be due to:
1. there being no change in BRS with OSAHS
2. the relatively low power of the study or
3. The lack of reproducibility of the baroreceptor test used.
Studies have shown that baroreflex sensitivity in OSAHS improved after CPAP
treatment (Bonsignore et al. 2002;Bonsignore et al. 2006;Logan et al. 2003;Tkacova
et al. 2000). Cooper et al (Cooper et al. 2004), found that BRS was reduced by
breathing with an inspiratory resistance in simulated obstructive sleep apnoea.
Bonsignore et al studied (Bonsignore et al. 2006) the effect of CPAP treatment on
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BRS for short periods (1-30 days). They assessed BRS by the sequence method using
activation and deactivation of pulse intervals and systolic blood pressure. They found
improved baroreceptor deactivation (downward sequencing) but not baroreceptor
activation (upward sequencing) but no significant change after CPAP treatment in
mean blood pressure or heart rate. Our study was more comprehensive in terms of
measuring BRS using sequence as well as spectral analysis of R-R intervals and
systolic blood pressure. Smoking may have an effect on sympathetic outflow in
humans and consequently increase in blood pressure and heart rate (Mancia et al.
1997;Narkiewicz et al. 1998). In our study there were 10 smokers among patients
and only one smoker among control that could have a bearing effect on the result.
More potential explanations will be discussed in depth in the chapters on
reproducibility and in the discussion.
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Chapter 7
Validity and reproducibility of BRS measurement methods
7.1 Introduction
Even the standard method of assessing BRS, which involves the intravenous
injection of a pressor agent such as phenylephrine(Smyth, Sleight, & Pickering 1969)
has technical difficulties. There is a high test failure rate in patients with an
attenuated BRS, and intra-subject reproducibility is poor even in normal controls. It
is invasive and requires an intravenous injection. Importantly, phenylephrine has a
negative effect on the sinus node (Schuessler et al. 1988). New methods to assess the
BRS have been developed lately to overcome these problems, combined with the
development of a non-invasive measurement of BP; these have resulted in simpler
measures of BRS. The new methods, either the sequence method or the spectral
analysis method, as described earlier, have been validated by comparing them with
the previous phenylephrine technique; generally, the relationship between results
obtained by the two methods was not impressive. The new approach was tested by
Bertinieri et al., who recorded arterial blood pressure for 3 +/- 0.4 hour (mean +/-
s.d) in 10 unanaesthetized, unrestrained cats. The recording was scanned by a
computer to identify the spontaneous sequences of three or more consecutive beats in
which SBP progressively rose and pulse interval progressively lengthened (type 1) or
SBP progressively fell and pulse interval progressively shortened (type 2) (Bertinieri
et al. 1985b). In this study, they found that all sequences had high correlation
coefficient (r >0.9) and type 1 had greater slope than type 2 (P<0.01). In another
114
study, 8 patients were studied using both the spontaneous or sequence method and
the drug method. The two methods yielded BRS slopes that were highly correlated (r
= .96, P < .001) (Parlow et al. 1995). Davies et al (Davies et al. 1999) compared four
methods of BRS assessment: the sequence method, spectral analysis or the alpha
index, controlled breathing time domain analysis, and the phenylephrine method, in
31 cardiac patients and 18 normal controls. In this study, all four measurements were
done at the same time in the afternoon and two test episodes were obtained for each
method of assessing BRS. The agreement among the four methods was tested with
Bland-Altman plot. The most reproducible method was the controlled breathing
protocol with a coefficient of variation of 19.6%. However, in the sequence method
and the spectral analysis LF and HF, the CoV were 40.4%, 33.7% and 52.1%
respectively. The phenylephrine technique was the least reproducible method with a
CoV of 52.2%. More recently, Lipman et al who studied 97 subjects aged 25 to 86
years, using spontaneous BRS measurement and a modified phenylephrine
measurement. They found that spontaneous indices after valsalva manoeuvre
correlated poorly with the drug method and they were not useful as surrogates for
baroreflex gain (Lipman, Salisbury, & Taylor 2003).
Mid- and long-term reproducibility of spontaneous baroreflex sensitivity was
assessed by Herpin and Ragot ((Herpin & Ragot 1997). They studied 14
normotensive subjects using three noninvasive plethysmography recordings of BP
(Finapres). Two recordings were performed one week apart and the third one was
performed one year later. BRS was estimated using the sequence method and the
spectral analysis. The data were analysed using the Bland-Altman method; they did
not find a significant difference between estimates of BRS from the three recordings
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and the reproducibility of BRS measures were satisfactory. Measurements performed
in the standing position had better repeatability than measurements made from supine
subjects. The mid-term (1 week) coefficient of repeatability (CR) was 10.4 for
sequence method and 3.8 for spectral analysis in the supine position, whereas for
standing position the CR was 1.9 and 1.6 for sequence and spectral analysis
respectively. Furthermore, the long-term (1 year) CR for supine position was 12.0 for
sequence analysis and 4.7 for spectral methods. However, standing position was also
more reproducible with CR of 2.0 and 2.2 for sequence and spectral analysis
respectively. In another study (Iellamo et al. 1996) spontaneous BRS evaluation was
moderately reproducible in two different days, 24 hours apart. Nevertheless, in this
study, the CoV (coefficient of variation) was ranged between 13.9 and 19.7%.
Dawson et al studied 39 normal subjects on two different occasions, whose breathing
rate was controlled at 15 breath/minute. They found that the coefficient of variation
ranged between 18.9 and 26.1%, but measurements obtained with the valsalva
manoeuvre had a CoV of 16.8% (Dawson et al. 1997). More recently, an important
study by Eckberg et al, showed that baroreflex sensitivity at low frequency varied
from day to day in 9 healthy subjects. These baroreflex fluctuations were
independent of the method used to estimate baroreflex sensitivity (Eckberg &
Kuusela 2005). In most of the previous studies, researchers used some provocative
mechanisms such as head tilting or valsalva manoeuvre in order to assess the
reproducibility and validity of the non invasive measurement of baroreceptor
sensitivity to give more power to the test. Eckberg studied the unprovoked
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7.2 Factors that may affect BRS Reproducibility
Factors that may affect the autonomic neural outflow has already been considered
(see Chapter 2). In this chapter, respiration will be considered as a major modulator
of BRS.
Respiration
Breathing is a readily observed human rhythm that exerts profound influences on
autonomic neural outflow. The most obvious manifestation of respiratory modulation
of human autonomic rhythms is the respiratory sinus arrhythmia. Respiration gates
the autonomic response to R-R interval fluctuations and it exerts influences on
arterial pressure and muscle sympathetic nerve activity. Haymet & McClosky
(Haymet & McCloskey 1975) found that vagal responses were greater when
baroreceptor stimuli were applied in expiration than inspiration. In the same study,
they found also that respiration gates the responsiveness of sympathetic
motoneurones to changes in baroreceptor input. Another study suggested that
respiratory gating of human vagal-cardiac responsiveness varied within the breathing
cycle, that is, the human vagal response is most marked when baroreceptor stimuli
begin in late inspiration and early expiration (Eckberg 1980). Gilbey (Gilbey et al.
1984) found that cardiac vagal motoneurones received an excitatory input during
post-inspiration and powerful inhibitory synaptic input during inspiration. Badra
(Badra et al. 2001) found that respiration greatly influenced the systolic blood
pressure, R-R intervals and muscle sympathetic nerve activity. They also found low-
frequency rhythms independent from respiratory activity as well as close correlations
between arterial pressure, R-R intervals, and muscle sympathetic nerve activity at
respiratory frequencies. These correlations resulted from the influence of respiration
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on these measures rather than from arterial baroreflex physiology, which makes these
autonomic and hemodynamic rhythms vary over time and frequency. See Figure 7.1
below
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Figure 7.1 Power spectral densities from all subjects during different breathing patterns, light
line in each panel are values from individual subjects, dark lines are group averages (Badra
etal. 2001).
Recently, Rothlisberger et al, (Rothlisberger et al. 2003) found that baroreflex
sequences occurred erratically at a frequency about one-third that of breathing.
However, when baroreflex sequences did occur, the timing of their onset was
dictated by the cycle of respiration. Parallel increases of systolic pressures and R-R
intervals began just before and after the beginning of expiration, and parallel
decreases of systolic pressures and R-R intervals began during late expiration and
early inspiration. However, they concluded that these parallel systolic pressure and
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R-R interval sequences were the expression of arterial baroreflex physiology, and the
timing of such sequences within breaths reflected respiratory gating of muscle
sympathetic bursts
The number of subjects used to study the reproducibility of spontaneous BRS
measurement varied between 8 and 49. In our study, 7 healthy subjects were studied
on three different occasions with no reproducibility as indicated by the coefficient of
variation. In addition, 15 subjects attended for testing on two consecutive visits.
These data were used to make a Bland-Altman plot.
7.3 Aim of the Study
The aim of this study was to test the reproducibility of BRS using the spontaneous
method, with spontaneous breathing, since the initial placebo-controlled study has
failed to show any significant difference between CPAP and placebo. A possible
explanation for this finding could be that this method of measurement of BRS is not
reproducible. To test this possibility, I used the spectral analysis of BRS to
investigate the fluctuations in R-R intervals and systolic blood pressure over time. In
addition, I tested the reproducibility of the spectral as well as the sequence method
using CoV and Bland-Altman plot.
7.4 Subjects and Protocol
The study was performed in a similar way as explained above. Fifteen healthy
subjects were recruited to perform the test. They breathed freely with no attempts
made to control the frequency. Seven subjects completed three visits in three
consecutive weeks and eight subjects were studied twice with one week in between.
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7.5 Data Analysis
BRS was estimated as in the previous procedure, to obtain the sequence BRS and
also the spectral analysis of BRS. We integrated power spectra of systolic pressure
and R-R interval within frequency range, 0.02-0.15 Hz (VLF and LF frequencies),
and took baroreflex sensitivity to be the square root of the ratio between the
integrated spectra of the R-R interval and systolic pressure (total BRS).
BRS= V (power R-R Interval/ power SBP)
We also used a more advanced programme to assess the data from some of the
subjects.
The analysis was performed on data samples of five minutes, moving two seconds at
a time, with analysis window width of 16 seconds. The same analysis was performed
using three consecutive 5-minute intervals.
7.6 Data Shuffling
I studied the possibility that a random relationship between the systolic power and R-
R interval power could cause similar values of BRS. To do this the input data were
modified so that the relationship between the systolic blood pressure and the heart
rate intervals was destroyed. This was done by interchanging the values for
individual randomly chosen pairs of systolic blood pressure values. This resulted in
the values for systolic blood pressure being "shuffled", but the R-R intervals and
time values remained unchanged. The shuffling was done by exchanging SBP values
from different positions in the time sequence. The diagram below explains this
process. The entire sequence of the systolic BP values (> 1000) was taken and all the
SBP values were shuffled which means that 1000 pairs of SBP and R-R intervals
were repositioned. Values were chosen and exchanged with another values, both
122
chosen at random from the time series. In this way, the mean systolic blood pressure












1 0.76 148.8 > *150.5
2 0.87 157.6 \ / 165.7
3 1.15 161.1 \ / 155.1
4 0.98 155:9k \ / 154.9
5 1.02 156.6 \ \ / *152.4
6 0.88 154.5 \V / 151.5
7 0.88 151.2 /V / 163.9
8 0.78 147.6 / V)C 152.9
9 0.81 151.6 / \ >4.149.1
9 0.83 152.5 / \ 155.9
10 0.81 151.1/' 14L2
11 0.72 150.5 / \l52.5
12 0.75 151.6 / ^5.4
12 0.75 152.3 / 148.8
13 0.78 151.9 / 151.3
14 0.70 147.1 / 146.6
15 0.78 151.5 / 146.4
16 0.88 152.4 136.6
16 0.75 148.7 149.6
Figure 7.2 Diagram demonstrates the shuffling process.
The original data and the shuffled data were then subjected to Fourier analysis and
used to calculate the BRS as before. Excel for windows was then used to analyse the
reasons for variation in BRS.
7.7 Statistics
Reproducibility was tested using coefficient of variation for the subjects who




7.7.1 Characteristics of the Participants
Table 7.2 Characteristics of the Participants
Mean St. deviation
Age (Years) 32 7
BMI (kg/m2) 24.8 4.1
SBP (mmHg) 112 12
DBP (mmHg) 77 8
The participants were 9 males and 6 females who were not taking any medication
and they were all non-smokers. They were young, not overweight, and normotensive
7.7.2 Preliminary Analysis
Figure 7.3 shows BRS from one subject in the first 5 minutes of recordings. The data





Figure 7.3 BRS fluctuation over 5 minutes period
We also studied one subject for 15 minutes continuously as it is shown in the figure
7.4, which indicates that BRS continue to fluctuate in spite longer period of analysis




Figure 7.4 BRS fluctuation over 15 minutes period
Since we use to study our subjects in three 5-minutes intervals, I tried to demonstrate
the variation of BRS in three consecutive 5-minute intervals which also was very
marked. The mean of BRS in the first, second and third 5-minutes were also variable,
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Figure 7.5 The BRS scores in three different 5-minutes intervals A, B &C. adding them
together in graph D in which blue line indicates the first interval, whereas pink and yellow line
indicates the second and third intervals respectively.
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Similarly in figure 7.4, comparing the BRS results on three different days, shows that
the variability of BRS is even more marked the mean of BRS for the first, second and
third day respectively 16.3± 7.8, 7.8± 4.9, 12.1±8 ms/mmHg.
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Figure 7.6 The BRS scores in three different days A, B & C. Graph D represent the three
days together in which blue line indicates the first day, whereas pink and yellow line
indicates the second and third day respectively.
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7.7.3 Baroreflex Sensitivity
To study the cause of this variation in the BRS scores, data from one subject were
examined in more detail. I considered the possibility that large values for the BRS
could occur if the denominator in the formula became very small, that is if there was
a negligible value for systolic pressure power. Total BRS scores were plotted against
total spectral power of the systolic pressure, using power in very low and low
frequencies and total spectral power of R-R intervals, figure 7.5. This plot shows that
high BRS scores occurred when there was an association with a small value for the
power spectrum of systolic pressure. The same relationship was inspected for the rest
of the recording periods and similar results were obtained. In contrast, the plot of
BRS in relation to the power of the RR interval did not show such an evident bias to
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Figure 7.7 Total power of systolic pressure and heart rate A: indicates the correlation
between total BRS and spectral power of systolic pressure; B: indicates the correlation
between total BRS and spectral power of R-R intervals.
7.7.4 After Data Shuffling
We have studied one subject uninterrupted for 15 minutes (900 seconds, spectral
width 2048 samples equal to 16 seconds of analysis time). We used data before and
after shuffling of the systolic pressure values. Figure 7.7 suggests that shuffling the
data and breaking the biological link between power of the arterial pressure and the
R-R intervals does not make any difference in terms of reproducibility of baroreflex
sensitivity. Table 7.3 below demonstrates the difference between shuffling and
134
unshuffling of the data. There was no significant difference (P=1.0) apart from total
BRS scores and as expected total power of systolic pressure (PcO.OOOl). These
results indicate that total systolic spectral power is the major factor in determining
BRS fluctuation, which is also obvious from the graphs below, figures 7.6 and 7.7.
These graphs indicate that there is major fluctuation in systolic pressure and with
lesser extent with heart periods (R-R intervals) when plotting the row data of these
two variables.
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Figure 7.8 The two graphs show the row data the fluctuation of the systolic pressure and R-








Figure 7.9 BRS before (A) and after (B) shuffling
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Table 7.3 comparison between shuffled and unshuffled data
Shuffled Unshuffled P
Mean SD. Mean SD
Total BRS
(ms/mmHg)
19.7 13.1 14.7 9.6 >0.0001
spectral period power (Hz) 1957.5 1900.6 1957.5 1900.6 --
Spectral systolic (Hz) 6880920 5503778 13974123 14627056 >0.0001
SBP(mmHg) 150 5 151 5 1.0
DBP(mmHg) 87 4 87.3 4.3 1.0
R-R intervals(ms) 0.8 0.08 0.8 0.08 1.0
7.7.5 Overall Analysis
Statistically the study was analysed in two ways; coefficient of variation (CoV) and
Bland-Altman plot for reproducibility of measurements.
CoV (coefficient of variations)
Seven subjects attended for measurement of BRS test on three consecutive weeks at
the same time of the day on each visit. The following tables show the BRS values of
three visits. These values are BRS with sequence analysis and BRS with spectral
analysis that include VLF, LF, HF and alpha.
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Visit 1 Visit 2 Visit3 COV%
Subject 1 23.8 18.1 14.5 24
Subject2 40.7 22.3 39.6 30
Subject3 32.4 79.5 48.1 45
Subject4 37.4 47.2 56.7 18
Subject5 11.8 12.4 10.9 7
Subject6 13.9 18.0 13.4 17
Subject7 19.9 25.8 15.1 26




Visit 1 Visit 2 Visit3 COV%
Subjectl 14.7 9.2 13.8 23
Subject2 16.7 9.9 10.9 29
Subject3 8.2 12.7 15.8 31
Subject4 29.2 30.3 21.3 18
Subject5 5.4 5.6 7.2 16
Subject6 11.2 7.2 8.9 22
Subject7 10.1 20.0 5.6 26





Visit 1 Visit 2 Visit3 COV%
Subjectl 35.0 17.3 26.2 34
Subject2 58.7 19.1 44.0 49
Subject3 26.4 52.8 44.0 33
Subject4 81.0 60.1 68.1 15
Subject5 12.8 12.1 11.6 5
Subject6 24.9 19.0 20.6 14
Subject7 21.9 55.1 26.0 52




Visit 1 Visit 2 Visit3 COV%
Subjectl 117.3 45.2 68.5 49
Subject2 75.9 39.2 65.1 31
Subject3 77.1 49.3 71.6 22
Subject4 94.8 89.5 96.5 4
Subject5 28.6 21.8 19.5 2
Subject6 41.7 43.9 37.5 8
Subject7 28.7 92.4 66.8 51
Mean 23.9 ± 20.6
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Table 7.8 Alpha BRS
Alpha BRS
(ms/mmHg)
Visit 1 Visit 2 Visit3 COV%
Subject 1 76.2 31.3 46.0 45
Subject2 67.3 29.2 53.0 39
Subject3 51.7 51.0 57.8 7
Subject4 87.9 75.2 82.3 8
Subject5 20.7 17.0 15.6 15
Subject6 33.3 31.4 29.2 7
Subject7 25.3 73.8 46.4 50
Mean 24.4 ± 19.4
CoV: coefficient of variation, ([standard deviation / mean] x 100.)
The mean coefficient of variation for all the five variables was greater than 20 %,
which indicates that the methodology of the study did not generate highly
reproducible data. Tables 8.4-8.8 show that there is wide range of CoV between
subjects. VLFBRS is less variable between subjects (16-26) compared to alpha BRS
(7-50), HFBRS (2-51), LFBRS (5-52), and sequence BRS (7-45).
Bland-Altman plot
The Bland-Altman plot is a statistical method used to compare two measurement
techniques. It may also be used to assess the repeatability of a method by comparing
repeated measurements using one single method on a series of subjects (Bland &
Altman 1986). Since for the repeated measurements the same method is used, the
mean difference should be zero. The Coefficient of Repeatability (CR) can be
calculated as 1.96 (or 2) times the standard deviations of the differences between the
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two measurements. In this study, I used Bland-Altman plots to test for the
reproducibility of BRS measurement on two different occasions. In the figure 8.8
below I have plotted the difference between measurements against the average of the
two visits for all the BRS measurement which includes sequential analysis, and
spectral analysis, VLF, LF, HF and alpha BRS.
BRS (Sequence analysis)
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Figure 7.10 Bland-Altman plot for five parameters of spontaneous BRS measurements used
in the study of BRS and OSAHS
These five graphs in figure 8.8 demonstrate the lack of agreement between the first
and second visits. The coefficient or repeatability is large in BRS (sequence analysis)
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(CR=27), LF (CR= 28), HF (42), alpha (30). VLF scores have the lowest coefficient
of repeatability (CR=8)
7.8 Discussion
There are several methods of directly assesing baroreflex gain. As I have discussed
above, these involve some perturbation that directly alters the system: the Valsalva
manoeuvre, carotid occlusion, neck suction, vasodilators and/or vasoconstrictors, and
postural changes. Recent research has made use of spontaneous oscillations in blood
pressure and heart rate as we have done in this thesis. The baroreflex, as I have
explained earlier in this thesis (Chapter 2), is the negative feedback that responds to
arterial pressure changes by altering heart period, which may result in turn in arterial
pressure changes. Physiologically it is difficult to assess baroreflex because it acts
within a closed loop system. Thus, without opening the closed loop system, it
remains uncertain whether heart period changes are responding to or adding to
changes in pressure. Only by opening the loop can the output-to-input ratio of the
feedback control system, termed gain or sensitivity be assessed. Nevertheless, the
gain of the closed system can be assessed spontaneously without opening the loop, as
in this study. It can be valid only if the input and output fluctuations of the system
are sufficiently large, the system encompasses feedback relations alone, and if the
gain is linear across all ranges. Unfortunately, all three of these conditions are
difficult to meet in human baroreflex studies (Chen & Bishop 1983;Ludbrook 1984).
Spectral estimates of BRS cannot explicitly distinguish between feedback and feed
forward gain of baroreceptor function (deBoer, Karemaker, & Strackee 1987).
Sequence analysis avoids this confound by limiting the data to only those
fluctuations wherein pressure changes precede parallel heart period changes,
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although only around 20% or fewer of beats in a time series fulfil these criteria
(Bertinieri et al. 1988). Thus, the physiological assumptions upon which spectral and
sequence indices rely are not the same, although they have been used
interchangeably (Hughson et al. 1993)
This study investigated the reproducibility of baroreflex sensitivity provided by the
spontaneous method in a group of healthy subjects who attended the test on more
than one occasion. We have evaluated BRS by the sequence method and more
importantly the spectral method. The analysis provides new insights into these
measurement methods. Firstly, baroreflex sensitivity appears to vary considerably
from minute to minute in subjects thought to be in a steady state. Secondly, this
fluctuation of baroreflex values is also obvious from day-to-day measurements which
could be oscillations occurring mainly at low frequency (Eckberg 1980;Eckberg &
Kuusela 2005). Finally, the width of the window used for analysis does not have a
major effect on baroreflex fluctuation, confirming the finding of Eckberg (Eckberg &
Kuusela 2005)., nor on different spectral outcomes mainly VLF and LF.
7.8.1 Data Shuffling
To investigate further the cause of this variation I tried in this study to separate the
relationship of R-R interval power changes from systolic blood pressure, by shuffling
the SBP values. The aim of shuffling was intended to provide data that were not
related; to see if the fluctuations were random or related to some link between R-R
intervals and the systolic power signal. Shuffling showed that random variation could
also generate large fluctuations in BRS. We have shown that systolic blood pressure
is the major determinant in this fluctuation as it is shown from the tables and graphs
above. However shuffling SBP values did affect the BRS values between shuffled
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and unshuffled data. Thus could be because the coherent relationship between SBP
and R-R intervals is disturbed.
This study compared the reproducibility of the spontaneous methods on more than
one visit. We tried to show the reproducibility of the spectral analysis as well as the
sequence analysis by two different statistical methods, coefficient of variation
(Iellamo et al. 1996) and Bland-Altman plot (Davies et al. 1999), which had been
used in other studies for the same purpose. Both statistical methods showed that
repeat measurements of BRS are only weakly reproducible.
The reproducibility of these methods has been studied, before this study was started,
as I have indicated in the introduction section. The reports of these studies did not
indicate or emphasise the same lack of reproducibility as we have demonstrated here.
However Lipman et al (Lipman, Salisbury, & Taylor 2003), did find that
spontaneous methods are inconsistent with arterial baroreflex gain. In that study,
baroreflex gain values fluctuated within a large range (12-27 ms/mmHg) making the
limits of agreement for all indices greater than the estimated mean of the baroreflex
gain of the population, thus indicating weak agreement. In the present study, the
Bland ltman plots showed confidence intervals that often approached the magnitude
of the measured variable, indicating a very limited confidence in these estimates.
Furthermore, the CoV values obtained from measurements on three different
occasions also suggest poor reproducibility of spontaneous BRS indices. Other
studies have reported lack of reproducibility of spontaneous baroreflex indices.
Maestri et al(Maestri et al. 1998), found only weak agreement between
phenylephrine BRS and spectral indices in post-myocardial infarction patients. He
attributed this variability to measurement errors in both methods. Similarly,
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Colombo et al (Colombo et al. 1999), found weak agreement between the two
methods in heart failure patients especially in uncontrolled breathing.
7.9 Conclusion
It is not likely that arterial baroreflexes are the sole reason for fluctuations of heart
period paralleling those in systolic pressure. Spontaneous indices, either spectral or
sequence analysis cannot be used to evaluate baroreflex gain since they cannot
directly assess the actual changes that take place within the closed loop. Early studies
of low frequency fluctuations in arterial pressure suggested that these could be
caused by changes in central sympathetic activity (Preiss and Polosa 1974) Thus,
these methods may be a poor way to evaluate treatment effects.
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Chapter 8
Methods for the Study of Sleep Apnoea and Endothelial
Function
8.1 Introduction
Vascular endothelium plays a key role in the biology of the arterial wall by the
release of vasoactive factors. Clinical methods for the study of the endothelial
function have recently developed considerably and endothelial function is now
recognized as a marker for evaluating cardiovascular diseases as well as the benefits
of drugs (Newby et al. 1999b;Newby et al. 1999a). In this section, the current
methods available for testing endothelial function are discussed.
8.1.1 Circulating Biomarkers
Among current markers used in testing endothelial integrity, are Nitric Oxide
metabolites, which are nitrites and nitrates metabolites were reported to be elevated
in hypertension (Baylis & Vallance 1998). Nevertheless, these metabolites are
strongly dependent on the diet. As discussed in Chapter 2, endothelin is also a
biological marker for endothelial function. In contrast, high circulating levels of C-
reactive protein (CRP) are well correlated with endothelial reactivity and are
predictive of major cardiovascular events (Mulvihill et al. 2001). However, CRP
level is influenced by non-vascular inflammatory phenomena, which must be taken
into account for individual interpretation. Other inflammatory markers are also
relevant. For example, levels of tumour necrosis factor-alpha (TNF-a) were related
to endothelium-dependent dilatation of skin resistance arteries in a heart transplant
recipient (Holm et al. 2000). Furthermore, high levels of tissue plasminogen activator
inhibitor are correlated with endothelial reactivity in hypertensive patients (Jansson,
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Olofsson, & Nilsson 1993;Ridker et al. 1993). Recently, asymmetric
dimethylarginine (ADMA) has been considered one of the biological markers for
endothelial function and it is observed to play a role in hypertension and ischaemic
heart diseases (Vallance et al. 1992b) (see Chapter2).
8.1.2 Brachial Artery Flow-mediated Dilatation
Post-ischaemic hyperaemia has been proposed as a method to evaluate the
endothelial function of peripheral arteries. Blood vessels have the capacity to adjust
blood flow in response to luminal physical and chemical stimuli (Joannides et al.
1995). An increase in blood flow will result in an increase in the shear stress to
which the local vascular endothelium is subjected and the vessel responds by
dilating, a phenomenon called flow-mediated vasodilatation (FMD) (Celermajer et
al. 1992). High-resolution ultrasound imaging is used to measure the blood vessel,
which is usually the brachial artery. A blood pressure cuff, placed either above or
below the transducer position, is used to create the flow stimulus in the brachial
artery. When placed above, the stimulus is greater, although accurate visualisation is
more difficult. After baseline diameter measurement, the cuff is inflated to
suprasystolic pressure for 5 minutes. Cuff deflation induces a brief high flow state
(reactive hyperaemia) that subjects the endothelium to shear stress causing it to dilate
(Alam, Seifalian, & Baker 2005). However, this procedure is operator-dependent and
the ultrasonographic assessment of the brachial artery is challenging; therefore, the
examination must be performed by well-trained sonographers.
8.1.3 Laser Doppler
Laser Doppler iontophoresis (LDI) is a non-invasive technique which was developed
to avoid the inconvenience of venous occlusion plethsmography. Iontophoresis is
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used to administer a minute quantity of a drug through the skin, using small electric
currents. The underlying principle is that the molecules of a drug in solution are
either positively or negatively charged, and will migrate across the skin under the
influence of an applied monopolar current (Morris & Shore 1996). Acetycholine and
sodium nitroprusside are used to generate endothelium-dependent and endothelium-
independent vasodilatation, respectively. The procedure is carried out using very
small currents (<100 pA) and it is painless. The forearm microvascular bed is usually
the site of choice, and iontophoretic electrodes are attached to the volar aspect. The
quantity of drug delivered is too small to have any systemic effects, although mild
allergic reaction and skin irritation have been reported (Ramsay et al. 2002).
Nevertheless, LDI technique is not without problems. The variability of skin
conductivity in different populations must be considered when designing studies and
interpreting results. A more significant problem is the tendency of the applied current
to cause vasodilatation, even in the absence of an administered drug (Berliner
1997;Ramsay et al. 2002). However, LDI is becoming increasing popular since it is a
non-invasive technique and provides a direct assessment of microvascular
endothelial function.
8.1.4 Pulse-wave Analysis
Pulse-wave analysis (PWA) (Wilkinson, Cockcroft, & Webb 1998;Wilkinson &
Webb 2001) is a fairly new technique that provides a non-invasive method of
assessing global endothelial functions. Arterial stiffness is partly dependent on
vasomotor tone, which in turn relies on an intact endothelium. As the arterial pulse
waveform travels from the central circulation to the periphery, its shape provides a
measure of systemic arterial stiffness, thus changes in the shape of the waveform will
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partly reflect endothelial function (Hayward et al. 2002). PWA is new technology
and it is also cheap, although it needs more validation with well-established methods
such as venous occlusion plethsmography.
8.1.5 Venous Occlusion Plethysmography
This is the main topic of this chapter and it will be discussed in depth below.
8.2 Principle of the forearm study
The underlying principle of forearm venous occlusion plethysmography is that when
venous drainage from the arm is interrupted for a short period, arterial inflow is
unaltered, so blood can enter the forearm but cannot escape. This results in a linear
increase in forearm volume over time, which is proportional to arterial blood inflow
until venous pressure rises towards the occluding pressure. Most of the forearm
blood flow is through skeletal muscle (70%) and most of the remainder circulates
within the skin. The hand should be excluded during the measurement, for it has a
different blood flow physiology and the blood flow might be non-linear (Wilkinson
& Webb 2001).
8.3 Plethysmography
The procedure itself consists of inflating a cuff, placed around the upper arm, to
above the venous pressure of around 40 mmHg. The cuff is inflated for 8 seconds,
followed by deflation for 4 seconds. This manoeuvre does not alter the blood flow
and allows venous emptying. The hands are excluded by a smaller cuff, placed
around the wrist, inflated to above systolic pressure of around 190 mmHg. This cuff
should be kept constantly inflated during the measurement of around three minutes.
The forearm must be positioned above the level of the heart to ensure adequate
venous emptying. Changes in forearm volume are measured by a plethysmography.
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A strain gauge made of mercury-in-rubber is placed around the widest part of the
forearm and acts as a resistor connected as one arm of a Wheatstone bridge. Changes
in forearm volume result in a corresponding change in arm circumference and thus
strain gauge length, which can be detected as an alteration in electrical resistance of
the gauge, and thus potential difference. It is very important that the length of the
gauge is equal to the resting circumference of the limb, and then changes in limb
volume are directly proportional to the changes in resistance (Raitakari & Celermajer
2000;Webb 1995;WHITNEY 1949). The measure of blood flow to the forearm is
usually expressed as ml per 100 ml of forearm volume per minute (Benjamin et al.
1994;Wilkinson & Webb 2001)
8.3.1 Drug Administration
venous occlusion plethysmography allows the study of the local effects of drug
infusions (Webb 1995). Drugs can be infused intra-arterially by placement of a fine
(27-gauge) needle into the brachial artery of the non-dominant arm under local
anaesthesia, which may cause minimal discomfort. Minor problems such as bruising
and local discomfort may appear at the time of cannulation, although they usually
settle rapidly without any further problems. The needle is connected to an infusion
pump by a tube with a similar calibre, which is set to deliver the appropriate flow
rate. In addition, venous cannulation with 17-gauge cannula should be performed in
both arms to allow blood sampling during the study.
8.3.2 Administered Drugs
Acetylcholine
Acetylcholine (Ach) is a potent endothelium-dependent vasodilator which acts on
muscarinic receptors, primarily of the M3 subtype, to release NO from the
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endothelial cells (Burning et al. 1994). It has a very rapid action with very short half-
life (1 minute) and produces dilatation of almost all vascular beds, including those of
the pulmonary and coronary vasculature. Although Ach is rarely given systemically,
its cardiac actions are of importance because of the involvement of cholinergic vagal
impulses. Small doses of Ach produce an evanescent fall in blood pressure because
of generalized vasodilatation, accompanied usually by reflex tachycardia. If a large
dose is given systemically, AV node block may be elicited with consequent
bradycardia (Brown & Taylor 2001). In this study, Ach is infused locally with very
small doses (5-20 micrograms) with great caution to avoid any systemic spillover.
Blood pressure and pulse are measured regularly to check for any systemic effect as
is indicated in the drug protocol below.
Substance P
Substance P is an endothelium-dependent vasodilator, which belongs to the
tachykinin family of peptides. Substance P is present in the central nervous system,
where it is a neurotransmitter, and in the gastrointestinal tract, where it may play a
role as a transmitter in the enteric nervous system (Reid 2001). Substance P is also a
potent vasodilator, producing marked hypotension in humans. The vasodilatation
results from a direct action on arteriolar smooth muscle, which is mediated by the
endothelial cell NK1 receptors. However, endogenous substance P does not appear to
contribute to the maintenance of peripheral vascular tone or systemic blood pressure
(Newby et al. 1999a).
Sodium Nitroprusside (SNP)
SNP is an endothelium-independent non-selective nitrovasodilator. It is metabolized
by blood vessels to its active metabolite, nitric oxide. It dilates both arterioles and
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venules, and the haemodynamic response to its systemic administration results from
a combination of venous pooling and reduced arterial impedance. SNP is an unstable
molecule that decomposes under strong alkaline conditions and when exposed to
light, hence, it should be kept in a dark place or covered once it has been prepared.
Its onset of action is within 30 seconds of infusion with the peak effect within 2
minutes. The effect disappears within 3 minutes of stopping the drug infusion. The
short-term side effects of SNP are mainly limited to hypotension. This is unlikely to
happen in this study, for very small doses (2-8 micrograms) are infused locally.
Nevertheless, close monitoring of BP and pulse rate was regularly performed. Less
commonly, toxicity may result from the conversion of SNP to cyanide and
thiocyanate, which may lead to severe lactic acidosis. However, such toxicity might
occur only if the drug is infused at a rate greater than 5 microgram/kg per minute
(Oates & Brown 2001).
8.4 Protocol
8.4.1 Subject Recruitment
Consecutive new patients with obstructive sleep apnoea/hypopnoea syndrome
confirmed by polysomnography at the Scottish National Sleep Centre, Edinburgh
Royal Infirmary, were invited to participate in the study. The patients were divided in
to two groups;
1. OSAHS with mild desaturations: AHI > 15, ESS >11 with 4% desaturation
index (4% DI) < 2.
2. OSAHS with severe desaturations: AHI > 15, ESS >11 but the 4% DI > 20.
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8.4.2 Exclusion
We excluded subjects who were unable to give written informed consent, subjects
with respiratory comorbidity such as chronic obstructive airways disease, interstitial
lung disease or pulmonary hypertension as defined on clinical and pathological
grounds. We also excluded patients with significant kyphoscoliosis; daytime
hypoxaemia of any cause defined as a oxygen saturation < 90% of breathing air; a
partial pressure of carbon dioxide > 45mmHg, chronic heart failure; myocardial
infarction within 3 months of the study; subjects aged < 18 or > 75 years; FEV1 <
65% predicted, subjects on ACE inhibitors and ACE receptor blockers; diabetic
patients; those who had problems with sleepiness when driving; and shift workers.
All the plethysmography procedures were done in the Wellcome Trust Clinical
Research Facility, Western General Hospital.
8.4.3 The Procedure
Written informed consent was obtained from each subject before entry into the study
(patient information sheet appendix 4). The study was approved by the local ethics
advisory committee. All participants had height and weight, and neck, waist and hip
circumferences measured. The Epworth Sleepiness Scale was completed at the start
of the study. Both groups had a full 48-hour ambulatory blood pressure recording
before coming to the forearm study. Blood pressure was taken from the second set of
24-hour readings, allowing for adjustment to the cuff and device over the initial 24
hours (similar to the baroreflex study). For the forearm study, subjects were required
to abstain from alcohol for 24 hours, and caffeine-containing drinks, tobacco, and
food for 6 hours before each study. All studies were carried out at 0900 hours in a
quiet, temperature-controlled room maintained at 22-24°C. Subjects lay recumbent
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on a bed for the study duration. Semi-automated blood pressure cuff, venous
occlusion cuffs, and strain gauges were applied. Pulses were checked. Intravenous
cannulae and brachial artery needle were inserted under lignocaine local anaesthesia.
A 27G needle was inserted in the non-dominant brachial artery. A 17G cannula was
inserted into an antecubital vein in each arm for withdrawal of blood samples. Saline
was infused at 1 ml/min to maintain patency of the arterial needle. Blood pressure
and heart rate were recorded throughout. Forearm blood flow measurements were
made every 20 minutes. After 30 min of saline infusion at 1 ml/min, intra-arterial
substance P at 2, 4, 8 pmol/min, acetylcholine at 5, 10, 20 pg/min and sodium
nitroprusside at 2, 4, 8 pg/min were infused for 6 min at each dose. There was a
washout period of 20 minutes between each agent. Each patient had his or her drug
order protocol randomly allocated by the research nurse to avoid any order bias. At
the end of the study, cannulae were removed and haemostasis ensured. Pulses were
rechecked. Subjects were observed for a period of 30 minutes and provided with a





Cuff inflated Cuff deflated




Table 8.1 Example of drug order








-7 min V V V
Omin Substance P
2 pmol/min
3 min V V V
6 min 4 pmol/min
9 min V V V
12 min 8 pmol/min
15 min V V V
18 min 0.9% NaCl
25 min V V
32 min V V
38 min Acetylcholine
5 pg/min
41 min V V
44 min 10 pg/min
47 min V V
Ci\50 mm 20 pg/min
53 min V V
56 min 0.9% NaCl
63 min V V
70min V V
76 min Sodium NP
2 pg/min
79 min V V
82 min 4 pg/min
85 min V V
88 min 8 pg/min
91 min V V




Note that the order of agents varied with each patient
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8.5 Data Analysis
Ten patients with a 4% oxygen Desaturation index (DI) > 20 and ten patients with
mild desaturation (DI 4% < 2 & 3% DI< 5) were studied. Measurement of the
forearm blood flow was done by chart for windows (chart4 for windows)
programme. The scoring was calculated by taking the difference between the peak
and the trough of the venous occlusion curve. The data were then moved to Excel for
further processing.
Figure 8.2 Example of plethysmography recordings: the upper section is the control arm and
the lower section the infused arm.
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Table 8.2 Example of the summary of changes of the forearm size that took place after
infusion with each dose of the drugs used
FBFxontrol FBF: % % Inf/control % A
arm infused arm Axontrol A:infused arm from
arm arm predose
baseline 1 1.11 4.00 -52.48 7.61 3.61 126.47
baseline2 2.33 3.72 0.00 0.00 1.59 0.00
SNP2 2.84 7.16 21.52 92.59 2.53 58.48
SNP4 2.25 9.02 -3.42 142.52 4.00 151.10
SNP8 2.99 11.41 28.30 206.90 3.81 139.21
washoutl 2.85 5.75 -3.50 3.90 2.02 7.67
washout2 2.95 5.53 0.00 0.00 1.87 0.00
subp2 3.00 7.44 1.45 34.49 2.48 32.56
subp4 2.46 7.93 -16.65 43.39 3.22 72.03
subp8 3.08 10.63 4.18 92.13 3.46 84.42
washout3 3.39 5.47 11.06 20.66 1.61 8.64
washout4 3.06 4.54 0.00 0.00 1.48 0.00
Ach5 3.37 8.99 10.22 98.14 2.67 79.77
AchlO 3.50 8.03 14.47 77.00 2.29 54.63
Ach20 3.27 12.56 7.10 176.78 3.84 158.43
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Changes of Forearm Blood Flow
Figure 8.3 Changes in forearm blood flow in the infused arm compared to the control arm in
one subject
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% A Blood Flow From Predose







Figure 8.4 The percentage of change of forearm blood flow from predose in one subject.
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Chapter 9
OSAHS and Endothelial Function Study Results
9.1 Introduction
This is an ongoing study of OSAHS and endothelial function. Twenty patients were
included in the analysis: 10 male patients from the severe group (4% DI > 20), and 9
males and one female from the mild group (4% DI < 2 & 3%DI < 5).
9.2 Aim
The aim was to investigate whether hypoxaemia caused by OSAHS can impair the
endothelial function. The hypothesis was that the severely hypoxaemic group might
have an impaired response to vasodilating drugs, compared with the mild non-
hypoxaemic patients.
9.2 Demographics of Patients
Table 9.1 compares the characteristics of the patients included in the analysis, using
independent t-test.
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Table 9.1 Comparison between mild and severe groups
Severe group Mild group
P-
ValueMean S.D. Mean S.D.
Age 51 7 51 9 0.97
BMI 38.6 7.7 28.8 3.4 0.004
AHI 53.5 19.4 19 4.4 —
4% DI 42.9 15.2 1.5 0.9 —
ESS 17 3 14 3 0.08
SBP 136 12 129 10 0.2
DBP 80 11 80 8 0.9
Neck 45.5 3 42.7 1.5 0.04
Waist 122.3 17.3 98.3 10.2 0.01
Hip 123 16.9 103.3 4.8 0.02
Hip/waist 1.0 0.08 1.1 0.07 0.2
None of the patients in either group had ischaemic heart disease, hypertension or
diabetes, although 2 of the severe OSAHS patients and 5 of the mild group were
smokers. The patients in the severe group were more obese (P < 0.05, for BMI, and
neck, waist, and hip size but not for hip/waist ratio P=0.2). Symptomatically, there
was no statistical significance (P = 0.08), although there was a trend for the ESS for
the severe group to be higher (17±3) compared with the mild group (14±3).
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Nevertheless, there was no significant difference in the systolic or diastolic blood
pressure.
9.3 Forearm Blood Flow Results
Based on the methodology of this study, the analysis of the data was performed in
two stages, first for the control arm and then for the infused arm.
9.3.1 Statistics
The recordings of the plethysmography were scored using the Chart for Windows
programme (see Chapter 9). The Independent-Samples T Test was used to compare
the means for the two groups of cases.
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9.3.2 Results
Table 9.2 Control (non-infused) forearm blood flow: comparison of mild and severe OSAHS
Mild group Severe group P-value
(2-tailed)Mean S.D. Mean S.D.
Baseline 1 2.5 0.7 3.6 1.5 0.07
Baseline2 2.8 0.6 3.6 1.4 0.1
Pre Sub. P 2.6 0.6 3.7 1 0.02
Sub. P 2 3.1 0.4 3.7 1.3 0.1
Sub. P 4 3 0.7 3.7 1.4 0.2
Sub. P 8 2.9 0.8 3.8 1.4 0.09
Pre Ach 3.2 1 3.6 1.4 0.5
Ach 5 3.0 1 3.9 1.3 0.1
Ach 10 3.1 0.8 4 1.3 0.08
Ach 20 3.6 1.3 4.1 1.5 0.4
Pre SNP 2.8 0.9 3.9 1.4 0.07
SNP2 3.9 1.7 4.1 1.6 0.7
SNP4 3.3 1.2 4.1 1.4 0.2
SNP8 3.2 0.8 0.3 1.6 0.3
Values are expressed in ml/100 ml of forearm per minute.
Sub P = substance P Ach= Acetylcholine SNP= sodium nitroprusside
The data of the non-infused arms were normally distributed and an independent t-test
was performed to obtain the p-value. Most of the results did not show any significant
difference in absolute values of the perfusion between the two groups except pre-
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substance P (P = 0.02). In addition, there was a trend with AchlO pg and Substance P
8 fxg (P = 0.08 & 0.09 respectively). Generally, the mean of the forearm blood flow
study in the severe group was higher than in the mild group. The comparison of the
severe and mild groups in infused arm is summarized in Table 9.4
Table 9.3 Comparison of the infused forearm blood flow in mild and severe OSAHS
Mild group Sever group P-value
(2-tailed)Mean S.D. Mean S.D.
Baseline 1 3.1 0.8 4 1.6 0.1
Baseline2 3.1 0.9 3.6 1.3 0.3
Pre Sub. P 3.5 1.2 3.9 1.3 0.5
Sub. P 2 6.4 1.4 6.8 1.1 0.5
Sub. P 4 7 1.8 7.4 1.2 0.5
Sub. P 8 7.6 2.1 7.9 1.7 0.7
Pre Ach 3.6 1 3.6 1.2 1
Ach 5 6.6 2.8 5.8 2.2 0.5
Ach 10 6.6 2.7 6.6 2.4 1
Ach 20 7.2 2.4 7.4 2.8 0.9
Pre SNP 3.4 1.2 4 1.2 0.3
SNP2 7.5 2.3 7 1.2 0.6
SNP4 7.6 2 7.9 1.1 0.7
SNP8 8 2.2 9.1 1.6 0.2
Values are expressed in ml/100 ml of forearm per minute.
Using the absolute values of the study, there was no significant difference between
the two groups in the infused arm at any stage (P > 0.1) with any of the three infused
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drugs. During substance P infusion, the mean of forearm circumference was higher
though statistically insignificant compared with the mild group. This finding has not
been observed with acetylcholine and sodium nitroprusside drugs. The graphs in
Figure 9.1 summarize the difference between the two groups, which also did not
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Figure 9.1 Difference between severe and mild group with maximum drug dose cs = control
arm severe group; is = infused arm of severe group; cm = control arm mild group; im =
infused arm of mild group
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9.4 Conclusion
I tried in this study to assess the endothelial function in OSAHS patients in relation
to the extent of nocturnal hypoxaemia. We used a comprehensive procedure to
evaluate the response of vascular reactivity to hypoxaemia. This procedure is widely
used to asses the endothelial function in cardiovascular diseases (Newby et al.
1999a;Webb 1995). To the best of my knowledge at the time this study was started, it
was the first to assess endothelial function in OSAHS patients using forearm blood
flow technique in relation to nocturnal hypoxaemia. My initial hypothesis was that
severe hypoxaemic OSAHS patients would have impaired endothelial function
compared to mild OSAHS patients. However, the null hypothesis could not be
rejected concerning vascular reactivity between severe and mild OSAHS. This may
reflect a genuine lack of difference, a lack of power in this study or other differences,
since patients with severe OSAHS were more overweight compared with the mild
group, which may result in technical difficulties in measuring forearm blood flow.
As discussed in chapter 2, impaired endothelium dependent function and
endothelium independent function in the forearm vascular bed is associated with an
increased risk of acute cardiovascular events, including cardiac death (Newby et al.
1999b;Newby et al. 2001). The endothelium is a major target of oxidative stress, and
this stress may play a role in the pathophysiology of vascular disease. In OSAHS,
recurrent episodes of hypoxaemia followed by re-oxygenation may trigger
endothelial damage, via oxidative stress, superoxide radical formation (Row et al.
2003), its combination with nitric oxide and reducing nitric oxide bioavailability in
the vessel wall, which leads to vasoconstriction. This study did not show that
hypoxaemia has an effect on endothelial function, which could have been caused by
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the above-mentioned factors. However, more recent studies have shown that
oxidative stress and lipid preoxidation do not appear to be the key mediator for the
cardiovascular diseases in OSAHS (Svatikova et al. 2004;Svatikova et al. 2005).
This finding contradicts the results of other studies which showed that OSAHS
patients have an increased status of oxidative stress such as thiobarbituric reactive
substances and peroxides (Lavie 2003) and decreased antioxidant capacity which
could be reversed by CPAP treatment (Barcelo et al. 2006;Lavie, Vishnevsky, &
Lavie 2004). More randomised case-control studies with larger samples are required
to clarify the role of oxidative stress in the development of cardiovascular diseases in
sleep apnoea patients.
Further details will be discussed in the final chapter.
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Chapter 10
Hypoxaemia and Hypertension in Patients with Obstructive
Sleep Apnoea Hypopnoea Syndrome
10.1 Background
As discussed earlier, hypoxaemia could trigger an increase in sympathetic activity,
mainly through chemoreflexes, which could increase systemic blood pressure
(Narkiewicz et al. 1998c). The triggering of chemoreflexes to hypoxia is cannot be
explained only by obesity, since obese subjects who are otherwise healthy with no
OSAHS have chemoreflex responses similar to those seen in control subjects
(Narkiewicz et al. 1999a;Narkiewicz et al. 1999c). In addition, both hypoxia and
hypercapnia have local vascular effects, causing vasodilatation, which lowers the
blood pressure initially, which in turn causes an increase in sympathetic stimulation
and release of catecholamines (Shepard, Jr. 1990). Furthermore, hypoxaemia might
perhaps cause endothelial dysfunction, which consequently causes hypertension (see
Chapter 2)
10.2 Aim of the Study
The study aimed to determine putative predictors of hypertension in OSAHS
patients.
10.3 Methods
Ambulatory blood pressure monitoring was measured as described in Chapter 3.
Hypertension was defined by:
1-patients taking antihypertensive treatment
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2-patients found to be hypertensive on 24-hour ambulatory blood pressure
monitoring with mean systolic and diastolic blood pressure more than 140/90 mmHg
Desaturation status was determined by 4% decrease of oxygen saturation from the
baseline detected during sleep studies (see chapter 3)
10.4 Subjects
Thirty-nine patients participated in this study as part of the endothelial function





















Nineteen patients of 39 patients had hypertension (14 by ABP and 5 by anti-
hypertension treatment criteria), 24 were nocturnal desaturators and 32 non-dippers
(< 10% nocturnal fall in mean arterial BP).
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10.5.3 Forward Regression of Determinants
Forward regression of determinants found that increasing age (exp B 1.11 per yr, p =
0.03) and desaturation (exp B 0.15, p = 0.02) were significant independent predictors
for hypertension, together explaining 31% of hypertension variance. Forcing known
hypertension risks into a confirmatory model (age, BMI, male gender, AHI, and loss
of nocturnal BP dipping) (Table 10.2 and Figure 10.1) explained 30% of variance
(step 1), estimating a 12% increased odds of hypertension with each added year of
age and 3% increased risk with each unit rise in AHI (p = 0.03). Those with male
gender, BMI and loss of nocturnal BP dipping (all p >0.6) accounted for 30% in
hypertension variance. In step 2 (forward conditional regression), desaturation
explained an additional 11% of variance in hypertension (R 41%).
Figure10.1 The contribution of hypertension by different factors
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Table 10.2 Summery of the analysis
Step Variable p-value expB
Total Variance
explained (R2)
1 (forced) Age (years) 0.03 1.12 Blank?
AHI 0.04 1.03
Male gender 0.65 2.41
BMI (kg/m2) 0.964 1.00
Nocturnal BP dip 0.63 0.61 30%
2 (forward conditional) desaturator 0.06 0.19 41%
10.6 Discussion
Age and AHI were significant predictors for the development of hypertension in
OSAHS. In addition to these factors, male gender, BMI, and loss of nocturnal dip
contribute to 30% of the total risk of hypertension in sleep apnoea patients. This
suggests that hypoxaemia is a predictor of the development of hypertension in
obstructive sleep apnoea. It explains 11% of the variance in hypertension, but this
was statistically not significant (p = 0.06). It has been shown that the degree of
nocturnal hypoxia, as a result of obstructive sleep apnoea, is more closely associated
with the daytime level of blood pressure than with sleep fragmentation (Peled et al.
1998). In the same study, stepwise multiple regression analysis revealed that systolic
BP was predicted by the combination of age and morning nor-epinephrine levels,
whereas diastolic and mean BP were predicted by Sa02 alone or in combination with
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age. The fact that minimal oxygen desaturation is a predictor for hypertension was
reported from dog models when sustained daytime hypertension developed 2-5
weeks of induced apnoeas (Brooks et al. 1997). The mechanism behind the elevation
of blood pressure as a result of hypoxia was thought to be due to tonic activation of
chemoreflexes, which activates the sympathetic nervous system (Kara, Narkiewicz,
& Somers 2003;Loredo et al. 2001;Narkiewicz et al. 1998c). In animal models,
peripheral chemoreceptors were involved in the blood pressure response to chronic
episodic hypoxia. Furthermore, chronic hypoxia with hypercapnia might cause
greater increase in BP, similar to the OSAHS subjects, than hypocapnia hypoxia
(Fletcher 2000). Activation of the renin-angiotensin system may also contribute to
the elevation of blood pressure in chronic episodic hypoxia. Upregulation of the
tissue angiotensin n system appears to be necessary for the chronic blood pressure
changes that occur from episodic hypoxia (Fletcher, Orolinova, & Bader 2001). In
healthy subjects, interaction between chemoreceptor and baroreceptor reflexes
caused by hypoxia and hypercapnia (Cooper et al. 2005), and this may contribute to
the development of hypertension in OSAHS patients. Correction of intermittent
nocturnal hypoxaemia by CPAP therapy might reduce blood pressure in OSAHS
subjects as discussed before. However, a study by Norman et al. found that nocturnal
supplemental oxygen did not affect blood pressure, although 2 weeks of CPAP
therapy reduced both daytime and nighttime blood pressure (Norman et al. 2006).
Thus CPAP may reduce BP by other mechanisms, such as reducing repetitive
arousals in addition to abolishing the episodic hypoxaemia caused by the apnoea or





In this thesis, the relationship between OSAHS and hypertension has been
investigated. The initial discussion centred on the relationship between the two
disorders from the epidemiological as well as some of the physiological aspects of
the associations. The focus of the first study was to investigate the role of the
baroreflex in the development and modulation of hypertension in patients with
obstructive sleep apnoea/hypopnoea syndrome. The study was carefully designed to
measure baroreflex activity during wakefulness without any interruption by an
external stimulus such as light or sound, and no influences from ingested stimulants
(caffeine, alcohol and smoking). The study showed no significant difference between
the sequential domain measure of baroreceptor sensitivity or the spectral domains
between the OSASH patients and controls. Furthermore, there was no change in BRS
following one month of CPAP treatment.
In the intervention study, the patients improved symptomatically with CPAP,
compared with the placebo (ESS, P = 0.02), but not with FOSQ (P = 0.3). FOSQ has
been shown in one study to improve in OSAHS patients (Faccenda et al. 2001c) on
CPAP and the lack of difference in this study might perhaps be explained by low
power, although more severely affected patients were studied than those of Faccenda
et al. in terms of desaturation (4% desaturation index was 18.8 in this study,
compared with 7 in the Faccenda et al. study. Nevertheless, patients in this study
were less symptomatic - the median ESS in this study was 13, compared with 15 in
the Faccenda et al. study - which may explain the positive result in their study.
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However, the study did not show any significant difference between CPAP and
placebo treatment in the 48-hour BP measurement. This lack of difference was
present when the data were analysed either on an-intention-to-treat basis or after sub-
analysis by selecting the groups in whom greater changes might have been expected,
the desaturating and compliant patients. Furthermore, there was no difference
between CPAP and placebo when diurnal changes of BP data were analysed. The
lack of difference in BP could perhaps be explained by the small sample size.
Faccenda et al. found that there was a significant but marginal (1.4mmHg; P = 0.04)
decrease in diastolic BP after 4 weeks of CPAP, compared with the placebo, with a
sample size of 68 patients (Faccenda et al. 2001c). The CPAP-versus-placebo
component of this study was only based on 29 patients, although 10 of them used
their CPAP for more than 4 hours/night. Thus, a positive BP effect would not be
expected with these small numbers.
The main focus of this study was the baroreflex sensitivity using non-invasive
measures, and no significant difference was shown between the sequential domain
measure or the spectral domains of baroreceptor sensitivity between the OSASH
patients and controls. Furthermore, there were no changes in any measure of BRS
with CPAP compared with the placebo. To the best of the writer's knowledge at the
beginning of the study, this was the first trial that aimed to understand the role of
baroreflex sensitivity in OSAHS during wakefulness in normotensive patients with a
randomized trial of placebo and CPAP treatments. To understand the non-significant
outcome of this treatment study, it is necessary to explore the methodological and
physiological factors that perhaps might have contributed to the results.
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11.1.1 Technical and Methodological Factors
The time limit of the study was determined by the four-weeks crossover study, for
it has been shown that diastolic BP is reduced by CPAP over that period
(Faccenda et al. 2001c). However, MSNA has been shown to decrease
significantly after 6 months of CPAP treatment (Narkiewicz et al. 1999b).
Other studies have used a similar technique in evaluating BRS in a before-and-
after trial extending the CPAP treatment to three months (Bonsignore et al.
2002). Thus, a further study with an extended duration of therapy might be
needed to determine whether there is any long term benefit. Although there
have been studies that have measured the change in BRS after one night of
CPAP treatment, they were small and not randomized (Logan et al.
2003;Tkacova et al. 2000). Tkacova et al. studied 8 OSAHS patients with
congestive heart failure. CPAP increased the slope of BRS from 3.9 ms/mmHg
pre CPAP to 6.2 ms/mmHg during one night of CPAP treatment. Bonsignore et
al. found that three months of CPAP treatment increased BRS slope during
nocturnal wakefulness (P < 0.01) and stage-2 sleep (P = 0.0.5) (Bonsignore et
al. 2002). In a study by Logan at al., one night of CPAP treatment improved
the slope of BRS (P < 0.05) in 11 OSAHS with refractory hypertension (see
below).
Laboratory environment, such as noise in the corridor outside the bedroom, might
have a stimulatory effect on patients. Every effort was made to minimize noise
and the rooms were well soundproofed. Nevertheless, a change in the timing of
the study might prevent this disturbance by avoiding the daily activities in the
ward. Many studies examining the relationship between sleep apnoea and
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baroreflex during sleep have been done (Mateika, Kavey, & Mitru 1999). A
study by Logan (Logan et al. 2003) found that BRS slope improved while
patients were using CPAP for one night. In this study, BRS was measured
during stage-2 sleep to control for potential influences of the sleep state on the
outcome variables. However, CPAP will alter lung volume while it is
administered - but not in the daytime after CPAP use as in the current study -
which could affect autonomic tone and thus BRS. Similarly Tkacova (Tkacova
et al. 2000) studied OSAHS patients with congestive heart failure - not a pure
OSAHS group - before and after CPAP treatment during stage-2 sleep for one
night with a positive improvement in BRS slope while patients were on CPAP
for 2-3 hours. However, this improvement did not last after CPAP, so the
change in BRS was transitory. Furthermore, BRS was not been measured after
CPAP when patients were fully awake during the morning, as in our study. In
addition, the study was not well randomized and had a small sample size, as
discussed below, and some heart failure patients were on beta blockers
(Tkacova et al. 2000). Another study by Cooper et al,(Cooper et al. 2004)
found in simulated obstructive sleep apnoea that breathing with inspiratory
resistance reduces the sensitivity of the baroreceptor control of the vascular
resistance. They also found that asphyxia produces an increased set point of the
baroreceptor-vascular resistance reflex. However, they used neck chamber,
which works by applying suction or pressure to the neck overlying the carotid
sinuses.
Our sample size was relatively small which resulted in the low power of the study.
Furthermore, in the sub-analysis of the compliant patients (CPAP use > 4
180
hour/night) and more hypoxic patients (4% DI > 10), the sample size became
too small to show any significant difference (n = 9). The study was started by
another researcher (Dr J. Faccenda), in which 13 OSAHS patients were
included with no significant results either in whole or in part (13 + 29 = 42
patients). Most of the studies examining BRS in non-OSAHS populations used
a larger sample power of more than a hundred subjects (Lantelme et al.
2002;Pinna et al. 2002). However significant changes in BRS with acute
interventions have been reported in studies of samples of only 8 subjects
(Tkacova et al. 2000) and 11 OSAHS patients with refractory hypertension
(Logan et al. 2003). Bonsignore et al studied 29 normotensive OSAHS patients
and 11 normal subjects, which is almost similar to our sample (Bonsignore et
al. 2002).
Table 11.1 Sample Power calculation




Mean S.D. Mean S.D.
BRS (ms/mmHg) 4.9 2.5 5.5 4.4 2.6
VLFBRS(ms/mmHg) 3.1 1.3 3.5 2.3 1.4
LFBRS (ms/mmHg) 5.2 2.6 6.5 5.8 3.9
HFBRS (ms/mmHg) 8.7 6.5 9.5 9.3 6.0
AlphaBRS(ms/mmHg) 7.0 4.2 8.0 7.3 4.5
S.D. = standard deviation.
N = 29 patients
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A two-tailed t-test was used for the power calculation, which was based on the
data from our BRS study. From Table 12.1, it is clear that the sample size used
in this study was small and larger numbers of patients are required to show any
significant difference. In addition, it is now clear that the tests are very
insensitive, particularly for the high frequency baroreflex (HFBRS), which is
indicated by the higher mean difference required, eliciting a significant result.
However, the study was time-consuming for staff and participants, and large
resources would be needed to run the study with 80% power.
Validation of the methodology was probably the most important factor in the
negative outcome of the study. The standard method of calculating BRS in the
past was the change of pulse interval in response to infusion of phenylephrine
(Floras et al. 1988). The sequence technique, a fairly new method, was
introduced to replace the invasive method and it was validated in experimental
animals (Bertinieri et al. 1988) and in humans (Parlow et al. 1995), though with
different clinical conditions. It has been shown that there was a selective
impairment of BRS in normotensive sleep apnoea patients during wakefulness,
using the phenylephrine method (Carlson et al. 1996;Gerritsen et al.
2000;Mateika, Kavey, & Mitru 1999;Narkiewicz et al. 1998b). However,
before this study was begun, there had been studies using the new technique of
testing BRS, as discussed earlier, although in different settings and clinical
conditions (Gerritsen et al. 2000;Mateika, Kavey, & Mitru 1999). At the
beginning, our study was based on advice from the Professor David Webb's
group, but we were not aware that the method was insufficiently validated.
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Therefore, we undertook the validation reported here and found that the
reproducibility of the tests was low. A separate study, at a later stage,
demonstrated the lack of reproducibility of the spontaneous method of
measuring BRS, both the sequence and, more importantly, spectral techniques.
Spontaneous BRS measurement methods were very variable with time. This
fluctuation may perhaps reflect baroreceptor physiology in addition to other
factors, mainly respiration. Nevertheless, we also showed that spontaneous
measurements were not a valid tool to assess baroreceptor sensitivity. It seems
likely that this lack of reproducibility of the spontaneous baroreceptor gain is
the main cause of the negative results of this study.
Patient selection. It could be argued that the patients who participated in our study
did not have OSAHS that was severe enough (median AHI = 44.3 and 4%DI =
18.8). Bonsignore et al. found that CPAP improves baroreflex control of heart
rate during sleep in OSAHS patients with mean AHI of 77 and Sa02 during
NREM and REM of 81.2 and 67.7 respectively (Bonsignore et al. 2002).
Patient compliance was fair (median CPAP use = 4 hours/ night) which is good
compared with other RCTs (Engleman & Douglas 1993b;Faccenda et al.
2001c) though perhaps not ideal. Pepperell et al. found that CPAP use of 5
hours/night reduced blood pressure (Pepperell et al. 2002) Compliance is often
the main problem in CPAP use, and can be improved by intensive education
and support programs (Hoy et al. 1999). In this study, patients were not only
given standard care but were also contacted by me during each treatment to
check for any problems.
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11.1.2 Physiological Effect
1. Respiratory influences (see Chapter 7 on reproducibility). The human
respiratory gate has a major influence in vagal and sympathetic control of the
heart rate (Eckberg 2003). The heart rate interval (RRI) is very much under
the influence of respiration by the respiratory cardiac coupling.
Figure 11.1 Schematic block diagram of the major physiological mechanisms that contribute
to heart rate variability and blood pressure variability (Belozeroff, Berry, & Khoo 2003)
The most obvious marker of this respiratory influence is respiratory sinus
arrhythmia. In this study, the patients were asked to breathe normally (tidal
breathing). However, there was no control on patients to track the random
breathing. This confounding respiratory factor can be accounted for if a
mathematical model is used that relates changes in RRI to respiration and
changes in systolic blood pressure. The model partitions the RRI fluctuation
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into a component mediated by respiratory-cardiac coupling and one mediated
by baroreflexes (Belozeroff, Berry, & Khoo 2003;Jo et al. 2003). It is non¬
invasive and a simpler means of quantifying the key aspects of autonomic
control in spontaneously breathing OSAHS patients during wakefulness.
2. Age of the patients: BRS may diminish with age (see section 2.6.3).
Furthermore, it has been shown, using different techniques, that age is
negatively correlated with BRS (Lantelme et al. 2002). The decrease in
baroreflex buffering with aging is related to increases in basal sympathetic
nerve activity and reductions in systemic alphal-adrenergic vascular
responsiveness (Jones et al. 2003). The mean age of the patients in our study
was 50 years. Nevertheless, there was no significant age effect (P > 0.05) in
any parameter, although it is worth mentioning that the mean of BRS of
patients above and below the age of 50 (the mean age) was 5.2 and 5.7
respectively. The rest of the measurements are in the table below.








































12 and 17 were the number of patients below and above the age of 50
respectively.
3. Diurnal changes. Normally, BRS increases at the transition from
wakefulness to sleep (NREM sleep) and it decreases as subjects awake and
resume their daily activities (Conway et al. 1983). Since in our study, all
measurements were made at the same time of day, this cannot be a factor in
our finding no change with CPAP. However, we cannot comment on changes
at other times of the day.
4. Other physiological factors such as gender, neurohumeral and physical
deconditioning (see section 2.6.3) might have a role in the outcome of this
study. However, I do not have enough data in this study to comment further.
11.2 Vascular Endothelial Function Study
Venous occlusion plethysmography, coupled with brachial artery drug
administration, has been widely used to study forearm blood flow (FBF) (Benjamin
et al. 1995). It provides a safe and convenient arterial bed in which to test the
vascular effects and endothelial function in sleep apnoea. In control arms (non-
infused), the mean of forearm blood flow measurements was higher, though
insignificant, which could be attributed to the difference in body size, since the
severe OSAHS patients had higher BMI (P = 0.03) and neck and waist
circumferences (P = 0.03 and P = 0.04 respectively). The non-infused arm is
generally used as a contemporaneous control for the experimental arm, taking
account of any minute-to-minute changes in blood flow that might affect both arms,
such as those due to emotion or minor changes in the basal state (Benjamin et al.
1995). The data from the FBF measurement in the infused arm in the obstructive
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sleep apnoea study found no significant difference between severe and mild OSAHS
patients. This could be explained by the small sample size and thus low power, or
genuine lack of difference. However, this study has not yet been completed and these
patients represent only 25% of the projected number. In addition, the patients still
need to be compared with matched healthy control subjects and also randomized for
CPAP and sham CPAP in future.
Nevertheless, the study has its own limitations, for it is an invasive and technically
demanding procedure, especially in overweight participants (mean BMI of the severe
group was 38.6). Before this study was begun, there had been a few studies that had
examined the endothelial function and OSAHS. An early study by Carlson et al.
(Carlson, Rangemark, & Hedner 1996) indicated that endothelium-dependent
vascular relaxation was attenuated in patients with sleep apnoea independently of
hypertension. They used the FBF method to evaluate the endothelial function with
acetylcholine and sodium nitroprusside infusion. A study by Kato et al. found that
OSAHS patients had an impairment of resistance-vessel endothelium-dependent
vasodilatation. However, they found no significant difference between sleep apnoea
patients and control subjects, using the FBF method. In addition, endothelial function
was assessed by measuring the brachial artery diameter, in which they found that
there was a vascular response to sublingual administration of nitroglycerin (NTG)
with a significant difference between sleep apnoea patients and control subjects
(Kato et al. 2000). Nevertheless, the sample size of the study was small with 8
obstructive sleep apnoea patients and 9 healthy controls. In Kato et al's study, the
patients had not been randomized to any treatment, and a non-invasive procedure of
conduit-vessel dilatation was employed to obtain the difference. Another study was
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conducted by Ip et al., in which the endothelial function was also evaluated by
measuring the brachial artery diameter after sublingual nitroglycerin (Ip et al. 2004).
In this study, the patients were randomized to receive CPAP treatment or no
intervention. Ip et al. found that patients who received CPAP had a significant
increase in flow-mediated dilatation. Our study was more comprehensive since it was
a case-control study with different levels of severity. Furthermore, the more complex
though standard procedure of plethysmography was employed in evaluating the
endothelial effect of OSAHS with three different vasodilating drugs. Recently, it was
found that CPAP therapy improved endothelial function in a non-randomised trial
(Lattimore et al. 2006). They used similar methods to our study but a different drug
protocol. They found that the response to Ach after 3 months of CPAP therapy was
significantly greater compared to pre-CPAP response. N-monomethyl-L-arginine (L-
NMMA) was co-infused with Ach 20pg. They also found no correlation between
severity of nocturnal hypoxaemia and the magnitude of the change in vascular
function with treatment. However, there was no comment about the correlation of the
vascular function and hypoxaemia before the treatment.
11.3 Future Work
This thesis raises questions regarding the mechanisms of change in blood pressure in
obstructive sleep apnoea. Further investigations are required to evaluate the
autonomic nervous system and its relationship with the cardiovascular system as well
as the endothelial function and growing understanding of the role of the endothelium
in cardiovascular and cerebrovascular diseases in relation to OSAHS.
It would have been ideal if a better and validated methodology of the baroreflex
sensitivity study had been used to test the baroreflex sensitivity in OSAHS with more
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resources available. The reproducibility was the main problem in this study, which
could be attributed to the factors previously discussed. In addition to the
physiological and other methodological factors that have to be taken into
consideration, the study would have been improved by having a higher power, longer
period of time (for example, three months), and better control of confounding factors
such as respiration. I would also suggest comparing the effect of CPAP during sleep
and wakefulness to test the immediate and sustained effect of the treatment. This
could also be tested with and without CPAP applied during wakefulness. More
severe OSAHS patients should be included in any future work; who have more Sa02
desaturation and more symptomatic patients with higher ESS scores. However,
recruiting hypertensive OSAHS patients might give a clearer picture about the
relationship between obstructive sleep apnoea and hypertension and the role of the
baroreflex (Floras et al. 1988;Lantelme et al. 2002;Siche et al. 1995). Nevertheless, it
would be extremely difficult to recruit sufficient untreated hypertensive patients, thus
it might be necessary to be less purist than in this study and include patients who are
already on antihypertensive treatment. Because the relationship between sleep
apnoea and hypertension is not confined to the baroreflex, other aspects should be
explored. The role of the kidney should be investigated with more research on the
effect of OSAHS on renal function (Fletcher 1993) and also the relationship between
OSAHS and proteinuria. Although there have been a few studies that suggested an
association between obstructive sleep apnoea and proteinuria, as discussed before,
they were limited and none of them had been randomized, and they have produced
divergent results. Earlier studies had shown that proteinuria is not uncommon in
obese patients with OSAHS, which could be reversible (Sklar & Chaudhary
189
1988;Sklar, Chaudhary, & Harp 1989). However, more recent studies have reported
that proteinuria is weakly associated with OSAHS (Casserly et al. 2001;Chaudhary,
Rehman, & Brown 1995;Iliescu et al. 2001). Thus, a more comprehensive study is
required to explore the role of the kidney in the development of hypertension in sleep
apnoea patients. The study should be a case-control and randomized trial measuring
renal function, BP, proteinuria with symptomatic assessment of urination habits.
The endothelium can greatly influence vascular tone and structure by releasing NO.
Thus, the study of the endothelial function came with the mainstream of
understanding the mechanism of development of hypertension and cardiovascular
disorders in OSAHS. However, more studies are required to explore this issue, such
as measuring free radicals or reactive oxygen species (Lavie 2003) that might be
produced by hypoxia in patients with sleep apnoea. Furthermore, a few studies have
shown increased expression of adhesion molecules (Lattimore et al. 2005) and
production of reactive oxygen species in leukocytes of sleep apnoea patients
(Dyugovskaya, Lavie, & Lavie 2002;Schulz et al. 2000). Pro-inflammatory factors
such as interleukins, C-reactive protein, leukocyte adhesion molecules such as CD 15
(Dyugovskaya, Lavie, & Lavie 2002) might also contribute to the pathogenesis of
developing cardiovascular diseases, and merit further evaluation. In addition,
prothrombotic factors (Robinson et al. 2004) such as fibrinogen, plasminogen
activator inhibitor, and reduced fibrinolytic activity with enhanced platelet activity,
may play a role in the process (Parish & Somers 2004). Thus, further randomized
case-control studies would be of great value in understanding the pathogenesis of
cardiovascular diseases in OSAHS. As I have discussed in chapter 9 there are other
190
methods of evaluating the endothelial function which could be used to evaluate the
effect of CPAP therapy in OSAHS patients.
OSAHS has been shown to be associated with elevation of blood pressure. Much
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Appendices
Appendix 1 EPWORTH SLEEPINESS SCALE
MW Johns. Sleep 1991, 14(6), 540-5.
Name: Study:
Date:
How likely are you to doze of or fall asleep in the following situations, in contrast to
feeling just tired? This refers to your usual way if life in recent times. Even if you
have not done some of these things try to work out how they would have affected
you. Use the following scale to choose the most appropriate number for each
situation.
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
SITUATION Chance of dozing
Sitting reading
Watching TV
Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances
permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic




FUNCTIONAL OUTCOMES OF THE SLEEP QUESTIONNAIRE
(FOSQ)
Some people have difficulty performing everyday activities when they feel tired or
sleepy. The purpose of this questionnaire is to find out if you generally have
difficulty carrying out certain activities because you are too sleepy or tired. In this
questionnaire, when the words "sleepy" or "tired" are used, it means the feeling that
you can't keep your eyes open, your head is droopy, that you want to "nod off', or
that you feel the urge to take a nap. The words do not refer to the tired or fatigued
feeling you may have after you have exercised.
DIRECTIONS: Please put a tick (3) in the box for your answer to each question.
Select only one answer for each question. Please try to be as accurate as possible.
All information will be kept confidential.
(0) (4) (3) (2) (i)
I don't do No Yes, Yes, Yes,
this difficult a little modera extreme
activity y difficult te difficult
for other y difficult y
reasons y
1 Do you have difficulty
concentrating on the things you
do because you are sleepy or
tired?
2 Do you generally have difficulty
remembering things, because
you are sleepy or tired?
3 Do you have difficulty finishing
a meal because you become
sleepy or tired?
4 Do you have difficulty working
□
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
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on a hobby (for example,
sewing, collecting, gardening)
because you are sleepy or tired?
©Weaver, September 1996
Functional Outcomes of Sleep questionnaire (FOSQ)
(0) (4) (3) (2) (i)
1 don't do No Yes, Yes, Yes,
this difficult a little modera extreme
activity y difficult te difficult
for other y difficult y
reasons y
5 Do you have difficulty
doing work around the
house (for example,
cleaning the house, doing
laundry, taking out the
rubbish, repair work)
because you are sleepy or
tired?
□ □ □ □ □
Do you have difficulty
operating a motor vehicle | [ 1 | | | 1 I 1 I
for short distances (less
than 100 miles) because
your sleepy or tired?
7 Do you have difficulty
operating a motor vehicle | | | | | | | | | |
for long distances (greater
than 100 miles) because
your sleepy or tired?
8 Do you have difficulty
getting things done because ] | | | | | 1 | 1 1
you are too sleepy or tired
to drive or take public
transportation?
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Do you have difficulty





records, filling out tax
forms, etc) because you are
sleepy or tired?
□ □ □ □ □
10 Do you have difficulty
performing paid or
volunteer work because
you are sleepy or tired?
□ □ □ □ □
11 Do you have difficulty
maintaining a telephone
conversation because you
become sleepy or tired?
□ □ □ □ □
©Weaver, September 1996
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12 Do you have difficulty
visiting with your family
or friends in your home
because you become
sleepy or tired?
(0) (4) (3) (2) 0)
I don't do No Yes, a Yes, Yes,
this difficult little modera extreme
activity y difficult te difficult
for other y difficult y
reasons y
□ □ □ □ □
you have difficulty
ting with your family
riends in their home
ause you become
□ □ □ □ □
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14 Do you have difficulty
doing things for your [ I | j [ j j ] [ ~|
family or friends because
you are too sleepy or
tired?
(4) (3) (4) (5)
No Yes, Yes, Yes,
a little moderatel extremely
y
15 Has your relationship with
family, friends or work □ □ □ □
colleagues been affected
because you are sleepy or
tired?
In what way has your relationship been affected?
(0) (4) (3) (2) (i)
I don't do No Yes, a Yes, Yes,
this difficult little modera extreme
activity y difficult te difficult
for other y difficult y
reasons y
16 Do you have difficulty
exercising or participating □ □ □ □ □
in a sporting activity
because you are too sleepy
or tired?
17 Do you have difficulty
watching a film or I 1 I I I I I I 1 I
videotape because you
become sleepy or tired?
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(0) (4) (3) (2) (i)
I don't do No Yes, a Yes, Yes,
this difficult little modera extreme
activity y difficult te difficult
for other y difficult y
reasons y
18 Do you have difficulty
enjoying the theatre or a
lecture because you
become sleepy or tired?




20 Do you have difficulty
watching TV because you
are sleepy or tired?
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
21 Do you have difficulty
participating in religious | [ | | | | | | | |
services, meetings or a ~ "
group or a club because
you are sleepy or tired?
22 Do you have difficulty
being as active as you □ □ □ □
want to be in the evening
because you are sleepy or
tired?
23 Do you have difficulty
being as active as you □ □ □ □
want to be in the morning
because you are sleepy or
tired?
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24 Do you have difficulty
being as active is you □ □ □ □
want to be in the
afternoon because you are
sleepy or tired?
24 Do you have difficulty . . . , .
keeping pace with others I I I I I 1 I 1
your own age because you
are sleepy or tired?
26 How would you rate your
general level of activity?
(1) (2) (3) (4)
Very low Low Medium High
□ □ □ □
©Weaver, September 1996
Functional Outcomes of Sleep Questionnaire (FOSQ)
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Appendix 3
Patient information sheet for the baroreflex sensitivity study
Patient Information Sheet
Blood pressure in sleep apnoea/hypopnoea study
The relationship between sleep apnoea and blood pressure remains controversial, we
want to perform a study looking at the relationship between sleep apnoea and blood
pressure, and also looking at the possible mechanism for the increases in blood
pressure.
What does the study involve?
The study takes two months to complete, this is split into two 1-month blocks, and
you will receive two different treatments, one for each month. We are using the
standard treatment for sleep apnoea - CPAP (continuous positive airway pressure),
and comparing this with a trial treatment. The second treatment involves taking an
oral capsule once a day to see if it helps your symptoms and to see if it alters your
blood pressure.
At the end of each month block we will measure your blood pressure for about 48
hours using a portable device which is worn around the waist. You will be asked to
continue your normal activities whist wearing the device. Further recordings of blood
pressure will be done in the morning with you lying down from your finger in a quiet
room for approximately an hour while we also record your heartbeats.
I will also be asking you to fill out some questionnaires. I will also measure your
weight and waist and neck size at each visit to the Sleep Centre and will take urine
sample.
We will come out to your home to fit the blood pressure monitor at a convenient time
for you and it will involve you coming up to the centre two days later for 1-2 hours
in the morning, ideally before 10am. We will refund the travel costs for the extra two
visits to the centre. At the end of the study you will be issued with a standard CPAP
machine.
You are under no obligation to participate in this study and you can withdraw at any
time without detriment to your future care.
All data collected will be confidential. Your General Practitioner will be informed of
your participation in the study and of any abnormal results.
You can also contact Dr T.Mackay on 0131 536 1000 for unbiased advice on aspects
of this study.
If you have any further questions please do not hesitate to get in touch, telephone
0131 536 4192/4196, or leave a message on 0131 536 2355.
Dr M Al-Abri
Clinical Research Fellow
Dr J F Faccenda
Specialist Registrar in Respiratory and General Medicine
Professor N J Douglas
Professor of Respiratory & Sleep Medicine
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patient information sheet for endothelial function
Patient Information Sheet
Title: THE EFFECT OF CPAP ON VASCULAR BIOLOGY IN
THE OBSTRUCTIVE SLEEP APNOEA/HYPOPNOEA
SYNDROME
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it
with friends, relatives and your GP if you wish. Ask us if there is anything that is
not clear or if you would like more information. Take time to decide whether or not
you wish to take part.
Consumers for Ethics in Research (CERES) published a leaflet entitled 'Medical
Research and You'. This leaflet gives more information about medical research and
looks at some questions you may want to ask. A copy may be obtained from
CERES, PO Box 1365, London N16 OBW.
Thank you for reading this information sheet.
Patients with disordered breathing patterns during sleep have been shown to have
increases in blood pressure that may have a bad effect on the heart and brain. This
disordered breathing may result in detrimental effects on the blood vessels and lead
to heart attacks and strokes. We seek to show that abnormal blood vessel responses
are associated with low overnight oxygen levels and that treatment to assist breathing
during sleep improves blood vessel function in people with low oxygen levels
associated with their sleep apnoea. In addition we hope to look at a number of
different genes and proteins to see if they can change the regulation of blood vessel
responses. This will lead to an improvement in our understanding of such complex
processes and the development of a new preventative treatment to reduce the risk of
heart disease. It is up to you to decide whether or not to take part. If you do decide to
take part you will be given this information sheet to keep and be asked to sign a
consent form. If you decide to take part you are still free to withdraw at any time and
without giving a reason. You have been diagnosed with sleep apnoea and will be
looked after and treated like any other patient that we see in our clinic. We will also
ask to monitor your blood pressure using a special cuff over a period of 48 hours the
two days before you have the test outlined below. The test itself consists of lying
continuously on a bed for 2-3 hours in a warm room. During this time, some bands
that will be placed around both arms will tighten up for short periods and from time
to time will restrict your movements. A very small needle will be placed in the
artery of one arm and two plastic tubes (cannulae) will be placed into the veins, one
in each arm. This part of the study is associated with some slight discomfort and we
use local anaesthetic to minimise this. The needle in the artery can occasionally
become dislodged which would cause an ache and a slight bruise or swelling. If this
does occur, the swelling usually resolves rapidly after stopping the study and
removing the needle. You should, however, let us know if you experience any
discomfort.
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Small amount of drugs (substance P, acetylcholine and sodium nitroprusside) will be
administered at very small that should only affect the arm. They can cause flushing
and some mild swelling in the forearm. The effects are however self-limiting and of
short duration.
Blood samples will be taken at intervals throughout the study and analysed for
components of the blood that play a part in the clotting mechanism. The total amount
of blood taken throughout the study will be less than 300 ml (or half a pint). Some
blood samples may be retained to test for additional relevant proteins or genes,
which could be important in determining the mechanisms under study. These
samples will be destroyed at the end of the experiments.
.All information collected about you during the course of the research, including
blood samples and test results, will be kept strictly confidential. Any information
about you that leaves the hospital will have your name and address removed so that
you cannot be recognised from it. We will inform your General Practitioner of your
participation in this study.
If taking part in this research project harms you, there are no special compensation
arrangements. If you are harmed due to someone's negligence, then you may have
grounds for a legal action but you may have to pay for it. Regardless of this, if you
wish to complain about any aspect of the way you have been approached or treated
during the course of this study, the normal National Health Service complaints
mechanisms will be available to you.
The Lothian Medicine/Clinical Oncology Research Ethics Sub-Committee has
reviewed the study.
You will be given a copy of the information sheet and a signed consent form to keep.
Please do not hesitate to ask the investigators any questions and you may also ask for
advice from the Local Independent Advisor, Dr Thomas Mackay, who is not directly
involved with the study.
Once again, thank you for your attention.
Dr M Al-Abri









Department of Respiratory Medicine
Royal Infirmary
Edinburgh, EH16 4SA
Tel: 0131- 242 1872
Dr M Cross






Consent form for the OSAHS and baroreflex study
LOTHIAN RESEARCH ETHICS COMMITTEE
STANDARD CONSENT FORM
TITLE OF THE PROPOSED RESEARCH;
Hypertension in Steep AprweaTtypopnoca Syndrome.
N AME OF INVESTIGATOR:
Dr M Aiibn Dr J. F Twcenda
ADDRESS:
Sleep Centre, Ward AS, Royal Inftrmafy of Edinburgh
TELEPHONE:
QUI »6 2JSS
rt'RTHEK INFORMATION IS AVAILABLE FROM: <A person wbo is «n involved in -he wudv i
Dr T Mickey
LIST ANY DRUGS TO BE GIVEN IN THE STUDY EXPLAINING THEIR ACTION:
Trial capsule to improve upper airway tone
LIST ANY' PROCEDURES REQUIRED IN ADOITION TO THE STANDARD PROCEDURES:
48 Soar blood pressure monitoring, beat by beat Mood pressure
• I agree lo parttopilbto tke patient/subject perttetpaiins* in this study.
a I hate read this masent ferns and Partirat/Subyeet Information Sheet and had the
•ppartuaity to aatt questions about tbent
• I agree for aodee la be sent in tnyttbe paHtntViabjKl'i' General Practitioner about
my/their* participation In tuts study.
• I agree to the provision a! any ciloicaily significant information le ttswihe patientVsubject's
General Prattltioatr.
< I uaderstand that I ansdhc patknUMibjett la* under an obligation to lake part In this study
and that a decision not to participate will not aher the treatment that I/the patient subject"
would normally receive.
• I understand that I base the patirnl'subjcct has* the right lo withdraw from ibis study at
any stage and thai in da so wig not affect asy/their* treatment.
• I uaderstand that (Ms is no«-!hcrapeulic research Prom which Lthe pattentfsubjeci* cannot
espect in derive any benefit."
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